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Summary
Patients with chronic renal failure (CRF) have a 20-fold increased risk of 
cardiovascular death compared to the general population, with sudden death, cardiac 
failure and atherosclerotic vascular disease being the commonest underlying 
problems. For many years it has been postulated that accelerated atherosclerosis 
occurs in uraemia and that this may be secondary to a multitude of “traditional” 
cardiovascular risk factors including dyslipidaemia, hypertension, smoking and 
diabetes mellitus, all of which are prevalent in this population. Other authors have 
suggested that “non-traditional” risk factors are more important including 
accumulation of endogenous inhibitors of nitric oxide synthase and homocysteine, 
hyperparathyroidism, increased oxidative stress and other, as yet unidentified, 
uraemic factors. Whatever the mechanism, these risk factors are likely to act by 
causing endothelial damage and dysfunction.
The vascular endothelium lies at the interface between the blood and tissues and has 
several important roles which together prevent atherosclerosis : control of vessel tone, 
inhibition of platelet aggregation, control of the passage of cells and macromolecules, 
inhibition of vascular smooth muscle cell proliferation and inhibition of monocyte 
adhesion and migration. The majority of these anti-atherogenic effects are mediated 
by endothelium-derived nitric oxide. Dysfunction of the vascular endothelium is 
thought to be a key initial event in the development of atheroslcerosis and has been 
demonstrated in a number of conditions/risk factors including diabetes, hypertension,
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smoking, dyslipidaemia and ischaemic heart disease. Few studies have examined 
endothelial function in chronic renal failure.
The work presented in this thesis was performed to examine endothelial function in 
patients with CRF and in particular to examine endothelium-dependent vasodilatation 
as this is the easiest aspect of endothelial function to study in humans. Using the in 
vivo method of forearm venous occlusion plethysmography, endothelium-dependent 
(EDV) and endothelium-independent (EIDV) vasodilatation was assessed in 16 
uraemic patients (pre-dialysis and on CAPD) and 18 controls. The order of infusion of 
drugs (SNP for EIDV and carbachol for EDV) was randomised. Overall there were no 
differences between the groups but it was apparent that infusion of SNP as the first 
agent was having a prolonged effect. Thus when 10 patients and controls were 
examined, in whom carbachol was infused followed by SNP, EIDV was similar but 
EDV to carbachol was attenuated in the uraemic patients. This pattern suggested 
endothelial dysfunction in the uraemic patients, with the most likely defect being 
impaired endothelial NO production, release or effect. No correlates were found in the 
background laboratory or blood pressure data to predict the response to these agents.
Since many authors have postulated that the most important cause of endothelial 
dysfunction in uraemia is likely to be the accumulation of circulating factors such as 
asymmetric dimethylarginine (ADMA), an endogenous NO synthase inhibitor, a 
second in vitro study was performed to further examine endothelial function in CRF. 
Utilising wire myography, subcutaneous resistance artery function was assessed in 12 
uraemic patients and 8 controls, with vessels removed from the uraemic milieu. This 
study again revealed a significantly attenuated EDV in the uraemic group with normal
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EIDV to SNP, and the results therefore suggest that endothelial dysfunction in CRF is 
not readily reversible and is not entirely secondary to a short-lived circulating factor. 
The study did not completely rule out an effect of ADMA, however, as this agent may 
accumulate within cells. Together, both studies confirm the presence of endothelial 
dysfunction in uraemia with the underlying mechanism being unclear. In this 
myography study, responses to the vasoconstrictors endothelin-1 and noradrenaline 
were also assessed. Both agents had a tendency to a greater and more long-lasting 
effect in the uraemic group compared to controls, perhaps reflecting reduced 
counterbalancing endothelial NO production or increased vessel wall smooth muscle.
As blood pressure in uraemic patients on renal replacement therapy is usually 
dependent on blood volume a further small study was undertaken to examine the 
effects of altered fluid balance on endothelial responses in CAPD patients. 
Recruitment for this study proved difficult and results are presented for just 3 patients. 
Endothelium-dependent vasodilatation and EIDV were assessed using forearm strain- 
gauge plethysmography before and after a 2kg weight gain. Results were conflicting 
and no clear pattern was observed. A larger study is required to assess the hypothesis 
that increased blood volume is associated with reduced endothelium-dependent 
vasodilatation and consequent hypertension.
Since the increased cardiovascular risk of patients on dialysis persists following renal 
transplantation, a final study was performed to examine endothelial function in renal 
transplant recipients. Using forearm venous plethysmography, EIDV and EDV were 
assessed in 16 patients with stable renal allograft function and in 12 controls. Overall 
there was a trend toward attenuated EDV in the transplant patients, but this was only
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significant for those patients on cyclosporin-based immunosuppression. Surprisingly, 
the patients taking prednisolone and azathioprine only (n=7) appeared to have 
preserved endothelial function, although this may be a result of the small numbers. 
Thus, the patients taking cyclosporin had impaired stimulated endothelial function 
evidenced by reduced EDV and preserved EIDV. To assess whether basal endothelial 
NO production was also abnormal, a further study was performed using L-NMMA as 
an inhibitor of basal NO production, and noradrenaline as a control vasoconstrictor in 
9 cyclosporin-treated transplant recipients and 11 controls. As expected, 
vasoconstriction to L-NMMA was reduced in the transplant recipients suggesting 
impaired basal NO production in this group. Surprisingly, some of the patients 
responded abnormally, with vasodilatation to noradrenaline, and this appeared to be 
related to age. The reason for this phenomenon is unclear and warrants further study. 
It is possible that cyclosporin treatment alters adrenergic receptor number or function 
such that noradrenaline vasodilates via P-adrenoceptors. Overall, the studies in the 
transplant patients suggested impaired stimulated and basal endothelial NO 
production, and altered adrenergic responses in those patients treated with 
cyclosporin, an agent known to play a major role in post-transplant hypertension.
Thus, the studies performed for this thesis demonstrate that there is endothelial 
dysfunction in patients with CRF including those patients who have been transplanted 
and are treated with cyclosporin. As the in vitro study confirmed these results, it is 
likely that a short-lived circulating factor is not wholly responsible, although the 
studies performed do not allow a more detailed assessment of the causation of 
endothelial dysfunction in uraemia. Further work is required with repeat studies 
including hypertensive control groups and in the presence of NO synthase inhibitors,
to assess the relative contribution of NO to the defect in endothelial function. A more 
detailed study of the vascular effects of cyclosporin is also warranted, perhaps 
infusing cyclosporin locally at plethysmography or by adding cyclosporin to the 
myography chamber.
The studies confirm endothelial dysfunction in a high-risk cardiovascular group. As 
endothelial dysfunction is potentially reversible using lifestyle changes, anti­
hypertensive agents, statins, anti-oxidants and homocysteine-lowering, these studies 
provide a platform for future intervention studies using improvements in endothelial 
function as a surrogate marker for reducing cardiovascular end-points in CRF.
Chapter 1
Introduction
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1.1 OVERVIEW OF CARDIOVASCULAR DISEASE IN CHRONIC RENAL 
FAILURE
The increased availability o f dialysis therapy and renal transplantation has unmasked 
an epidemic o f cardiovascular disease in patients with chronic renal failure (CRF). 
Data from the European Renal Registry reveal that patients receiving renal 
replacement therapy (RRT) experience a 16-19 fold increased risk o f myocardial 
infarction and ischaemia compared with age and sex-matched populations without 
renal disease (Raine 1992). The picture is similar in North America - figures from the 
U.S. Renal Data System (USRDS) confirm that 50% o f American RRT patients die o f 
cardiovascular disease (Figure 1.1).
Unknown
8%
Other
18%
Ml/Heart failure 
29%
Cardiac arrest 
19%
Malignancy 
4%
CVA
6%
Infection
16%
Figure 1.1 Cause o f death for ESRD patients aged 45-64, 1991-1993, USRDS 1996.
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Many would say that this is not surprising as cardiovascular disease is the commonest 
cause o f death in the general population. However, patients with ESRF die 
prematurely from cardiovascular disease with, for instance, the CVD mortality rate in 
dialysis patients aged 25-44 being around 100 times that o f the general population 
(Foley 1998a; Figure 1.2).
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Figure 1.2. Cardiovascular disease mortality by age, race and gender in the general 
population and in dialysis patients from USRDS 1994-1996. (From Foley 1998a).
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The increased risk is seen across populations with different background risks of 
cardiovascular disease, with a 20-fold increased risk of cardiovascular death in both 
the UK and Italy (Raine 1992). This compares with the 3-fold increased risk of 
cardiovascular death in diabetics, a group with widely recognised increased 
cardiovascular risk. Thus, it seems that we have gone full circle. Before dialysis was 
available, uraemic patients often died of pericarditis. Now that RRT in its various 
forms is widely available, patients are again succumbing to cardiovascular disease, 
and unlike the general population, the incidence of cardiovascular disease in this 
group is not falling (Raine 1992).
The precise mechanisms underlying the markedly increased risk of cardiovascular 
death in uraemia are unclear. We do know that while myocardial infarction and 
atherosclerotic vascular disease are common, this does not afford the entire 
explanation for the high mortality rate, as patients on long-term dialysis often have 
symptomatic ischaemic heart disease with patent coronary arteries (Roig 1981). Left 
ventricular hypertrophy, with its associated risk of sudden arrhythmic death, is very 
common in this population as a result of years of hypertension. Left ventricular 
dilatation and heart failure are also common - reflecting chronic fluid overload 
especially in dialysis patients. As nephrologists we see evidence of atherosclerotic 
vascular disease on a daily basis with stroke, angina, myocardial infarction and 
peripheral vascular disease causing great morbidity in our patients. Therefore, it is 
apparent that the excess of cardiovascular disease in this population reflects changes 
in both the heart and the vasculature.
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1.2 THE HEART IN CHRONIC RENAL DISEASE
There are four main manifestations of cardiac disease in renal failure : ischaemic heart 
disease (IHD) secondary to coronary atherosclerosis, left ventricular hypertrophy, 
heart failure and sudden death.
Atherosclerosis is accelerated in uraemia and will be discussed later. While IHD is 
usually caused by coronary atherosclerosis, other mechanisms may play a role, and in 
up to a quarter of haemodialysis patients with angina the coronary arteries are not 
significantly narrowed or occluded at coronary arteriography (Rostand 1984). The 
symptoms are presumably related to reduced coronary reserve secondary to left 
ventricular hypertrophy, and microvascular disease with capillary rarefaction and 
arteriolar wall thickening (Amann 1996).
Left ventricular hypertrophy and failure develop in response to LV pressure and 
volume overload (Parfrey 1999). Left ventricular pressure overload in uraemia is 
caused by systemic hypertension, arteriosclerosis (reduced arterial compliance) and 
(calcific) aortic stenosis, and in turn leads to concentric LV hypertrophy. In contrast, 
left ventricular volume overload develops in response to salt and water retention, 
anaemia and increased cardiac output secondary to arteriovenous fistulae (Parfrey 
1999), and results in eccentric LV hypertrophy. With both forms of LV hypertrophy 
the initial changes are beneficial to cardiac function. However, with on-going pressure 
and volume overload the LV cavity dilates, the density of capillaries is reduced and 
myocyte death ensues. Heart failure and death follow.
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The epidemiology of cardiac disease in uraemia varies with the stage of a patient’s 
“renal life” (Figure 1.3).
Pre-Dialysis CRF Renal Transplant
CAPD
Haemodialysis
Figure 1.3. A “Renal Life” involves the pre-dialysis phase, followed directly by either 
pre-emptive transplant, CAPD or haemodialysis. Patients often move from one group 
to the other.
1.2.1 Pre-dialysis CRF
Data are lacking for this group. We do know that young patients with CRF have 
increased LV mass and diastolic dysfunction compared to normal controls (Johnstone 
1996). In addition, as GFR declines, LV mass rises progressively : in a cross-sectional 
study, 27% of those with GFR >50ml/min had LV hypertrophy, 31% of those with 
GFR 25-49ml/min, and 45% of those with GFR <25ml/min had LVH (Levin 1996). 
Moreover, this progressive rise in LV mass holds true in individual patients with 
declining renal function (Levin 1999).
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Ischaemic heart disease is very common in patients starting dialysis : 41% in the 
United States and 28% in Canada (Foley 1998a), while heart failure was present in 
40% of patients starting haemodialysis in the U.S. (USRDS 1997).
1.2.2 Haemodialysis
One of the largest studies to examine cardiac abnormalities in uraemia was performed 
by Parfrey et al in Newfoundland, Canada (Parfrey 1996). Using echocardiography, 
they studied 432 patients who survived for more than 6 months on haemodialysis, and 
showed that only 16% had a normal heart by echocardiography at the initiation of 
dialysis therapy. Forty-two percent had concentric left ventricular hypertrophy 
(LVH), 23% eccentric LVH, 4% left ventricular (LV) dilatation and 16% LV systolic 
dysfunction. In those patients with systolic dysfunction starting dialysis, median 
survival was 38 months. The presence of concentric LVH, LV dilatation or LV 
systolic dysfunction at baseline was associated with a 3-fold increased risk of 
subsequently developing symptomatic heart failure.
Left ventricular hypertrophy and dilatation progress on haemodialysis. In Parfrey’s 
echocardiography study (Parfrey 1996; Foley 1998b), a subgroup of patients had 
annual echocardiography whilst on haemodialysis : LV cavity volume was 73ml/m2 at 
baseline, increased by 13ml/m at 18 months and by a further 5ml/m at 30 months. 
Left ventricular mass index rose in a similar way. Silberberg showed that LV mass 
index correlated with outcome : if LV mass index was >125g/m , 5-year mortality 
was 52%. If LV mass index was <125g/m2 mortality was 23% over the same period of 
follow-up. Thus, LVH is an important adverse prognostic factor in patients on RRT.
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Ischaemic heart disease carries a worse prognosis in dialysis patients. In a study of 
34,189 long-term U.S. dialysis patients the 1 yr survival following myocardial 
infarction was only 41% with the 5 yr survival being just 10% and the greatest risk 
being in diabetics and older patients (Herzog 1998).
1.2.3 Peritoneal Dialysis
CAPD may be more “cardio-protective” than haemodialysis, with a more constant 
blood volume, absence of AV flstulae and less anaemia. LV hypertrophy and 
dilatation are said to be less common in patients on CAPD, however, there is often a 
strong selection bias in choosing the dialysis modality with younger, fitter patients 
opting for CAPD. Despite this, data from the USRDS suggest that the prevalence of 
IHD and cardiac failure are both around 40% in CAPD patients, and that patients on 
CAPD have 9.7% annual cardiovascular mortality (c.f. 9.5% for
haemodialysis)(Levey 1998).
1.2.4 Renal Transplantation
Left ventricular hypertrophy remains common post-transplantation, reflecting the high 
incidence of post-transplant hypertension, often cyclosporin-related. McGregor et al 
performed echocardiography on the eve of transplantation and showed that the 
average LV mass index was 134 g/m2 in those who survived compared to 167 g/m2 in 
those who died during the 7.5 year follow-up (McGregor 1999).
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Cardiac abnormalities are therefore extremely prevalent in chronic renal disease and 
contribute greatly to the overall cardiovascular mortality and morbidity. Changes in 
the blood vessels are also common and lead to premature atherosclerosis with 
resultant IHD, cerebrovascular disease (CVD) and peripheral vascular disease (PVD).
1.3 THE BLOOD VESSELS IN CHRONIC RENAL DISEASE
Blood vessels have two principal functions : conduit and cushioning (London 1997). 
The conduit function simply involves the transfer of blood from the heart to the 
tissues with minimal pressure drop, while cushioning refers to the elasticity of major 
vessels and their ability to smooth out the arterial pressure wave generated by the 
cardiac contraction, thus maintaining a constant flow of blood to the tissues. Both of 
these functions may be altered by disease, including renal failure.
Blood flow through a vessel is normally maintained until the lumen is narrowed to 
20% or less of its resting diameter (Gould 1976). A reduction in the conduit function 
is usually caused by luminal narrowing secondary to atherosclerotic plaque formation, 
and this most commonly occurs at sites of arterial bifurcation or branching, 
preferential areas being the carotid, coronary, femoral and renal arteries, as well as the 
infra-renal aorta (Glagov 1988). The mechanisms of atherogenesis and risk factors 
will be fully discussed in sections 1.7 and 1.8.
Atherosclerosis is a common condition in the general population, but is said to be 
accelerated in chronic renal failure. The pioneering study in this field was published 
by Lindner and Charra in the 1970’s (Lindner 1974). This group examined outcomes
in the first 39 patients receiving long-term haemodialysis in Seattle from 1960 
onwards. Fourteen of the 23 deaths were attributed to cardiovascular disease, 
confirmed by post-mortem in 19, and this occurred in an era when death from sepsis 
and technical accidents were still commonplace. Their first patient died from 
myocardial infarction in 1971 after 11 years of haemodialysis and at post-mortem was 
found to have “the most severe generalised atherosclerosis” the pathologist had ever 
seen. This seminal paper therefore described, for the first time, the high 
cardiovascular mortality in CRF and introduced the concept of accelerated 
atherosclerosis in uraemia. Subsequent studies confirmed their findings (Lowrie 
1974; Ibels 1979; Rostand 1979), although many have questioned whether 
atherosclerosis is actually accelerated in uraemia or whether we are in fact seeing the 
cumulative effects of several standard cardiovascular risk factors.
While most research has focussed on changes in the conduit function of blood vessels 
in CRF, Gerard London and his group have highlighted the importance of changes in 
cushioning function, and the link between the heart and blood vessels (London 1997). 
The cushioning function of blood vessels transforms the pulsatile cardiac output into a 
smooth, continuous blood flow to the tissues such that during systole 50% of the 
stroke volume is projected forward to the tissues while 50% is “stored” within the 
aorta and larger vessels. Elastic recoil of these distensible arteries in diastole releases 
this stored blood to continue the constant blood flow required for organ and tissue 
function. The efficiency of the process depends on the distensibility (or compliance) 
of the arterial walls.
While atherosclerosis is the main pathological change affecting conduit function, 
arteriosclerosis is the principal change affecting cushioning (and has no effect on 
conduit function at all). Arteriosclerosis occurs primarily in the aorta and larger blood 
vessels and is characterised by vessel wall dilatation, intimal medial thickening and 
reduced compliance or stiffening (London 1997). These changes, associated with 
normal aging, are accelerated in hypertension and CRF and lead to increases in 
systolic blood pressure and pulse pressure, both known to be linked to increased 
cardiovascular mortality. In addition, increased arterial stiffness increases afterload 
and results in compensatory left ventricular hypertrophy. It is partly through this 
mechanism that changes in vascular endothelial function may ultimately lead to 
alteration in cardiac structure or function.
Studies have shown that changes in blood flow alter the calibre of blood vessels along 
with the thickness and structure of their walls through release of endothelial-derived 
vasoactive substances. Increases in blood flow increase the calibre of vessels and their 
intimal medial thickness (Kamiya 1980), while decreases in flow have the opposite 
effect (Langille 1986). Thus, CRF being a state of chronic fluid overload is associated 
with increased systemic and regional blood flow, and this in turn leads to 
arteriosclerosis (London 1996). In addition to chronic volume/flow overload, blood 
vessels in uraemic patients are exposed to high tensile stress accompanying systemic 
hypertension. Over a long period tensile stress promotes intimal medial hypertrophy 
with a reduction in lumen diameter (Roman 1992), reduced arterial distensibility and 
increased pulse pressure.
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The vascular endothelium lies at the interface between the blood and the tissues, and 
plays a key orchestrating role in the pathogenesis of both atherosclerosis and 
arteriosclerosis.
1.4 STRUCTURE OF THE VASCULAR ENDOTHELIUM IN HEALTH
For many years, scientists have described the vascular endothelium as a simple 
cellular monolayer which lines the inside of blood vessels and provides a barrier 
between the blood and tissues. In fact, the endothelium is one of the body’s largest 
and most complex organs containing around 1x1012 cells, and with a multitude and 
diversity of functions paralleling those of the liver (Bom 1998). To illustrate it’s size, 
Bom et al estimated that the total surface area of the vascular endothelium was 
equivalent to 6 tennis courts.
Around 1960, following the development of electron microscopy, came the realisation 
that the endothelium was more than just a barrier. Through his descriptions of the 
passage of macromolecules through the endothelium, Howard Florey’s pioneering 
work laid the foundations for our current understanding of endothelial structure and 
function (Florey 1960). With a multitude of cell surface receptors, pores and inter­
cellular connections, the endothelial cell can sense and respond to mechanical stimuli 
such as shear stress, to changes in the local milieu such as hypoxia, and to circulating 
and locally released hormones and transmitters.
Endothelium in culture and in vivo is a simple monolayer o f cells (figures 1.4 and 1.5) 
approximately 3 pm thick at the nucleus and thinning to around 0.2 pm at the 
periphery (Florey 1966). These elongated cells are usually around 30 pm long by 10 
pm wide, and are connected to each other by tight intercellular junctions o f the fascia 
occludens type (Burkitt 1993 ed).
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Figure 1.4. Electron micrograph illustrating a capillary o f the continuous endothelium 
type (From : W heater’s Functional Histology 3rd edition).
(E=endothelial cell, M=marginal fold, BM=basement membrane, P=pericyte, 
BMp=basement membrane o f pericyte, O co llag en  fibrils, F=fibroblast)
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In capillaries, the thin endothelial cell layer rests on its basement membrane, and is 
supported by pericytes, cells which provide a “scaffolding”. Around these cells lie the 
connective tissue comprising fibroblasts and collagen fibrils. In arterioles (Figure 
1.5), the endothelial cell layer constitutes the tunica intima and is again supported by a 
thin basement membrane which separates it from the tunica media. This layer 
comprises up to 6 concentric layers o f vascular smooth muscle cells, supported by the 
collagen and elastin o f the tunica adventitia.
Figure 1.5. Electron micrograph o f a small arteriole (From : W heater’s Functional 
Histology 3rd edition with permission. (E=endothelial cell, BM=basement membrane, 
M=smooth muscle o f tunica media, EL=extemal lamina, A=axon o f sympathetic 
neuron, S=Schwann c e ll)
36
Each endothelial cell contains components o f the muscle cell contractile apparatus - 
actin, myosin, tropomyosin and alpha-actinin -  organised in 3 structures : the cortical 
web, the junction-associated actin filament (JAE) system, and striated myofibril-like 
stress fibres (see figure 1.6)(Bom 1998). The luminal surface o f the endothelial cell 
has occasional microvilli o f uncertain function, as well as receptors for numerous 
vasoactive substances, hormones and neurotransmitters (table 1.1).
ENDOTHELIAL CELL SURFACE RECEPTORS
Endothelin A______________________________________
Endothelin B_______________________________________
Angiotensin II______________________________________
Angiotensin I______________________________________
Acetylcholine (muscarinic M2)______________________
Bradykinin (BK2)__________________________________
Histamine (H2)____________________________________
A DP (P2)_________________
Thrombin__________________________________________
5-HT1_____________________________________________
Adrenaline (alpha2)________________________________
Vasopressin (VP1)_________________________________
TGFbeta___________________________________________
LDL
Table 1.1 : Receptors present on the vascular endothelial cell surface.
The cortical web serves as an anchor for adhesion molecules such as E-selectin and 
adherin, and for proteins such as annexin which is thought to play a major role in 
exocystosis and endocytosis (Bom 1998). In addition, the cortical web maintains the 
structure o f the cell. Passage o f molecules between cells is controlled by the JAF 
system, while the striated stress fibres allow the cell to change shape and maintain 
form and structure when resisting high levels o f  shear stress.
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Structure of vascular endothelial cells
Stress fibre 
(lum inal);
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Microtubule 
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Figure 1.6. Structure o f vascular endothelial cells. (From : Clinician’s Manual on 
Endothelium and Cardiovascular Disease, Ed. Born G, Science Press, London, U.K. 
with permission.)
A further interesting feature o f the endothelial cell membrane is the presence o f 
caveoli : vesicular structures rich in lipids, receptors and actin. These structures are 
involved in the transport o f molecules across the cell membrane, and are thought to 
play a major role in signal transduction.
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1.5 FUNCTIONS OF THE VASCULAR ENDOTHELIUM IN HEALTH
1.5.1 Control of vessel tone : Vasodilators
The vascular endothelium responds to changes in blood pressure, shear stress and 
concentrations of circulating mediators, by releasing both vasoconstrictors and 
vasodilators. These vasoactive mediators are listed in table 2.
VASODILATORS VASOCONSTRICTORS 1
Nitric oxide (NO) Endothelin
Endothelium-derived hyperpolarizing factor 
(EDHF)
Angiotensin II
Prostacyclin (PGI2) Thromboxane A2
C-type natriuretic factor Prostaglandin H2
Superoxide Anion
Table 1.2 Vasoactive substances released by the endothelium.
1.5.1.i Nitric Oxide
The identification of NO as the principal endothelium-derived relaxing factor is one 
of the major scientific discoveries of the last 2 decades and has opened a new chapter 
in cardiovascular biology. This discovery was made serendipitously in Robert
39
Furchgott’s laboratory in 1978 during studies of P-adrenoceptor function in rabbit 
thoracic aortic strips. These strips, mounted in a standard organ bath usually had little 
response to the addition of acetylcholine to the organ bath. However, on one occasion, 
a research assistant noticed that a strip of aorta, pre-constricted with noradrenaline, 
relaxed with the addition of acetylcholine, and thus it was realised that the standard 
method of preparation of the strips damaged the endothelium. When great care was 
taken to avoid damage to the endothelial surface, the preparation consistently relaxed 
(in a dose-dependent manner) to acetylcholine, and other muscarinic agonists 
(Furchgott 1993; Figure 1.7).
Figure 1.7. Loss of relaxing response of preparations of rabbit aorta to acetylcholine 
(ACh) after removal of endothelial cells by rubbing. (Furchgott 1980).
Similarly, treatment of the aortic strips with collagenase abolished the endothelium- 
dependent relaxation. Furchgott went on to perform “sandwich” experiments, in 
which a strip of aorta denuded of its endothelium was placed next to a strip with intact
BING
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endothelium, and made to relax with the addition of acetylcholine. He postulated that 
a diffusible “relaxing substance” was released from the endothelium of the second 
strip in the sandwich experiment. Subsequently, the term endothelium-derived 
relaxing factor or EDRF was coined in 1983 (Cherry 1983).
A multitude of experiments examining endothelium-dependent relaxation rapidly 
followed. Besides acetylcholine, several agents were shown to produce endothelium- 
dependent vasodilatation, including 5-HT, bradykinin, histamine, thrombin, ADP, 
substance P and vasopressin (Furchgott 1989), although there were often species 
differences and even differences in the response of vessels from different sites within 
the same species.
The evidence began to accumulate that EDRF may be nitric oxide :
■ Endothelium-dependent vasorelaxation was accompanied by a rise in cyclic GMP 
(Rapoport 1983).
■ Relaxation of vascular smooth muscle by nitro-vasodilators was accompanied by a 
rise in cyclic GMP (Gruetter 1979).
■ EDRF was inhibited by methylene blue (an inhibitor of guanylate cyclase) and by 
haemoglobin (Martin 1985).
■ Acidified solutions of sodium nitrite (releases NO and NO2) produced strong, 
transient relaxations of rabbit aorta (Furchgott 1988).
■ Superoxide anion inactivates EDRF and this effect is blocked by superoxide 
dismutase (Gryglewski 1986).
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■ The characteristics of the relaxation of rabbit aorta by acetylcholine-released 
EDRF and NaNCVreleased NO were identical : this led Furchgott and Ignarro 
(almost simultaneously) to propose that EDRF was in fact NO (Furchgott 1988; 
Ignarro 1987).
■ Moncada and Palmer finally demonstrated using chemiluminescence that the 
amount of NO released by bradykinin could fully explain the relaxation attributed 
to EDRF (Palmer 1987).
Since these early experiments much work has been performed to elucidate the biology
of NO:
i NO is a colourless, odourless, hydrophobic, free radical gas which diffuses 
freely through cell membranes.
ii NO has a half-life of 3-5 seconds (Rubanyi 1985).
iii The precursor for NO is L-arginine (Palmer 1988).
iv The production of NO is inhibited by No-monomethyl-L-arginine (L-NMMA) 
and this can be overcome by adding L-arginine (Rees 1989).
v Nitric oxide synthase (NOS), the enzyme responsible for synthesis of NO has 2 
main types : constitutive (activity expressed in the absence of external 
stimulation) and inducible. The constitutive type exists in 2 main forms : 
neuronal (nNOS; also found in kidney macula densa, pulmonary epithelium and 
skeletal muscle) and endothelial (eNOS)(Moncada 1999). The conversion of L- 
arginine to NO by eNOS is a two-step process which yields N-hydroxy-L- 
arginine as an intermediate product then NO and L-citrulline. Co-factors for 
eNOS include NADPH, tetrahydrobiopterin (BH4), flavin adenine dinucleotide
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(FAD) and flavin adenine mononucleotide (FMN). Constitutive NOS is calcium- 
dependent, whereas iNOS is not.
vi eNOS can be activated by shear stress and hypoxia, and by receptor-G protein 
coupling in response to a wide variety of agonists including 5-HT, acetylcholine, 
substance P and bradykinin (Henderson 1996). The amount of NO produced is in 
the picomolar range and takes place within seconds (Dattilo 1997).
vii iNOS is found in vascular smooth muscle, hepatocytes, neutrophils and 
macrophages. It does not produce background NO like eNOS; instead it requires 
“switching on” by endotoxin, cytokines or shear force within the vascular wall. 
Production of NO takes 4-6 hours and lasts up to 24 hours, with levels reaching 
the nanomolar range. This NOS is much more important in pathophysiologic 
states (Datillo 1997).
viii Nitric oxide produced by nNOS acts as a neuro-modulator or as a 
neurotransmitter in nitrergic nerves.
ix NO is rapidly oxidised by oxygen and superoxide anion (02’) to nitrite and 
nitrate. A modified Griess reaction is often utilised to measure nitrite as an 
indirect measure of NO production. Reaction of NO with 0 2’ also leads to 
the production of peroxynitrite, a toxic free radical, which is rapidly 
protonated and decomposes to N 0 2 and OH» , both of which are tissue- 
damaging agents (Beckman 1990).
Nitric oxide is continuously produced in endothelial cells from L-arginine by eNOS 
and diffuses readily through cells to act in the vascular compartment and on adjacent 
vascular smooth muscle cells (VSMCs). The mechanism of vasodilatation involves 
the binding of NO to the haem moiety of soluble guanylate cyclase, producing a
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conformational change in the enzyme that “pulls” the haem component away from the 
enzyme molecule and allows easier access for the substrate. Activation of guanylate 
cyclase catalyses the conversion of glutamyl 5’-triphosphate (GTP) to cyclic 
guanosine monophosphate (cGMP). Cyclic GMP has several effects that lead to 
vasorelaxation (Dattilo 1997):
(1) lowering the cytosolic calcium concentration by inhibiting calcium influx and 
promoting sequestration of calcium in sarcoplasmic reticulum.
(2) hyperpolarizing the cell membrane by increasing K+ conductance.
(3) activating protein kinases which phosphorylate myosin light chains, preventing 
the actin/myosin interaction.
NO is produced continually under resting conditions and contributes to basal vascular 
tone thus infusion of NOS inhibitors such as No-monomethyl-L-arginine (L-NMMA) 
raises blood pressure (Haynes 1993).
1.5.1.ii Endothelium-derived Hyperpolarising Factor (EDHF)
Acetylcholine was first shown to cause endothelium-dependent hyperpolarisation of 
vascular smooth muscle in 1984 (Bolton 1984). This hyperpolarisation occurs in the 
presence of indomethacin and L-NMMA, and therefore is not likely to be caused by 
prostacyclin or NO. While there are occasional membrane-membrane connections 
between endothelium and vascular smooth muscle cells, there have been several 
studies demonstrating that a diffusible substance is involved (Vanhoutte 1993). This 
substance has been termed EDHF and its identity is unknown. The release of EDHF 
by endothelial cells is calcium and calmodulin-dependent, and unlike NO, is not 
thought to contribute to resting vascular tone. In addition to acetylcholine, several
agents have been shown to stimulate EDHF release : bradykinin, histamine, ADP, 
thrombin and substance P (Vanhoutte 1993). Endothelium-derived hyperpolarising 
factor vasodilates by opening K+ channels, an effect that can be blocked in some 
vessels by ouabain. The relative contribution of NO and EDHF to endothelium- 
dependent vasodilatation is not clear.
1.5.1.iii Prostacyclin
Prostacyclin is a major product of arachidonic acid metabolism in endothelial cells 
(Moncada 1976; Figure 1.8).
Membrane Phospholipid
Phospholipase A 2
Arachidonic Acid
Cyclo-oxygen 5-Lipoxygenase
Prostaglandin 
G2 (PGG2)
5-s-hydroperoxy- 
eicosatetraenoic acid 
(15-HPETE)
Prostaglandin 
H2 (PGH2)
Leukotrieues 
LTA4 -LTF4
Prostacyclin
Synthase /  \/  \
Thromboxane
Synthase
Prostacyclin
(PGI2)
Thromboxane
A2 (TxA2)
Figure 1.8 : A simplified metabolic pathway for the conversion of arachidonic acid to 
prostacyclin and thromboxane A2.
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Prostacyclin (PGI2) is produced when the enzyme phospholipase A2 liberates 
arachidonic acid from membrane phospholipids, and this process is inhibited by 
glucocorticoids. Arachidonic acid is converted to PGG2 by cyclo-oxygenase (inhibited 
by aspirin) which in turn is converted to PGH2 and to PGI2 by prostacyclin synthase. 
The synthesis of PGI2 is continuous under resting conditions, and can be stimulated 
by shear stress (Bhagyalakshmi 1989), hypoxia and chemical stimuli such as 5-HT, 
bradykinin, thrombin, platelet-derived growth factor (PDGF), interleukin-1 and ADP 
(Epstein 1990). Prostacyclin acts as a local mediator with plasma levels below those 
required to have a systemic effect (Blair 1982). The half-life is short and the main 
metabolite ( 6-keto-prostaglandin F la) is chemically stable, biologically inactive and 
excreted in the urine.
Prostacyclin has two principal actions : vasodilatation (Moncada 1979) and inhibition 
of platelet aggregation (Moncada 1976). The mechanism underlying vasodilatation is 
activation of adenylate cyclase, causing a rise in intracellular cyclic AMP (cAMP) 
and lowering of the cytosolic calcium level (Moncada 1979). In most blood vessels 
the contribution of PGI2 to endothelium-dependent vasodilatation is negligible, and its 
effect is essentially additive to that of NO (Vanhoutte 1999). However, PGI2 is a 
potent inhibitor of platelet aggregation and adhesion, and its effects are synergistic 
with those of NO (Moncada 1979). Overall, the effects of PGI2 are anti-atherogenic. 
Not surprisingly, the ability of blood vessels to generate prostacyclin declines with 
advancing age, diabetes and in atherosclerosis (Vane 1990).
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1.5.1.iv C-type Natriuretic Peptide
C-type natriuretic peptide (CNP) is a 22-amino acid peptide which is structurally 
related to atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). CNP 
immunoreactivity has been found in endothelial cells, plasma and kidney, and this 
recently described peptide has a specific receptor , the NPR-B receptor (Chen 1998). 
In the systemic circulation CNP potently induces venodilatation with a resultant 
reduction in cardiac output and coronary artery dilatation, while its renal effects are 
minimal. The localisation of NPR-B receptors on vascular smooth muscle cells and 
CNP within endothelial cells suggests that this peptide may have a significant 
vasoregulatory role.
1.5.2 Control of Vessel Tone : Vasoconstrictors
The effects of the endothelium-derived relaxing factors are counterbalanced by the 
production of several constricting factors, some of which are cyclo-oxygenase 
dependent. The production of these factors is stimulated by increased stretch and 
pressure, and in conditions of hypoxia.
1.5.2.i Thromboxane A2 and prostaglandin H2
Soon after the discovery of EDRF came the realisation that, in certain vascular beds 
and circumstances, agonists such as acetylcholine could also stimulate endothelium- 
dependent vasoconstriction. In veins, cerebral and ophthalmic arteries, acetylcholine,
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histamine, 5-HT and arachidonic acid can stimulate endothelium-dependent 
contractions mediated by thromboxane A2 and prostaglandin H2 (Moncada 1979). 
These prostaglandins act through the thromboxane receptor on vascular smooth 
muscle cells, and their contraction is inhibited by indomethacin. In the cerebral 
circulation, a potent stimulator of endothelium-dependent contraction is rapid stretch. 
Presumably, this has a role in cerebral autoregulation, in that a rapid rise in blood 
pressure stretches the vessel and the resulting vasoconstriction reduces cerebral blood 
flow and pressure towards normal.
1.5.2.ii Superoxide anion
Superoxide anion is an oxygen-derived free radical which can be produced in 
endothelial cells in circumstances of increased oxidative stress. The first report that 
this free radical may be an endothelium-derived contracting factor came from work in 
the canine basilar artery. Katusic et al showed that contractions induced by calcium 
ionophore A23187 were effectively abolished by superoxide dismutase (Katusic 
1989). Although a clear contraction was observed, it is likely that superoxide anion 
has no direct effect on vascular smooth muscle but rather that it inactivates NO, 
reducing its effect on basal vascular tone.
1.5.2.iii Angiotensin II
As angiotensin converting enzyme (ACE) is expressed on the endothelial cell surface, 
these cells are a local source of angiotensin II, the most potent pressor agent known. 
Angiotensin II also activates ATI receptors on endothelial cells to stimulate the
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production of endothelin, another powerful vasoconstrictor. Previously it was thought 
that most of the conversion of angiotensin I to II occurred in the lungs. However, the 
so-called “tissue renin-angiotensin system” is now recognised to play a significant 
role in cardiovascular regulation.
1.5.2.iv Endothelin
The most powerful vasoconstrictor substances produced by the vascular endothelium 
are the endothelin family of peptides (Yanagisawa 1988). Three isotypes have been 
identified containing 21 amino acids : endothelin-1 (ET-1), endothelin-2 and 
endothelin-3 (Inoue 1989). Endothelin-1 is the most powerful vasoconstrictor and the 
main isotype found in blood vessels, with major expression of its precursor’s mRNA 
in endothelial cells (Inoue 1989). It is also found in kidney, CNS and cardiac tissue, 
and in smaller quantities in vascular smooth muscle cells. Endothelin-2 is produced in 
smaller amounts in endothelial cells, heart and kidney, while endothelin-3 is mainly 
found in the gut and CNS (Haynes 1998).
The precursor for ET-1, preproendothelin-1 is cleaved to form proendothelin-1, which 
in turn is cleaved to form big endothelin-1, a 38 amino acid peptide devoid of 
cardiovascular action. The active peptide, ET-1, is generated by the action of a 
metalloprotease called endothelin converting enzyme. This enzyme exists in two 
forms of which ECE-1 is physiologically active. ECE-la is the subtype responsible 
for the conversion of big endothelin-1 to ET-1 in the endothelial cell; ECE-lb is 
expressed in the cell membrane of vascular smooth muscle cells where it converts 
extracellular big ET-1 to ET-1 (Haynes 1998).
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Two endothelin receptor subtypes have been characterised. Endothelin-1 produces its 
characteristically sustained vasoconstriction by acting on the ETa receptor which is 
present on the surface of vascular smooth muscle cells and absent from the 
endothelium (Hosoda 1991). The ETb receptor is expressed mainly in endothelial 
cells where its stimulation leads to production and release of NO and prostacyclin, 
and thus is involved in a negative feedback or control mechanism. ETb receptors are 
also found in vascular smooth muscle cells where they may be involved in 
vasoconstriction (although to a lesser degree than ETa receptors)(Haynes 1995). A 
summary of the 2 receptor types is detailed in table 1.3.
Receptor ETa ETa/b ETb
Order of potency ET-1 >ET-2»ET-2 ET -1 =ET-2=ET-3
Affinity ET-l ~ 10'9 mol/1 
ET-3 ~ KT6 mol/1
ET-l ~ 10'9 mol/1 
ET-3 ~ 10'9 mol/1
Tissue Vascular smooth 
muscle
Endothelium 
Vascular smooth 
muscle
Vessel type Conduit and 
resistance
Endothelium of all 
vessels. VSMC of 
resistance and 
capacitance vessels
Action Constriction Dilatation 
(endothelium) and 
constriction 
(VSMC)
Agonists None ET-l ET-3
Sarafotoxin S6c
Prototype BQ-123 Bosentan BQ-788
antagonists TAK-044
Table 1.3 Endothelin receptors (adapted from Haynes 1998).
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Thus, the vascular endothelium orchestrates the control of vascular tone through 
production of both vasoconstrictor and vasodilator substances, the most important 
being NO and endothelin-1.
1.5.3 Regulation of vascular smooth muscle cell proliferation
In the presence of an overlying healthy, intact endothelium, vascular smooth muscle 
cells (VSMCs) remain in a relatively static state. However, when the endothelium is 
denuded in experimental animals there is a marked proliferation of medial smooth 
muscle cells to form a neointima (Clowes 1983). In cell culture, endothelial cells 
produce a number of factors which inhibit VSMC proliferation, including heparin, 
heparan sulphate and nitric oxide (Nakaki 1990). These inhibitors are counterbalanced 
by the production of various growth promoters including endothelin, transforming 
growth factor-P (TGFP; Kirschenlohr 1995), angiotensin II and platelet derived 
growth factor (PDGF). It is thought that where endothelial damage occurs, the balance 
of these endothelium-derived factors is disrupted such that promoters of VSMC 
proliferation predominate.
1.5.4 Control of endothelial permeability
One of the oldest known functions of the vascular endothelium is its ability to control 
the passage of water, solute and cells from the vascular compartment to the tissues. 
Water, ions and small molecules cross the endothelium using a small pore system, 
while larger molecules and proteins traverse the endothelial cell layer by passing 
between cells through intercellular junctions, the diameter of which is controlled by
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the junction-associated actin filament system (JAF; Bom 1998). Several substances, 
including histamine, bradykinin and platelet activating factor, stimulate contraction of 
the JAF thereby increasing the size of the intercellular gaps and thus increasing 
endothelial permeability while nitric oxide stabilises the JAF and reduces 
permeability (Bom 1998).
As part of the normal response to inflammation, leucocytes also traverse the vascular 
endothelium by passing through the intercellular junctions. Endothelial cells express 
two major groups of adhesion molecules (Springer 1990) which facilitate binding of 
leucocytes, the selectin family and members of the immunoglobulin superfamily 
including ICAM-1 and -2 (intercellular adhesion molecule) and VCAM-1 (vascular 
cell adhesion molecule). The vascular endothelium is therefore not only a simple 
physical barrier between the blood and the tissues but actively controls the passage of 
water, molecules and leucocytes by varying the expression of adhesion molecules on 
the cell surface and changing the size of intercellular pores.
1.5.5 Modulation of Thrombosis and Haemostasis
In health, there is a delicate balance between thrombosis and fibrinolysis, with the 
vascular endothelium playing a major role. Firstly, endothelial cells provide a non- 
thrombogenic surface allowing uninterrupted blood flow to the tissues. This is 
accomplished in part by expression of plasminogen-activating factor, and of 
glycosaminoglycans which inactivate Factor X and thrombin, and thrombomodulin 
which binds thrombin and converts it to a protein C activator (Pearson 1993). 
Second, endothelial cells oppose the effects of platelet-derived thromboxane A2 by the
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production of prostacyclin and NO which both vasodilate and inhibit platelet 
aggregation (Radomski 1987).
1.5.6 Tissue Growth and Repair
Vascular endothelial cells have a remarkable capacity to adjust their numbers and 
arrangement to suit local requirements, and the ability of the endothelium to extend 
and remodel its network of cells allows tissue growth and repair. Embryology 
research has shown that arteries and veins develop from small vessels comprising 
only endothelial cells and a basal lamina, with the surrounding smooth muscle and 
connective tissue being added later where required on the instruction of the 
controlling endothelial cell (Alberts 1989).
The normal lifespan of a vascular endothelial cell is 6-12 months. However, turnover 
is much higher at branchpoints of arteries where shear stress is increased. Endothelial 
cells are therefore capable of cell division and movement, and can be shown to 
proliferate and cover areas of denuded endothelium in damaged arteries and to 
migrate over the surface of synthetic grafts inserted by vascular surgeons in a process 
known as “endothelialisation” In addition to repair, endothelial cells are capable of 
creating new blood vessels. Angiogenesis is important during growth, remodelling of 
existing tissues and in repair. One of the most easily visualised examples of this is 
rubeosis iridis in diabetic retinopathy where new blood vessels grow onto the 
normally avascular surface of the cornea. In addition, through angiogenesis, 
endothelial cells are intimately involved in the growth of tumours with important
53
mediators including vascular endothelial growth factor, basic fibroblast growth factor 
and nuclear factor-KB.
1.6 ENDOTHELIAL DYSFUNCTION
A healthy vascular endothelium is essential for the maintenance of normal blood flow 
to the tissues. Endothelial dysfunction occurs in response to damaging insults to the 
endothelial cell and is usually manifest as a reduction in endothelium-dependent 
vasodilatation. Most studies suggest a reduced production and/or effect of NO, 
although production of other endothelium-dependent vasodilators may also be 
affected. Many authors have described an alteration in the balance of production of 
vasodilators and vasoconstrictors in favour of the vasoconstrictors. This “see-saw” 
effect is illustrated in Figure 1.9.
ET-l
NO ET-l
*
Normal endothelial function Endothelial dysfunction
Figure 1.9. Endothelial function and dysfunction
In addition to changes in the production of vasoactive mediators, endothelial 
dysfunction may involve altered permeability, increased expression of cell surface
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adhesion molecules and a loss of control over proliferation of underlying vascular 
smooth muscle cells. However, abnormal endothelium-dependent vasodilatation is 
more easily measured and has been documented in many different conditions 
including hypertension, diabetes mellitus, hypercholesterolaemia and in cigarette 
smoking. The clinical consequence of endothelial dysfunction is atherosclerosis.
1.7 ATHEROSCLEROSIS
Atherosclerosis, the disease process which leads to occlusive coronary, 
cerebrovascular and peripheral vascular disease, is responsible for around 50% of all 
deaths in the general population in the Western world (Ross 1993). Patients with CRF 
may have accelerated atherosclerosis, first suggested by Lindner in the 1970s, 
although the exact proportion of deaths in this group which can be directly attributed 
to atherosclerosis is unclear, as sudden (out of hospital) death is common.
1.7.1 Histology
The earliest visible lesion in the development of the atherosclerotic plaque is the fatty 
streak, a focal thickening of the vascular intima (Ross 1993). This initially represents 
a collection of lipid-laden macrophages (foam cells) and T lymphocytes within the 
intima, and then progresses to an intermediate lesion containing smooth muscle cells 
and an increased extracellular matrix. Lipid deposition can be both intra- and extra­
cellular, recent evidence suggesting that a matrix proteoglycan, biglycan, avidly binds 
lipoproteins including LDL and apolipoprotein E (O’Brien 1998). Fatty streaks are 
ubiquitous in the aorta by the early twenties; one large postmortem study of 2876 
people who died aged 15-34 of trauma showed that all had evidence of aortic fatty
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streaks (Strong 1999). Even younger children, aged 10-14, will have evidence of 
coronary artery fatty streaks in around 50% (Ross 1993).
The next step in the evolution of the atherosclerotic plaque is the development of a 
more complex lesion termed a fibrous plaque (Ross 1993). This is characterised by 
migration and proliferation of smooth muscle cells within the intima, apoptosis of 
deeper smooth muscle cells with the resulting attraction of further macrophages, and 
more lipid deposition. Gradually increasing in size, the fibrous plaque begins to 
project into the arterial lumen and impede the flow of blood to the tissues. An 
advanced lesion ensues with a thickened fibrous cap and necrotic core. Rupture of this 
fibrous cap leads to thrombosis and occlusion of the artery.
1.7.2 Pathogenesis
The pathogenesis of atherosclerosis is complex and involves various factors including 
dyslipidaemia, endothelial dysfunction and inflammation.
1.7.2.i Dyslipidaemia
There are several observations supporting the belief that lipids are intimately involved 
in the genesis of atherosclerotic plaques :
1. Histological examination of plaques reveals lipid-laden cells within the plaques.
2. Animals fed a cholesterol-rich diet develop lesions of atherosclerosis.
3. In population studies, the incidence of atherosclerosis (and its consequences) is 
linearly related to serum cholesterol levels.
4. Lipid-lowering trials have reduced the clinical sequelae of atherosclerosis.
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Low-density lipoprotein is now known to play a pivotal role in the pathogenesis of 
atherosclerosis.
• High serum LDL levels are a strong risk factor for the development of 
atherosclerosis (LaRosa 1990); high serum oxidised LDL levels are associated 
with coronary artery disease ( Holvoet 1998).
• Oxidised LDL is present in lesions of atherosclerosis in humans (Yla- 
Herttuala 1989). Oxidation of LDL can occur within any of the cells of the 
artery : endothelium, smooth muscle cells, macrophages and T-lymphocytes. 
The oxidative process involves a lysine residue of apolipoprotein B (Rosenson 
2001).
• Oxidation of LDL is required before uptake by macrophages (via scavenger 
receptors) to form foam cells (Yla-Herttuala 1989). The most important 
scavenger receptor is CD36 (Rosensen 2001)
• Radiolabelled oxidised LDL rapidly accumulates in the foam cells of 
atherosclerotic plaques (Iuliano 2000).
• Oxidised LDL can cause reduced endothelium-dependent vasodilatation 
(Anderson 1996) and reduced NO production through the inhibition of L- 
arginine uptake by the endothelial cell (Vergnani 2000).
• Oxidised LDL is chemotactic for monocytes and can up-regulate the genes for 
macrophage colony-stimulating factor and monocyte chemotactic protein 
derived from endothelial cells (Ross 1999).
• Foam cells may rupture with release of oxidised LDL, other free radicals and 
enzymes that can further damage the vessel wall (Ross 1999).
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While LDL is clearly the most important lipid involved in atherogenesis, other 
lipoproteins and triglyceride may play a role :
• Lipoprotein(a) : may be involved through inhibition of conversion of 
plasminogen to plasmin, thereby promoting thrombus formation, or though 
chemo-attraction of monocytes and promotion of monocyte binding (Rosenson 
2001).
• Triglycerides/VLDL : role uncertain as high levels usually associated with low
j
HDL levels. However, hypertriglyceridaemia is associated with 
hypercoagulability and increased blood viscosity which may promote 
atherogenesis.
• High density lipoprotein (HDL) : anti-atherogenic actions include reverse 
cholesterol transport, maintenance of endothelial function and low blood 
viscosity. Therefore, low HDL levels are associated with atherosclerosis
i
(Rosenson 2001).
i
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1.7.2.ii Endothelial Dysfunction and Atherosclerosis
An intact and healthy vascular endothelium is necessary to prevent the development 
of atherosclerosis. Many factors are known to damage the endothelial cell including 
excessive shear stress in hypertension, oxidised LDL and factors contained in 
cigarette smoke. Impaired endothelium-dependent vasodilatation has been 
documented in patients with many different risk factors for atherosclerotic vascular 
disease including diabetes mellitus, +ve family history, cigarette smoking 
hypertension, hyperhomocysteinaemia and hypercholesterolaemia. The mechanisms 
by which endothelial dysfunction promotes/is involved in atherogenesis include :
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• reduced production of NO with resultant loss of inhibitory effects on smooth 
muscle proliferation and platelet aggregation.
• enhanced endothelin-1 production plus reduced NO production will cause 
abnormal vasoconstriction.
• oxidised LDL can induce expression of cell surface adhesion molecules on 
endothelial cells (Ross 1993) with increased binding of platelets and 
monocytes; in addition, circulating levels of adhesion molecules are raised in 
acute coronary syndromes.
• damaged endothelium may be more permeable to lipoproteins, and to 
monocytes through the effects of oxidised LDL and through increased 
production and release of monocyte chemotactic protein-1, osteopontin, 
platelet-derived growth factor(PDGF) and macrophage colony stimulating 
factor (M-CSF) (Ross 1999).
• damaged endothelium may synthesize and release powerful mitogens for 
smooth muscle proliferation including fibroblast growth factor, PDGF and 
transforming growth factor p (TGF-P), as well as activating factors for 
underlying macrophages such as M-CSF, oxidised LDL and granulocyte- 
macrophage colony stimulating factor (GM-CSF) (Ross 1993).
To summarise, dysfunction of the endothelium leads to the development of 
atherosclerosis through increased stickiness for cells, influx of lipoproteins and cells 
into the intima, vasoconstriction and promotion of underlying VSMC proliferation.
I
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1.7.2.iii Inflammation and atherosclerosis
Atherosclerosis, like glomerulosclerosis, is an inflammatory process and involves 
humoral and cell-mediated pathways. Indirect evidence for the role of inflammation 
comes from the observation that C-reactive protein levels are elevated in patients with 
angina and further still in those with myocardial infarction (Anderson 1998). CRP 
also predicts vascular events in apparently healthy people and may therefore be a 
surrogate marker for atherosclerosis (Ridker 1998a).
Macrophages, platelets, endothelial cells and smooth muscle cells release a variety of 
cytokines, growth factors and inflammatory substances, all of which may play a role 
in the development of the atherosclerotic plaque. These factors include :
1. Interleukin-1 (IL-1), IL-3 and tumour necrosis factor (TNF)-a induce the 
expression of cell surface adhesion molecules and promote smooth muscle 
proliferation (Ross 1999). TNF-a also promotes macrophage differentiation 
and foam cell development, and increases endothelial permeability.
2. M-CSF and GM-CSF are produced when monocytes come into contact with 
the endothelium and promote the differentiation of monocytes into 
macrophages (Rosenson 2001)
3. Monocyte chemotactic protein-1 promotes adhesion and transgression of 
monocytes to and through the endothelium.
4. The chemokine RANTES (regulated on activation normally T-cell expressed 
and secreted) is laid down by platelets on the surface of damaged endothelial
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cells and induce “monocyte arrest” on the damaged surface (von 
Hundelshausen 2001).
5. Activated neutrophils release alpha-defensins which stimulate the binding of 
LDL to endothelial cells (Rosenson 2001).
1.7.2.iv Other factors which may play a role in the development of 
atherosclerosis
a) Angiotensin II : in addition to being a potent vasoconstrictor, 
angiotensin II may promote atherosclerosis. Macrophages in 
atherosclerotic plaques contain angiotensin II; release of this may be 
involved in regulation of VSMC proliferation and extracellular matrix 
production (Potter 1998). Interestingly, the angiotensin receptor 
antagonist losartan, when given to hypercholesterolaemic monkeys 
reduced the formation of fatty streaks by 50% through a mechanism 
that appeared to involve reduced oxidation of LDL and chemotaxis of 
monocytes (Strawn 2000). In addition, angiotensin II can inhibit NOS 
and induce oxidative stress through the activation of nicotinamide 
adenine dinucleotide oxidase (Taddei 1998). The beneficial effects of 
ACE-inhibitors will be discussed in Chapter 7.
b) Tissue factor : present in advanced plaques and directly responsible 
for activation of coagulation upon plaque rupture.
c) Endothelin-1 : oxidised LDL increases the production and release of 
ET-l from the endothelium. ET-l is both a powerful vasoconstrictor 
and VSMC mitogen.
d) Infections : infection may theoretically promote atherogenesis in two 
ways -  direct damage to the endothelium by an infectious agent such 
as a virus, or a chronic low grade systemic inflammatory response to a 
chronic infection. Some studies have shown an association between the 
severity of coronary atherosclerosis and the number of antibodies to 
different pathogens (Zhu 2000) which would back up the second 
theory. There is certainly some evidence of a link between 
atherosclerosis and Chlamydia pneumoniae, Helicobacter pylori and 
Cytomegalovirus infections, although data are often conflicting and no 
studies in humans have shown a benefit of antibiotic treatment in this 
situation (Rackley 2001).
1.7.3 Clinical Consequences
Atherosclerosis has few clinical effects in its earliest and intermediate stages. 
However, when the vessel lumen is narrowed by 70% or more, distal ischaemia 
ensues : this may present as stable exertional angina, intermittent claudication or 
occasionally, transient ischaemic attacks. Rupture of the atherosclerotic plaque often 
brings catastrophic consequences : myocardial infarction, sudden death, gangrene of 
an extremity or stroke.
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1.8 “TRADITIONAL” CARDIOVASCULAR RISK FACTORS IN CRF
1.8.1 Dyslipidaemia
The following lipid abnormalities are established risk factors for atherosclerotic 
coronary heart disease in the general population :
• Raised total serum cholesterol (Stamler 1986)
• Rasied LDL cholesterol (LaRosa 1990).
• Raised small dense LDL cholesterol (Gardner 1996).
• Low HDL cholesterol (Gordon 1977).
• Raised total/HDL cholesterol ratio (Kinosian 1994).
• Raised lipoprotein(a) (Danesh 2000).
Confusion remains over hypertriglyceridaemia : some studies show a link with CHD 
but this may be through the association of hypertriglyceridaemia with low HDL and 
raised small dense LDL ( Avins 2000).
Dyslipidaemia is common in renal disease, however the pattern varies between 
different groups of patients (Table 1.4). In contrast with the general population, 
dyslipidaemia is less clearly associated with adverse cardiovascular risk in patients 
with renal disease. In fact, one of the first studies to question the importance of 
dyslipidaemia showed an increased mortality in haemodialysis patients with low total 
serum cholesterols (Lowrie 1990). While this goes against most data from the general 
population, it does not necessarily mean that high cholesterols are good for HD
patients, nor that lowering cholesterol is dangerous, but more likely reflects
malnutrition in sicker HD patients.
In terms of dyslipidaemia predicting adverse cardiovascular outcome in renal disease
the only known associations are :
■ Increased lipoprotein(a) is associated with CV events in haemodialysis patients 
(Cressman 1992, Kronenberg 1999).
■ In diabetic patients on haemodialysis, raised total cholesterol, LDL cholesterol, 
LDL/HDL ratio and apolipoprotein B predicted cardiac death (Tschope 1993).
■ In pre-dialysis CRF with creatinine clearance between 20 and 50 ml/min/1.73m2 
BSA, the only lipid-related correlate of MI was low HDL (Jungers 1997).
■ Increased risk of MI and CV death in nephrotic syndrome (Ordonez 1993); 
although there are no prospective studies linking dyslipidaemia in nephrotics to 
increased CV risk.
■ Raised intermediate density lipoprotein (IDL) is correlated with carotid 
atherosclerosis in haemodialysis patients (Shoij 1998).
Patient Group Total chol LDL Small
dense
LDL
HDL Triglycerides Lp(a)
Nephrotic
syndrome
t t t n t I t t t
Pre-dialysis CRF -> -» t I f t t
CAPD t t t I t t
Haemodialysis -» -» t I t t t
Transplant n t -r t t
Table 1.4. Patterns of dyslipidaemia in renal disease. (Data adapted from Kasiske 
1998, Wheeler 1994, Deighan 2000).
1.8.2 Hypertension
In the general population, both systolic and diastolic hypertension are well-established 
risk factors for chronic renal failure (Klag 1996), stroke (MacMahon 1990), coronary 
heart disease (Kannel 1971) and left ventricular hypertrophy (Frohlich 1992). In the 
MRC Mild Hypertension Trial, pulse pressure was also a powerful predictor of 
coronary events (Millar 1999).
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While hypertension is an almost invariable accompaniment of CRF and is clearly 
associated with progression of CRF, the evidence linking hypertension with adverse 
cardiovascular outcome in patients with end-stage renal failure is conflicting. In fact, 
the picture is similar to that seen in hyperlipidaemia with increased mortality in 
dialysis patients with lower systolic blood pressures (Port 1999). A recent study has 
confirmed this, and has demonstrated a U-shaped curve in haemodialysis patients for 
pre-dialysis SBP (Mazzuchi 2000). It is now recognised that low blood pressure in 
haemodialysis patients is often indicative of cardiac failure. Thus, high blood pressure 
(at least post-dialysis) is likely to be a significant risk factor for adverse 
cardiovascular outcome in haemodialysis patients. To date, there is little evidence 
linking hypertension to cardiovascular events in CAPD patients (Cheigh 1999) and 
renal transplant recipients (Kasiske 1996). The prevalence and aetiology of post­
transplant hypertension will be discussed fully in chapter 4.
1.8.3 Tobacco Smoking
The American Heart Association has stated that “smoking is the single most alterable 
risk factor contributing to premature morbidity and mortality in the United States, 
accounting for more than 400,000 deaths annually” (Ockene 1997). The following 
general information is now accepted regarding the cardiovascular risks of tobacco 
smoking in the “non-renal” population :
• Smoking increases all-cause mortality by 62% and cardiovascular mortality by 
63% (Qiao 2000).
• The incidence of MI is increased 6x in women and 3x in men who smoke at 
least 20 cigarettes a day (Prescott 1998).
• Smoking doubles the risk of stroke (Kawachi 1993).
• The increased cardiovascular risk associated with smoking is worse in those 
who drink no alcohol (Foody 2001), perhaps explaining the “French paradox”.
Through its atherogenic effect, cigarette smoking is likely to play a prominent role in 
the genesis of renovascular disease and ischaemic nephropathy. In addition, newer 
data now suggest that smoking increases the chance of developing microalbuminuria 
in type 1 diabetes mellitus, increases the rate of decline of GFR in type 1 and 2 
diabetes and increases the risk of developing ESRF in a number of primary renal 
diseases (Orth 2000).
In patients with ESRF :
• Smoking increases the mortality rate in haemodialysis patients (USRDS 
2000).
• Smoking is associated with a doubling of mortality in diabetic dialysis 
patients (McMillan 1990).
• Smoking increases the risk of renal transplant loss, through death from 
cardiovascular disease with a functioning graft (Kasiske 2000).
• In our own renal transplant population, smoking was associated with a hazard 
ratio of 1.81 for survival (Woo 2002).
1.8.4 Diabetes Mellitus
Coronary heart disease, stroke and peripheral vascular disease are major causes of 
morbidity and mortality in patients with diabetes mellitus. In the Framingham Study,
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types 1 and 2 diabetes mellitus, as well as glucose intolerance, were strong 
independent risk factors for coronary death (Kannel 1979). More recently, type 2 
diabetes mellitus has been viewed as predominantly a vascular disease with patients 
exhibiting a triad of insulin resistance, dyslipidaemia and hypertension. 
Atherosclerotic vascular events are particularly common in these patients, and ESRF 
secondary to type II diabetes mellitus is becoming increasingly prevalent.
In the U.K., around 20% of patients under 65yrs of age starting dialysis have diabetic 
nephropathy, while the figure is 12% in those over 65. In the USA, 45% of prevalent 
RRT patients have diabetic nephropathy (USRDS 2000). The combination of diabetes 
mellitus and chronic renal failure confers a particularly high cardiovascular risk, and 
it is widely accepted that diabetes mellitus is an independent risk factor for 
atherosclerotic CVD in patients with CRF (Foley 1994). Data from the USRDS and 
ERA show that survival in haemodialysis patients is considerably worse in those 
patients whose primary renal disease is diabetic nephropathy (USRDS 1998; ERR 
2000), with the majority of deaths being cardiovascular. Brown et al assessed 
comparative mortality rates in haemodialysis patients in Manchester Royal Infirmary 
and showed that mortality from CVD was 10 times higher in dialysis patients 
compared to the general population and 44 times higher in those dialysis patients who 
were diabetic (Brown 1994). In the renal transplant population, Kasiske showed that 
diabetes carries a relative risk of ischaemic heart disease of 3.25 and of peripheral 
vascular disease of 28.18 (Kasiske 1996).
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1.8.5 Family History
A positive family history is a significant independent risk factor for myocardial 
infarction in the general population. The GISSI investigators showed that the relative 
risk for MI in an asymptomatic individual was 2.0 if one parent affected, 3.4 if a 
sibling affected and 20.0 if two or more relatives had an MI before the age of 50 
(Roncaglioni 1992). There are no studies to suggest that the effect of a positive family 
history would be different in those with renal disease.
1.8.6 Other “Traditional” Risk Factors in CRF
There are several other risk factors for CHD for which there is some evidence in the 
general population, but none in the CRF population. These include obesity, lack of 
physical exercise, diet deficient in fresh fruit and vegetables and abstinence from 
alcohol consumption.
1.9 “NON-TRADITIONAL” RISK FACTORS FOR CHD IN CRF
While patients with ESRF often have one or more of the risk factors detailed above, 
there are a number of less traditional risk factors for CHD in this group.
1.9.1 Anaemia
Anaemia secondary to erythropoietin deficiency almost always accompanies end- 
stage renal failure, and is clearly associated with increased morbidity and mortality in
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haemodialysis patients (Ma 1999). A considerable body of evidence now exists 
linking anaemia in CRF with cardiac structural and functional changes, most 
commonly left ventricular hypertrophy and dilatation (Parffey 1999). In the pre­
dialysis phase, the haemoglobin begins to fall when GFR is between 25 and 50 
ml/min. Levin showed that in a cohort of pre-dialysis patients, each 0.5g/dl fall in 
haemoglobin was associated with increased left ventricular growth (Levin 1999). In 
the dialysis cohort followed by Parfrey and Foley, anaemia was independently 
associated with progressive LV dilatation on echocardiography, the development of 
de novo cardiac failure and overall mortality (Foley 1996a). The mechanism linking 
anaemia to LV hypertrophy and dilatation is complex but principally involves volume 
overload - lower blood viscosity plus arterial and venous dilatation lead to reduced 
peripheral resistance and in turn, to increased venous return.
Correction of anaemia with erythropoietin has been shown in some studies to partially 
reverse left ventricular hypertrophy (Silberberg 1990). However, the target 
haemoglobin or haematocrit is a subject of debate and on-going research, one recent 
study being terminated early as the high haematocrit (Hct 42% v 30%) group had a 
slightly increased number of cardiovascular events and vascular access thromboses 
(Besarab 1998). Many believe that the problem with such trials is that we are 
intervening too late when LVH and heart failure are well-established, and that EPO 
should be used at an earlier, pre-dialysis, stage to maintain a near-normal 
haemoglobin throughout a patient’s renal life.
Are all the cardiovascular changes related to anaemia in CRF limited to the heart? 
Certainly, there is no evidence in the general or uraemic populations that anaemia
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promotes atherosclerosis. Theoretically, however, one could postulate that as 
haemoglobin “mops up” nitric oxide, then anaemia would be associated with a 
relative increase in the bioavailability of this anti-atherogenic molecule with a 
reduction in atherosclerosis. Enhanced NO bioavailability has already been postulated 
as the mechanism linking anaemia with a “hyperdynamic circulation” (Anand 1993). 
While endothelial dysfunction and atherosclerosis have not been directly linked to 
renal anaemia, arterial remodelling has. Gerard London’s group have shown that 
vessels such as the common carotid artery have an increased internal diameter and 
intima-media thickness in anaemic ESRD patients and that these measurements 
correlate inversely with haematocrit. These changes are thought to occur in response 
to increased cardiac output, blood flow and shear stress in the central arteries 
(Metivier 2000).
1.9.2 Hyperparathyroidism
In common with anaemia, secondary hyperparathyroidism is one of the hallmarks of 
chronic renal failure, driven by chronic hyperphosphataemia and hypocalcaemia. 
Elevated calcium-phosphate product plays a major role in metastatic calcification of 
organs and tissues including the blood vessels. Despite great improvements in dialysis 
adequacy and management of anaemia, nephrologists have made little impact on 
phosphate control over the last decade, and it is only recently that newer calcium-free 
and aluminium-free phosphate binders have become available. Large registry data 
demonstrate that phosphate is an important independent predictor of outcome on 
dialysis (perhaps simply reflecting dialysis adequacy). The importance of deranged 
calcium-phosphate homeostasis in the advanced atherosclerosis seen in uraemia is
demonstrated by the high calcium content of atherosclerotic plaques from patients 
with ESRF (Schwarz 2000). When the concept of accelerated atherosclerosis was first 
put forward, PTH was considered by many to be a prime candidate for the unknown 
“uraemic factor” that promoted atherosclerosis. This remains unproven, but certain 
facts are now known about hyperparathyroidism and altered calcium-phosphate 
homeostasis with regard to their adverse effects on cardiovascular function :
• As PTH is a calcium ionophore at a cellular level, chronic exposure to high 
PTH levels leads to intracellular hypercalcaemia which in turn results in 
cellular and organ dysfunction (Block 2000).
• PTH promotes cardiac interstitial fibrosis and cardiac arteriolar thickening in 
uraemic rats (Amann 1995).
• PTH may inhibit hepatic triglyceride lipase and lipoprotein lipase, causing 
hypertriglyceridaemia, raised LDL and reduced HDL levels (Block 2000).
• Raised calcium-phosphate product may lead to cardiac valve calcification and 
dysfunction (Block 2000).
• Raised PTH and calcium phosphate product is associated with vascular 
calcification. Electron-beam computed tomography detected much greater 
coronary artery calcification in haemodialysis patients compared to control, 
with the highest calcification scores in those with highest PTH values (Braun 
1996).
• In dialysis patients, elevated serum phosphate is independently associated with 
left ventricular dilatation (Block 2000), all cause mortality and cardiovascular 
mortality (Block 1998).
• Calcium-phosphate deposition within the myocardium may be associated with 
cardiac failure (Rostand 1988).
• Using high resolution ultrasound, serum phosphate and PTH levels have been 
associated with both carotid and femoral atherosclerosis (Kawagishi 1995).
Thus, there is now a body of evidence supporting a role of increased serum phosphate, 
calcium-phosphate product and PTH in the excessive cardiovascular disease burden of 
uraemic patients.
1.9.3 Hypoalbuminaemia
In Parfrey and Foley’s cohort of haemodialysis patients, falling serum albumin levels 
were highly predictive of the development of cardiac failure, ischaemic heart disease, 
cardiac mortality and overall mortality (Foley 1996b). Similarly, they found that in 
peritoneal dialysis patients, hypoalbuminaemia was associated with LV dilatation, de 
novo cardiac failure and all-cause mortality (Foley 1996b). It is unclear how one 
should interpret these data as hypoalbuminaemia is a marker for under-dialysis, 
chronic sepsis, inflammation and malnutrition, factors which in themselves may be 
related to cardiac disease. The role (if any) of hypoalbuminaemia in promoting 
atherosclerosis in CRF is unclear.
1.9.4 Oxidative Stress
Reactive oxygen species, including peroxynitrite, hydrogen peroxide (H2O2), 
superoxide (O2 ') and hydroxyl (OH*) are continuously formed in vivo by many cell
types including macrophages, endothelium and vascular smooth muscle cells. 
Production of these molecules is counterbalanced by the activity of antioxidant 
enzymes such as superoxide dismutase (SOD), catalase and glutathione peroxidase. 
Superoxide is converted to H2O2 by the activity of SOD, while in conditions of low 
SOD activity, O2 ' reacts with NO to form peroxynitrite (ONOO'). Peroxynitrite is 
relatively stable, but exists in equilibrium with its acid HOONO which rearranges to 
form nitrate and OH’ which is highly reactive. What are the consequences for 
vascular biology of accumulation of these reactive oxygen species?
• When excess O2" is produced or SOD activity is low, NO is scavenged and its 
protective, "anti-atherogenic", properties are negated.
• Reactive oxygen species are involved in the oxidation of LDL to a form that is 
toxic to endothelial cells, is more easily taken up by macrophages to form 
foam cells, and is involved in recruitment of monocytes (Becker 1997)
• Lp(a) is also oxidised to a form which is again toxic to endothelium and is 
more readily taken up by macrophages to form foam cells (Becker 1997).
Studies of the cardiovascular effects of increased oxidative stress are hampered by the 
lack of a standardised test. In the general population there is some evidence from 
large population studies that diets high in beta-carotene and vitamin E (both anti­
oxidants) may be protective against myocardial infarction (Rimm 1993). A direct 
causative effect is difficult to show however as such diets (high in fresh fruit and 
vegetables) are also associated with higher social class, increased exercise and non­
smoking. Oxidised LDL clearly plays a major role in atherogenesis, and there is 
evidence that titres of anti-oxidised LDL antibodies correlate with the risk of
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progressive atherosclerosis in non-uraemic subjects (Becker 1996). To date, no study 
has proven that oxidative stress is a major factor in the development of atherosclerotic 
vascular disease in the general population.
In CRF, the antioxidant capacity of uraemic patients is low (Westhuyzen 1995) 
perhaps reflecting depletion of antioxidants such as vitamin C and E during dialysis, 
and there is enhanced oxidation of LDL and raised anti-oxidised-LDL antibody levels, 
suggesting increased oxidative stress (Maggi 1994). A recent study has shown an 
eight-fold increase in oxidised LDL levels in uraemic patients compared to controls 
(Itabe 1996). In addition, Miyata et al have demonstrated that in uraemia there is 
accumulation of advanced glycation end products (AGE), more usually seen in 
diabetes (Miyata 1999). These AGEs are not related to hyperglycaemia, but rather 
reflect “carbonyl stress”, with accumulation of small carbonyl precursors of AGEs 
produced through oxidation of carbohydrates and lipids. The mechanisms underlying 
increased oxidative stress in uraemia remain unclear. Uraemic toxins may be 
important, as may intravenous iron, leptin, and haemodialysis, particularly using bio­
incompatible membranes, which increases the generation of oxygen free radicals 
(Westhuyzen 1995; Haklar 1995).
1.9.5 CRP and Inflammation
C-reactive protein (CRP) is a hepatic-derived acute phase protein which rises in a 
multitude of acute and chronic situations including infection, inflammation, trauma, 
infarction and some malignancies. The acute phase response is driven by cytokines 
including interleukin-6, IL-1, interferon gamma, TNF-a and TGF-p, and besides CRP
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includes serum amyloid A protein, fibrinogen, lipoprotein(a), caeruloplasmin, ferritin 
and alpha-1 antitrypsin. Recent evidence has pointed to a link between atherosclerotic 
cardiovascular disease and CRP. In healthy men and women, elevated CRP is a 
predictor for future cardiovascular events (Koenig 1999; Ridker 1998b), while in 
patients with unstable angina it predicts short- and long-term outcome (Liuzzo 1994). 
The predictive effects of CRP appear to be additive to those of established coronary 
risk factors such as increased total :HDL cholesterol ratio. Several investigators are 
cynical believing that CRP is simply a marker, for example of the size of the 
ischaemic area in unstable angina, of the effects of other risk factors such as smoking 
and dyslipidaemia or a marker of the inflammatory nature of atherosclerosis. 
Nevertheless, there are several pieces of evidence that point to a more direct 
atherogenic role for CRP :
• CRP has been found within atherosclerotic plaques (Podrid 2001).
• CRP binds to LDL and allows uptake by macrophages without the need for 
oxidation (Zwaka 2001).
• CRP induces adhesion molecule expression on endothelial cells (Pasceri 
2000).
CRP levels tend to be higher in patients with ESRF, and again, most of the studies 
with a relatively long follow-up have shown that CRP is predictive of cardiovascular 
mortality in both haemodialysis and CAPD patients (Yeun 2000). The role of CRP in 
renal transplant recipients is not yet known. Postulated reasons for elevated CRP in 
ESRF include (Yeun 2000):
• A direct inflammatory effect of uraemia.
• Bio-incompatibility of haemodialysis membranes and CAPD fluids.
• Chronic infection of vascular access.
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• Dialysis water impurities.
The evidence linking CRP with adverse cardiovascular outcome in the general and 
ESRF populations appears moderately strong, but it remains unclear if the relationship 
is causal.
1.9.6 Hyperhomocysteinaemia
Homocysteine is a sulphur-containing amino acid that is formed during the 
conversion of methionine to cysteine, and that accumulates in homocystinuria, an 
autosomal recessive condition marked by premature cardiovascular death. It was this 
observation by McCully in 1969 that led to the concept of homocysteine being 
atherogenic. Mild elevations in serum homocysteine are seen in 5-7% of the general 
population where observational studies have clearly shown an association between 
hyperhomocysteinaemia and atherosclerotic vascular disease and recurrent venous 
thromboembolism (Welch 1998, Bostom 1999a). Meta-analyses have suggested that 
the relative risk of CV events (after adjustment for standard risk factors) associated 
with a fasting tHcy of >15pmol/l is 1.4 (Bostom 1999a).
Hyperhomocysteinaemia can occur in a number of ways. Normal metabolism of this 
amino acid is by one of 2 pathways : transsulfuration to cysteine (requires vitamin B6) 
or remethylation to methionine (requires vitamin B12 and folate). Deficiencies of the 
vitamins, mutations of the enzymes involved, high methionine intake, liver disease, 
CRF and drugs may all cause elevation in plasma homocysteine (tHcy) levels (Welch
1998). The mechanism in CRF is debated : despite their being a linear inverse
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relationship between tHcy levels and GFR, tHcy excretion in urine is not thought to 
be significant in normal states (Yeun 2000). Studies now suggest that the defect in 
CRF is in the remethylation pathway (van Guldener 1999). The result is that 
hyperhomocysteinaemia (fasting tHcy >13.9 pmol/l) is around 100 times more 
common in dialysis patients and around 18 times more common in stable renal 
transplant recipients compared to matched controls without renal disease (Bostom 
1999).
In keeping with the data for the general population, hyperhomocysteinaemia has been 
independently associated with increased cardiovascular mortality in patients with 
ESRD (Bostom 1999b). The pooled data from three prospective studies (two in 
dialysis patients and one in pre-dialysis patients) reveal a relative risk of a 
cardiovascular event being 2.8 times greater in the group with the highest tertile of 
homocysteine (C.I. 1.6 to 5.0) (Bostom 1999b). Moreover, in a recent prospective 
study of 84 haemodialysis patients, hyperhomocysteinaemia was associated with 
vascular access thrombosis, with each ljumol/1 increase in fasting tHcy being 
associated with a 4% increased risk of access thrombosis (Shemin 1999).
The mechanism whereby homocysteine promotes atherosclerosis and thrombosis is 
not yet fully understood. Some authors have suggested reverse causality i.e. the 
elevated homocysteine is simply a marker of the underlying atherosclerosis. This is 
unlikely as children with homocystinuria develop atherosclerosis at an early age and 
this can be partially prevented by lowering homocysteine. Similarly, acute 
hyperhomocysteinaemia (induced by oral methionine loading) leads to impaired 
endothelium-dependent vasodilatation in otherwise healthy individuals (Chambers
1999). Several studies have now shown impaired endothelium-dependent 
vasodilatation in hyperhomocysteinaemia (Tawakol 1997; Kanani 1999; Chambers
1999) and that this is reversible with vitamin C (Chambers 1999). These data lend 
weight to the theory that homocysteine’s principal atherogenic effects are mediated 
through endothelial dysfunction with the mechanism involving increased oxidative 
stress. Additional factors may play a role :
• There is in vitro evidence that homocysteine is directly toxic to vascular 
endothelium (Blundell 1996).
• Homocysteine enhances LDL oxidation (Bostom 1999b).
• Homocystinuria is associated with increased thromboxane-mediated platelet 
aggregation (Di Minno 1993).
• Homocysteine stimulates vascular smooth muscle proliferation (Tsai 1994).
• Homocysteine enhances binding of lipoprotein(a) to fibrin (Harpel 1992).
Several studies have looked at lowering homocysteine and these will be discussed 
further in chapter 7.
1.9.7 Endogenous inhibitors of NO Synthase
The synthesis of NO by NO synthase may be competitively inhibited by naturally- 
occurring analogues of L-arginine such as N^-monomethyl-L-arginine (L-NMMA), 
symmetric dimethylarginine (SDMA) and asymmetric dimethylarginine (ADMA), 
substances derived from the breakdown of proteins containing methylated arginine 
residues. Accumulation of ADMA (either from reduced excretion &/or metabolism) 
has been shown to occur in CRF with the original paper reporting an 8-fold rise in
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plasma ADMA concentrations (to 4pmol/l) compared to healthy controls (Vallance 
1992). This group were able to demonstrate that 5pmol/l ADMA inhibited NO 
production in vitro by around 17% in a cytosolic preparation of macrophage NO 
synthase, and that ADMA vasoconstricted rat aortic rings with the EC50 for ADMA 
being 26pmol/l. They also demonstrated that infusion of ADMA in guinea pigs to 
achieve a plasma concentration of 9pmol/l raised systolic blood pressure by 15%. It 
was concluded that accumulation of ADMA in ESRF may reach physiologically 
significant levels, and that the resultant inhibition of NO production may be involved 
in the pathogenesis of hypertension and immune dysfunction associated with ESRF.
However, a subsequent paper by MacAllister et al showed that ADMA concentrations 
only rose to around 0.9 pmol/1 in 10 uraemic subjects, a 3-fold increase over control, 
and the clinical relevance of ADMA in uraemia was therefore disputed (MacAllister 
1996). More recently, however, this issue has been examined again in a larger group 
of dialysis patients. Kielstein et al found that in 43 haemodialysis patients, ADMA 
concentrations were 6.0 pmol/1 pre-dialysis, a 6-fold increase over control, while the 
concentration was normal in 37 peritoneal dialysis patients (Kielstein 1999). The 
difference related to treatment modality was thought to be a result of differential 
dialytic clearance or metabolism of ADMA. The same group also found that L- 
arginine levels were unchanged in ESRF contrary to previous reports. It should be 
noted that each of the studies reported above give different "normal" values for 
ADMA (0.3 -1.0 pmol/1), reflecting differences in assays and laboratory technique.
Raised serum dimethylarginine levels have also been reported in other conditions 
including hypercholesterolaemia, cardiac failure, peripheral vascular disease and
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essential hypertension (Cooke 2000). In these situations (and possibly also in CRF) 
accumulation of ADMA, L-NMMA and SDMA is thought to be secondary to 
dysfunction of the enzyme dimethylarginine dimethylaminohydrolase (DDAH), an 
enzyme responsible for the breakdown of ADMA to citrulline (Cooke 2000). The 
activity of the enzyme may be directly inhibited by hypercholesterolaemia, 
hyperglycaemia and oxidative stress.
Thus, accumulation of ADMA certainly occurs in renal failure, the degree varying 
considerably between studies, and also with treatment modality. Whether the levels 
reached are physiologically significant has been a matter of debate until recently, 
although the intracellular ADMA concentrations may be many fold higher than the 
measured plasma levels (MacAllister 1994). Recent publications by Zoccali have 
thrown further light onto the clinical relevance of ADMA accumulation in ESRF. In a 
cohort of 225 haemodialysis patients followed for around 3 years, ADMA levels were 
independently predictive of overall and cardiovascular mortality suggesting that 
significant inhibition of NO synthase occurs in vivo (Zoccali 2001). A further study in 
90 haemodialysis patients revealed a strong link between ADMA levels and CRP, and 
the interaction between these factors was the most important predictor of progression 
of carotid intimal lesions (Zoccali 2002). Thus ADMA may be one of the most 
important “non-traditional” risk factors for atherosclerotic vascular disease in CRF.
In summary then, CRF is associated with many risk factors for atherosclerotic 
vascular disease, some traditional, others not (Figure 1.10). Many of the risk factors 
have been directly linked to atherosclerosis or adverse cardiovascular outcome in
I
CRF. Some are associated with endothelial dysfunction and this will be discussed 
further in Chapters 3-6, and in the general discussion.
Dyslipidaemia
Smoking
Family history
Hypertension
ADMA Inflammation
Atherosclerosis in 
CRF
Uraemic factor(s)
Homocysteine
PTH/Ca/Phos
Oxidative Stress
Hypertension
Fig. 1.10 Risk factors for atherosclerosis in uraemia.
1.10 Endothelial dysfunction in renal disease : background
As uraemic patients often have several risk factors for atherosclerotic vascular 
disease, and as many of these are associated with endothelial dysfunction, one would 
expect endothelial dysfunction to be present in CRF. Several groups have looked at 
markers of endothelial function in renal failure, with the majority of work being on 
the L-arginine/NO pathway. It has been known for many years that uraemic serum
inhibits growth or is cytotoxic to cell lines in culture (Delaporte 1982; Wessel-Aas 
1981). A recent study of the effects of pooled uraemic serum on cultured human 
umbilical vein endothelial cells (HUVECs) demonstrated that while the uraemic 
serum had no appreciable effect on HUVEC cell number or viability, the cells were 
less adhesive to gelatin-coated cover-slips, and the extracellular matrix (ECM) 
generated by the HUVECs was reduced in quantity and the fibrils disorganised 
(Aznar-Salatti 1995). It was concluded that the uraemic serum adversely affects 
endothelial ECM production and attachment of the endothelial cells to the 
subendothelium. Arese et al (Arese 1995) also demonstrated that uraemic serum 
inhibits NO synthesis (iNOS) in murine macrophage and endothelial cell lines, but not 
in HUVECs. However, it is still unclear whether NO production is reduced or 
elevated in uraemia, one reason being that nitric oxide is extremely difficult to 
measure in plasma owing to its short half-life. The stable metabolites of NO, nitrite 
and nitrate, are often measured as an indirect indication of NO production, although 
these results may be confounded by nutritional status. The observation that the 
prolonged bleeding time in uraemic rats may be corrected by L-NMMA, suggests that 
NO production may be enhanced (Remuzzi 1990). Noris et al (Noris 1993) examined 
this issue in humans and demonstrated enhanced NO production by uraemic platelets 
and by HUVECs exposed to uraemic plasma. The clinical relevance of enhanced NO 
production by platelets in uraemia may be dialysis hypotension and the uraemic 
bleeding tendency. It is quite possible that while endothelial NO production is 
reduced, platelet NO production is enhanced; this would reconcile the expected 
finding of endothelial dysfunction in uraemia and the observed increased NO 
production by uraemic platelets. Many questions remain unanswered.
Some authors have shown that there are markers of endothelial damage in uraemia. 
The vascular endothelium is the main site of production of the glycoproteins, von 
Willebrand factor (vWf), and tissue-type plasminogen activator (t-PA). Levels of 
these glycoproteins have been shown to rise in uraemia (Haaber 1995, Gris 1994) and 
are thought to reflect underlying endothelial dysfunction. In addition, two groups 
(Gris 1994, Nakayama 1994) have demonstrated raised soluble thrombomodulin in 
uraemia, a further marker of endothelial injury (Kazama 1991), and a reduced ability 
of the endothelium to release t-PA upon stimulation with desmopressin, a defect 
which may reflect general endothelial dysfunction and predispose to thrombosis.
All of the above studies use surrogate markers of endothelial function. In patients with 
nephrotic range proteinuria, Stroes et al demonstrated impaired stimulated but 
preserved basal endothelial NO production (Stroes 1995a) using venous occlusion 
plethysmography, an invasive technique which allows measurement of forearm blood 
flow and the effects of endothelium-dependent and -independent vasodilators. At the 
beginning of this research project in 1996 there was little published on endothelial 
function in vivo, and in particular on endothelium-dependent vasodilatation in 
uraemia. The studies performed for this thesis were designed to examine endothelial 
function in adult patients with CRF.
1.11 Aims of this project
The principal aims of this work were :
i To establish the presence or absence of endothelial dysfunction in patients with 
CRF including renal transplant recipients.
ii To identify correlates of endothelial dysfunction.
iii By using a combination of in vitro and in vivo techniques to determine the 
influence of circulating factors on endothelial function in CRF.
Secondary aims were:
iv To examine the effects of fluid balance on endothelial function in CAPD patients 
using forearm plethysmography.
v To assess the effects of imunosuppressive drug therapy on endothelial function 
in renal transplant recipients
1.12 Hypothesis
The studies performed are designed to test the hypothesis that patients with CRF
including those on renal replacement therapy and following renal transplantation have
endothelial dysfunction and that this is due to the presence of a circulating factor that
may be unique to uraemia
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1.13 Outline of the studies contained in this thesis
Four principal studies were performed and are detailed in Chapters 3-6 :
Chapter 3 : An in vivo study of endothelial function in CRF
Chapter 4 : An in vitro study of endothelial function in CRF
Chapter 5 : A study of endothelial function and fluid balance in CAPD patients
Chapter 6 : An in vivo study of endothelial function in renal transplant recipients
Chapter 2
Materials and Methods
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2.1 Introduction
The principal techniques used for this thesis were forearm venous occlusion 
plethysmography and wire myography. Chapters 3, 4 and 5 detail the forearm 
plethysmography studies while chapter 6 focuses on wire myography. Within each 
individual chapter, a description of methods particular to that study will be given. In 
this present chapter are described the materials, apparatus, experimental technique and 
physiological basis behind each of the main techniques used in the studies.
2.2 Ethics Committee Approval
The studies contained within this thesis were approved by the West Glasgow 
Hospitals University NHS Trust Ethics Committee. All subjects gave written 
informed consent, the forms being approved by the Ethics Committee.
2.3 Forearm Venous Occlusion Plethysmography
2.3.1 Plethysmography: History
Plethysmography is the measurement of variation in the volume of a part of the body. 
Venous occlusion plethysmography, first described by Brodie and Russell in 1905 
(Brodie 1905) has become the standard method for estimating the peripheral blood 
flow of limbs in man. This technique works by temporarily arresting venous return 
(without affecting arterial inflow), with recording of the subsequent change in volume
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of the limb under study. If arterial blood pressure remains constant, then the rate of 
swelling of the forearm equates to the rate of arterial inflow (Whitney 1953).
The historical studies measured absolute changes in volume of a body part by 
enclosing the part under study in a sealed jacket filled with air or water, and 
measuring the amount of air or water displaced (Whitney 1953, Brodie 1905, Hewlett 
1909). As this method was cumbersome, Whitney devised the strain-gauge 
plethysmograph in 1949 (Whitney 1949), and this was subsequently validated in 
direct comparisons with air-filled (Eickhoff 1980) and water-filled plethysmographs 
on several occasions (Whitney 1953; Dahn 1970, Clarke 1957). With in situ electrical 
calibration (Whitney 1953), the mercury-in-rubber strain-gauge plethysmograph has 
become the preferred method for the measurement of absolute forearm blood flow. 
This technique has been widely utilised to examine the effects of particular drugs on 
blood flow, and also to investigate vascular function in a wide range of clinical 
conditions compared to control subjects. It has the advantage of allowing the study of 
vessels and their responses to pharmacological manipulation within their normal 
physiological environment. There are now over 300 human forearm strain-gauge 
plethysmography studies published.
2.3.2 Plethysmography : Principles of the technique
The underlying principle of venous occlusion plethysmography is straightforward : "if 
venous return from the arm is obstructed and arterial inflow continues unimpeded, the 
forearm swells at a rate proportional to the rate of arterial inflow" (Benjamin 1995). 
Temporary venous occlusion is achieved by inflation of a pneumatic "collecting" cuff
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placed over the upper arm. Studies by Patterson and Greenfield in the 1950s 
confirmed that inflation of a collecting cuff to sub-diastolic pressures did not affect 
arterial inflow while the forearm volume increased by up to 2% (Greenfield 1954). As 
blood flow in the hand is mainly through skin, with a high proportion of arterio­
venous shunts (Benjamin 1995), the hand is excluded from the system by inflation of 
a wrist cuff to supra-systolic pressures. Venous occlusion plethysmography therefore 
measures blood flow in the forearm alone, with 50-70% of this being through skeletal 
muscle and the remainder through skin (Cooper 1995). Forearm arterial inflow 
becomes compromised when the forearm veins are fully distended and venous 
pressure reaches 40mmHg (Wilkins 1946). To prevent this, the venous collecting cuff 
is inflated for lOsecs during each 15secs, and the forearm is placed above the level of 
the right atrium, allowing rapid emptying of the forearm veins when the cuffs are 
deflated.
The strain-gauge method devised by Whitney measures percentage change in 
circumference of the forearm. Each gauge is a fine-bore rubber/silastic tube, filled 
with mercury and attached by copper plugs to a modified Wheatstone bridge. If the 
gauge is initially slightly extended, then minor changes in the length of the gauge are 
recorded as changes in resistance of the mercury. If the forearm is considered as a 
cylinder, and the length obviously remains unaltered during a study, then the 
percentage change in volume is approximately equal to twice the percentage change 
in circumference (Whitney 1953). This percentage change in volume is simply 
expressed as a blood flow of x ml/100ml of forearm volume/time recorded.
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A sample tracing from a plethysmography study is given in Figure 2.1. One can see 
that there is a pulsatile nature to the trace corresponding to the arterial waveform, and 
that there is a 1% calibration mark, which is produced by the in-built calibration on 
the plethysmograph. The measurements are taken from the linear section of the trace 
before any flattening occurs.
Figure 2.1 A sample plethysmography trace demonstrating the pulsatile rise of the 
pen tracing in response to distension of the forearm. Flow is measured from the linear 
section of each curve.
Time
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2.3.3 Plethysmography : Equipment and Technique
All forearm studies were performed in a sealed, soundproofed, vascular research 
laboratory maintained at 24-26°C. Subjects lay supine with arms supported above 
heart level on foam blocks. Bilateral plethysmography was performed with forearm 
blood flow measurements being made in both arms simultaneously. Paediatric cuffs 
(Hokanson TMC-7, PMS Instruments, Maidenhead, England) were placed around the 
wrists, and inflated to at least 40mmHg above systolic blood pressure for three 
minutes during each recording, to exclude the hand circulation from the system. 
Collecting cuffs (Hokanson SC 10) were placed around the upper arms and inflated 
(40mmHg) and deflated in a 15 second cycle to occlude venous return and allow 
distension of the forearms. Rapid cuff inflation was achieved using a Hokanson 
AG101 air source, linked to two Hokanson E20 rapid cuff inflators.
Blood pressure was measured at the end of each blood flow recording, using a 
semiautomatic oscillometric sphygmomanometer (Critikon Dinamap Plus, Florida) 
placed around the dominant arm, over the collecting cuff. Prior to each study, the 
maximal circumference of the forearm was measured and a mercury-in-silastic strain 
gauge (Hokansen forearm set) chosen 2cm shorter than the circumference. Strain 
gauges were calibrated electrically while in position using a built-in calibration 
method.
Under local anaesthesia (1ml 1% lignocaine), a sterile 27 gauge dental needle 
(Terumo, Japan) was inserted into the brachial artery of the non-dominant forearm. 
(Many authors report the use of 18 gauge brachial artery cannulae to allow the
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continuous measurement of intra-arterial blood pressure. However, this carries a 
greater risk of damage to the brachial artery and is only useful if measurement of 
forearm vascular resistance is required. Benjamin et al (Benjamin 1995) argue that 
such readings are not helpful and ethically difficult to justify). The needle was 
connected to an IVAC infusion pump using a modified 16-gauge epidural giving set 
(Portex, Hythe, England) with the connection being sealed with dental wax. Drugs or
0.9% saline (Baxter) were infused throughout the study at lml/min. Baseline 
measurements of FBF were obtained at 10 minute intervals for 30 minutes to allow 
acclimatisation to inflation and deflation of the cuffs. The final baseline reading was 
used as the baseline FBF. The equipment and technique is illustrated in Figures 2.2- 
2.4.
2.3.4 Plethysmography : Infusion Protocols
Details of infusion protocols for individual studies are given in Chapters 3-6. In all 
cases, following insertion of the needle, 0.9% saline was infused at lml/min while 
preliminary FBF readings were measured for 30 minutes. This allowed the subject to 
become acclimatised to the vascular laboratory and the routine of cuff inflation and 
deflation.
During this initial period any problems with the needle, cuff or patient position were 
identified and rectified if possible. Following the 30-minute acclimatisation period, 
baseline readings of FBF were made. Then, drug 1 was infused in incremental doses 
with FBF recordings being made at regular intervals, followed by a washout period of
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Figure 2.2 Photograph o f the forearm plethysmography set-up. This demonstrates a 
sample tracing on the monitor, and two Hokansen transducers.
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Figure 2.3. Photograph o f a subject undergoing forearm plethysmography. This 
illustrates the upper arm and wrist cuffs, the mercury-in-silastic strain gauge in situ 
and the subject’s position.
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Figure 2.4. Photograph o f the 27g dental needle in the brachial artery and the 
mercury-in-silastic strain gauge.
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20minutes when 0.9% saline was again infused at lml/min. Further baseline readings 
of FBF were measured and drug 2 infused, again in incremental doses with regular 
FBF measurements being made at each dose level. In some studies, there was a 
further washout period followed by infusion of a third drug. A typical infusion 
protocol is illustrated in Figure 3.1.
All drugs were diluted in 0.9% saline and were supplied in syringes by our pharmacy 
sterile productions unit. For simplicity, we opted for fixed doses of drugs and details 
are given in the individual chapters. Some authors have used doses corrected for 
forearm volume and/or body mass index (BMI), thereby using a fixed concentration 
of the drug within the forearm. However, the calculations involved are cumbersome 
and Benjamin et al in their review of the technique felt that a fixed dose was more 
valid. To avoid widely differing forearm sizes between groups, we have used groups 
with a similar age and sex distribution, and similar BMIs. In addition, basal FBF was 
similar between groups in each study (widely varying basal FBF would mean 
considerable differences in drug concentration within the forearm).
2.3.5 Plethysmography : Statistical Analysis
For each dose of drug infused, several FBF measurements were made over 3 minutes. 
The mean FBF of the final five readings was used as the FBF for that drug dose. For 
each subject, dose response curves were constructed with drug dose on the X-axis and 
percentage change in FBF ratio (infused:non-infused) from baseline on the Y-axis. 
For each group, dose response curves were constructed with mean ± sem values, 
allowing easy visual comparisons. However, the best method for the comparison of
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results between groups is debated (Chin-Dusting 1999) : the most frequently utilised 
options include repeated measures analysis of variance, simple comparisons at each 
dose using t test or Mann-Whitney test or the calculation of area under the curve 
(AUC) giving a single summary measure for each subject. The calculation of EC50 
for plethysmography curves is not often used, as one would need several more drug 
doses to allow attainment of the plateau phase of the dose-response curve. Matthews 
et al suggest that area under the curve is probably the best method available for 
analysis of serial measurements (Matthews 1990). In the plethysmography studies 
comprising this thesis, a variety of statistical methods of analysis are used : details are 
given within each chapter. Statistical comparisons and graphs were performed using 
Microsoft Excel 1997 or SPSS statistical package for Windows Versions 8.0 and 9.0.
Power calculations are difficult for these studies as the expected difference is not easy 
to estimate. However, we estimated that 12 patients per group would give an 85% 
likelihood of detecting a difference at a 5% level with a 8 of 1.25. To allow analysis 
of factors that might influence endothelial responses, it was planned that 20 patients 
would be required for correlation analysis in the uraemic and transplant studies
2.3.6 Plethysmography: Reproducibility
Within individuals, changes in FBF occur in response to alterations in circulating 
hormones, sympathetic tone and time of day. Thus, changes in blood pressure, room 
temperature, light levels, noise and mental arousal may all produce large changes in 
FBF. Several factors within the methodology help reduce this variability (Benjamin 
1995; Chin-Dusting 1999):
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• Local infusion of drugs avoids changes in limb perfusion pressure. The drug 
dose required for the forearm is often 100-1000 times smaller than a 
systemically effective dose.
• Maintenance of a quiet environment at fixed temperature.
• Measurement of FBF in both limbs simultaneously and expression of the 
result as a ratio between infused:non-infused arm reduces the effect of small 
changes in systemic blood pressure and sympathetic tone.
The use of the contralateral arm as a control was first described by Greenfield and 
Patterson in 1954. Work from our own centre has subsequently shown that bilateral 
forearm plethysmography is superior to unilateral plethysmography. Petrie et al 
measured unilateral FBF and bilateral FBF ratios in 9 healthy male volunteers on 3 
separate occasions (Petrie 1998). The coefficient of variation for the unilateral FBF 
measurements was 31-39%, while the coefficient of variation for FBF ratio was 19%. 
They concluded that bilateral forearm plethysmography was more reproducible, and 
in a subsequent “simulation analysis” have shown that the difference in
reproducibility was statistically significant (Petrie 2000).
Accepting that the coefficient of variation for FBF ratio within individuals is around 
19% in our laboratory, no further reproducibility studies were performed for this 
thesis.
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2.4 Wire Myography
2.4.1 Myography: History
Prior to the 1970's, researchers in the field of vascular physiology and pharmacology 
utilised ring preparations of arteries in standard organ bath experiments. The smallest 
vessel which had been studied with these techniques was the rat tail artery. In 1972, 
Bevan & Osher described the first wire myograph, a revolutionary technique that 
allowed the mounting of 200pm arterial rings on two wires (fixed at one end) and the 
recording of isometric responses to various agonists (Bevan 1972). The problem with 
this, and other similar set-ups (Hogestatt 1983; Nielsen-Kudsk 1986), was that the 
wires had to be reasonably thick to allow isometric contraction. This necessitated the 
use of larger vessels and mounting was often traumatic with resultant vessel damage.
Mulvany took the technique one step further when he developed a wire myograph 
using finer wires that were fixed at both ends (Mulvany 1976; Mulvany 1977), and 
allowed the isometric study of vessels down to 100pm internal diameter. Using this 
technique vessel rings, approximately 2mm in length, are mounted on two 40 pm 
stainless steel wires, with one wire being connected to a force transducer and one wire 
to a micrometer. This arrangement allows the wall tension to be measured at a pre­
determined internal circumference. A diagrammatic representation is shown in Figure
2.5 with a photograph of a vessel mounted in the myograph shown in Figure 2.6.
Stainless 
Steel Wires
Myograph
Chamber
2mm
Vessel
“Jaws”
Figure 2.5 Diagrammatic representation of a myograph chamber with mounted vessel. 
The jaws are connected to the micrometer screw and a force transducer.
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Figure 2.6 Photograph o f myography chamber with mounted vessel.
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The original studies were performed on rat mesenteric resistance arteries (Mulvany 
1976; Mulvany 1977) with the first human vessels being studied in 1981 (Aalkjaer 
1981). Using wire myography it has now been possible to study human resistance 
vessels in uraemia (Aalkjaer 1986), cardiac failure (Stephens 1998), polycystic kidney 
disease (Wang 2000), essential hypertension (Aalkjaer 1987) and pre-eclampsia 
(Aalkjaer 1985).
2.4.2 Myography : Resistance Vessels
The body controls the delivery of blood to the tissues through the resistance 
vasculature. While it was originally assumed that the resistance vasculature consisted 
solely of arterioles (internal diameter < 80pm), we now know that arterioles 
contribute only around 50% of this resistance and that all small arteries with an 
internal diameter < 500pm are involved in the control of peripheral resistance 
(Mulvany 1990).
Wire myography principally looks at the function of pre-arteriolar arteries with 
internal diameters of 100-500 pm. These vessels control blood flow to the tissues 
through changes in their tone, mediated either locally (tissue metabolites, autocrine 
factors and physical stimuli) or via neurohumoral mechanisms. Physical stimuli 
involved in changes in resistance artery tone include shear stress (the force per unit 
area acting in the direction of blood flow at the endothelium, and thus endothelium- 
dependent) and increased intravascular pressure, mediated by an endothelium- 
independent stretch response and an endothelium-dependent pressure response 
(Harder 1987). Resistance arteries are exposed to circulating humoral factors
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including histamine, noradrenaline and adrenaline, endothelin, vasopressin and 
angiotensin II. The principal innervation of these arteries comes from small 
sympathetic neurones (releasing noradrenaline) and parasympathetic neurones 
(releasing acetylcholine) lying within the adventitia of the vessel.
2.4.3 Myography : Retrieval and preparation of resistance arteries
Subcutaneous fat was obtained from patients and controls undergoing abdominal 
surgery. Further details are given in Chapter 6. At the time of operation, and prior to 
the use of diathermy, an ellipse of skin approximately 2cm x 1cm with adherent fat 
was removed to a depth of 2cm following the method of Aalkjaer (Aalkjaer 1986). 
The tissue was immediately placed into chilled 0.9% sodium chloride solution and 
transported to the laboratory where it was placed into physiological salt solution 
(PSS), composition in mmol/1: NaCl 118.4, KC1 4.7, MgSC^.FkO 1.2, NaHCCb 24.9, 
CaCb 2.5, glucose 11.1 and EDTA 0.023. When aerated with a 5% COi/95% O2 
mixture, the solution had a pH of 7.4.
All dissection was carried out at room temperature in un-oxygenated PSS (Aalkjaer 
1986). The tissue was initially examined in a Petri dish containing PSS using a 
dissecting microscope (Zeiss Stemi 2000). Resistance arteries were often found just 
below the skin with visualisation being aided by pinning the tissue down onto the 
Petri dish. The vessels were carefully dissected (along with some surrounding fat) 
from the block of tissue using micro-dissecting instruments (Vicarey, Davidson & 
Co., Glasgow). Once a resistance artery was freed from the tissue, it was transferred 
to a second Petri dish containing fresh PSS, and cleaned of surrounding fat and
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connective tissue using ocular dissection scissors while taking care not to handle the 
vessel directly. The artery was then stored in a small glass vial containing PSS 
overnight in the refrigerator at 4°C after first gently removing any blood from the 
lumen by careful manipulation using forceps. Where possible, several sections of 
resistance artery were removed from each block of tissue.
All myography experiments were performed on a 4-chamber myograph (Model 600) 
obtained from Myotech, Denmark (Figure 2.7). Experiments were carried out on the 
morning following dissection as studies within our department have shown that 
vessels are viable up to 24 hours after dissection. The resistance arteries were again 
placed in a Petri dish containing PSS and where possible, 4 segments of artery 
approximately 2mm in length were identified. Forty pm stainless steel wire was cut 
into lengths of 2-3 cm. Using micro-forceps to steady the vessel, each segment of 
artery was then threaded carefully onto a piece of stainless steel wire. The wire 
myograph chambers were filled with PSS and aerated with a 95%02/5%C02 mixture. 
Each wire in turn was placed in a myograph chamber with the resistance artery 
segment between the jaws such that the wire was clamped but the vessel untouched. 
The ends of the wire were then gently placed under the fixing screws on one side of 
the myograph, the screws tightened to secure the wire and the jaws opened again. A 
second wire was then gently threaded upwards through the artery from the proximal 
end, the wire sliding under the first wire. Again the jaws were closed, this time to 
secure the second wire, which was then secured under the fixing screws on the 
opposite side of the myograph, and the jaws opened so that the vessel was very 
slightly stretched (Figure 2.6). The wires at this point were levelled so that the plane
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Figure 2.7. Photograph o f 4-chamber Mulvany-Halpem myograph. This 
demonstrates 4 individual chambers with oxygen and suction tubing, funnels to allow 
addition o f drugs and solutions, and micrometer screws.
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containing the wires was horizontal. Any part of the vessel protruding from the jaw of 
the myograph was cut away.
The length of the vessel segment was then carefully measured using a micrometer 
eyepiece (attached to the Zeiss microscope) which had previously been calibrated 
using a graticule. Using the micrometer, the wires were then moved together until just 
touching and the micrometer reading recorded at that point (xo).
2.4.4 Myography: normalisation
Mulvany’s original work on rabbit vessels led to the development of a standardised 
normalisation procedure (Mulvany 1976/1977). This is required for 3 reasons :
i the size of an elastic vessel is influenced by transmural pressure and this needs to 
be defined.
ii the active response of a vessel is dependent on the degree of stretch it is under.
iii the sensitivity of a vessel to pharmacological agents is also dependent on the 
degree of stretch it is under.
After a 30-minute acclimatisation period, the vessel was normalised at L io o - This is 
the internal circumference that the vessel would have if it were relaxed and under a 
transmural pressure of lOOmmHg (Mulvany 1976). Normalisation involves the 
stepwise stretching of the vessel with simultaneous recording of the micrometer 
reading on the myograph and the force measured by the transducer connected to the 
pen recorder (as dictated by the active tension-internal circumference relationship). 
The length of the vessel was measured using a calibrated eyepiece on the dissecting 
microscope; the wall length is equal to twice the segment length (as there is an upper
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and lower wall to the vessel). The internal circumference was calculated from the 
known diameter of the mounting wires and the distance between the 2 wires as
measured on the micrometer. The internal radius = internal circumference/271. Thus,
wall tension is the measured force divided by the vessel length, and using the law of 
Laplace:
effective pressure = wall tension/internal radius ( or P=T/R).
Using a computer programme (devised in-house), after each stepwise stretch of the 
vessel, the micrometer reading (from this was calculated the internal circumference) 
and force (from this was calculated effective pressure) were entered, subtracting xO 
from the micrometer reading with each successive stretch. The force was measured 
from the displacement of the pen on the pen recorder; this was previously calibrated 
against a force of known magnitude. The stretching was carried out at one-minute 
intervals to allow for “stress relaxation” and stopped when the effective pressure 
reached 13.3kPa (lOOmmHg). Using the computer, an exponential curve was then 
fitted to the circumference/pressure data. From this curve, the circumference 
corresponding to lOOmmHg was determined ( L io o )  and the vessel circumference set at 
90% of this value (Li), as previous work by Halpem and Mulvany has shown that the 
active force generated by the vessel is maximal at this internal circumference 
(Aalkjaer 1986). The aim was to study arteries in the range of Ll=250-300 um, but 
they were not discarded unless LI was greater than 500um.
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2.4.5 Myography : ’’wake up” protocol
Following normalisation, the arteries were exposed twice to KPSS (PSS with KC1 
substituted for NaCl on an equimolar basis) and once to noradrenaline 10 pmol/1 as a 
"wake up" procedure (Aalkjaer 1981). The myograph chambers were carefully rinsed 
with PSS between each contraction. After a plateau had been reached with 
noradrenaline, 3 pmol/1 acetylcholine was added to assess endothelium-dependent 
vasodilatation and thus the presence of an intact endothelium. Vessels which failed to 
contract to KPSS or noradrenaline, or which failed to relax >50% to acetylcholine 
were discarded. Occasionally, if time and vessels permitted, it was possible at this 
point to mount a replacement resistance vessel.
Following the wake-up procedure, the myograph chambers were rinsed out several 
times with fresh PSS. The vessels were allowed to "rest" for 60 minutes prior to the 
commencement of the drug protocols : these are detailed in Chapter 6.
2.4.6 Myography : Evidence for the viability of mounted vessels
i
From the early work of Mulvany and Halpem there have been several observations 
that suggest that the mounted vessels are indeed viable :
1. The pressure response of vessels from normotensive individuals is > 20 kPa : at 
; least twice the pressure achieved in these vessels in vivo (Halpem 1978).
■ 2. The contractile response of the vessels correlates roughly with the amount of
smooth muscle present in the arterial wall (Halpem 1978).
i
i
i
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3. The cell membrane potential and sodium efflux rate of rat mesenteric vessels 
mounted in the myograph are similar to values obtained from larger vascular 
smooth muscle preparations (Mulvany 1996).
4. Similar agonist threshold concentrations are found for vessels mounted in the 
myograph compared to those in perfusion experiments (Mulvany 1996).
2.4.7 Myography : Measurement of responses
The response of a vessel to an agonist is presented as an increase in active effective 
pressure from baseline (AP). To calculate this it is first necessary to measure the 
resting force ( F r e s t i n g )  and the force achieved with the agonist ( F a g 0 n i s t ) :
Fresting alpha x (readingrestmg - readingbaseiine)
Fagonist alpha x (readingagonist - readingbaseiine) 
where alpha is the force transducer calibration and reading is the reading on the pen 
recorder.
The increase in force (A F) is Fagonist - Frestmg which is therefore alpha x (readingagonist - 
readingresting)-
The increase in wall tension (AT) is thus :
AT = AF/vessel length 
Using the Law of LaPlace, the increase in active effective pressure is thus :
AP =  A T /(L i/2 )
110
Responses for the vasodilators (acetylcholine and SNP) were calculated in a similar 
manner with the baseline being taken as the pre-constricted force after addition of 
noradrenaline, and the change in pressure calculated as above.
2.4.8 Myography : Data presentation & statistical analysis
Concentration-response curves were constructed for each drug with response on the y 
axis being denoted as AP. Where a complete concentration-response curve was not 
possible for technical reasons, then the data for that vessel were discarded.
For each agonist, responses were measured as detailed above. Agonist potency was 
expressed as the maximum response obtained and EC50 value, that being the 
concentration required to produce 50% of the maximum response. For the 
vasodilators, EC50 values were calculated and potency was also expressed as 
maximum % relaxation from baseline. Comparison between groups was by Mann- 
Whitney U test with significance defined at the 5% level. Graphs were produced using 
GraphPad Prism v2.01, and statistical analyses were performed with SPSS for 
Windows v7.5.
2.4.9 Myography : Cleaning, calibration and maintenance of myograph
The myograph was calibrated on a regular basis using Mulvany's method (Mulvany 
1996), and maintained by technical staff from the University of Glasgow Department 
of Physiology. Cleaning was performed after every protocol using 8% acetic acid to 
remove calcium deposits and deionised water to rinse thoroughly.
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Chapter 3
An in vivo study of endothelial function in uraemia
3.1 INTRODUCTION
I have already outlined the burden of cardiovascular morbidity and mortality in 
uraemia in Chapter 1. Patients with CRF have many traditional risk factors for 
atherosclerotic cardiovascular disease and many “newer” risk factors, some specific to 
uraemia. Endothelial dysfunction is a key initial event in the development of 
atherosclerosis, and has been demonstrated in several of the cardiovascular risk 
factors detailed in chapter 1. It would seem logical that uraemia would be 
characterised by endothelial dysfunction, perhaps severe, reflecting the number of 
cardiovascular risk factors present. At the inception of this project there were no 
published data using forearm plethysmography in this group, although some studies 
had shown that there were circulating markers of endothelial damage in uraemia.
This study was therefore designed to examine endothelium-dependent and 
independent vasodilatation in adult uraemic patients compared to controls using 
bilateral forearm strain-gauge plethysmography. The initial plan was to examine 3 
groups : pre-dialysis patients with advanced CRF, patients on continuous ambulatory 
peritoneal dialysis (CAPD) and controls. However, as recruitment proved difficult, 
the first two groups were combined to create a “uraemic group”.
3.2 METHODS
3.2.1 Subjects
Patients with advanced renal failure (median creatinine 786jumol/l) were recruited 
from the pre-dialysis (n=10) and CAPD (n=6) clinics at the Western Infirmary,
Glasgow. The recruitment process was random; one investigator (SM) attended the 
above clinics whenever possible for 1 year and asked all suitable patients if they were 
willing to participate. In addition to the 16 patients for whom entire studies were 
performed, another 10 patients attended but the studies were abandoned owing to 
problems including : need for micturition during study, inability to lie still for 2 hours 
and movement causing dislodgment of the brachial artery cannula (if the cannula was 
not easily re-manipulated back into position, the study was abandoned). Controls 
without renal disease were obtained from hospital staff and by advertisement within 
the hospital and University grounds. Those obtained by advertisement were paid £50 
to cover expenses and time away from work. All subjects gave written informed 
consent, and the protocol (including re-imbursement of controls) was approved by the 
local ethics committee.
The patient and control groups were comparable for age, sex and body mass index, 
and had similar smoking habits and total serum cholesterols. Background 
characteristics for patients and controls are detailed in Table 3.1. The primary renal 
disease was : unknown (2), chronic glomerulonephritis (6), adult polycystic kidney 
disease (2), reflux/chronic pyelonephritis (4), calculi (1) and medullary cystic disease 
(1). Patients were excluded i f :
• they were anticoagulated
• had diabetes mellitus
• had a systemic vasculitis
• were taking statins or ACE inhibitors
• were taking anti-anginal medication
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Patients were also excluded if they had severe hypertension such that anti- 
hypertensive drugs could not be withheld prior to the study, or if they had previously 
been treated by haemodialysis and had functioning AV fistulae. For those patients on 
CAPD the median (range) time on dialysis was 11.5 (7,32) months. Nine of the 16 
patients were taking anti-hypertensive drugs : 7 were taking a calcium channel 
blocker, 6 were taking a P-blocker and one patient was on doxazosin. No patients or 
controls were taking aspirin.
CONTROL URAEMIC p value
number 18 16 -
male 14 11 >0.5
smoker (no.) 9 5 >0.2
age (years) 38(25,51) 40 (21,59) 0.463
creatinine (jnmol/1) 84 (57,108) 786 (380,1197) <0.001
glucose (mmol/1) 4.8 (3.9,5.6) 4.7 (3.8,5.7) 0.551
cholesterol (mmol/1) 5.2 (3.1,7.0) 5.0 (2.8,8.8) 0.984
triglyceride (mmol/1) 0.9 (0.4,3.1) 1.8 (0.6,3.9) 0.005
haemoglobin (g/dL) 14.2(12.4,15.6) 10.5 (8.9,15.8) <0.001
S.B.P. (mmHg) 123 (104,158) 140(106,197) 0.007
D.B.P. (mmHg) 67 (50,78) 78 (62,101) 0.001
F.B.F. (ml 100ml'1) 2.85 (1.55,5.14) 3.52(1.85,8.22) 0.081
Body mass index 24.2 (22.0,34.7) 25.2 (19.9,32.5) 0.597
Table 3.1 Background characteristics for uraemic patients and controls.
Results are expressed as median (range). Comparison is by Mann-Whitney or Chi- 
Square test.
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All subjects were studied in the morning after an overnight fast, and were asked to 
omit anti-hypertensive medication for at least 48 hours before the study. Subjects 
were asked to avoid caffeine and alcohol, and to refrain from smoking, for at least 12 
hours prior to the study.
3.2.2 Blood Sampling
Prior to application of the plethysmography cuffs, 30 ml of venous blood was drawn 
and analysed in our hospital biochemistry and haematology laboratories (using 
standard analysers) for electrolytes, cholesterol, urea, creatinine, glucose and 
haemoglobin. A further sample of fasting blood was centrifuged and frozen within 20 
minutes of collection to -70°C. Plasma total homocysteine was measured by ion- 
paired, reverse-phase high performance liquid chromatography with electrochemical 
detection (Martin 1998).
3.2.3 Drugs and solutions
Throughout each plethysmography session, 0.9% sodium chloride solution (Baxter, 
U.K.) or drug solutions were infused at lml/min. The following drugs (supplier) were 
stored and diluted to the appropriate concentration by the sterile pharmacy production 
unit at the Western Infirmary, Glasgow : sodium nitroprusside (Faulding DBL, 
England), carbachol (Martindale Pharmaceuticals, England) and L-NMMA (ICN, 
England).
Sodium nitroprusside was chosen as the endothelium-dependent vasodilator as it is a 
readily available NO donor. Carbachol is a muscarinic agonist and was chosen as the 
endothelium-dependent vasodilator as it is more stable than acetylcholine and is not 
broken down by cholinesterase. There is a significant degree of inter-individual 
variation in the degree and rate of metabolism of acetylcholine by cholinesterase. The 
NO synthase inhibitor, L-NMMA, was chosen to assess basal NO production as 
previously published forearm plethysmography studies had used this agent (Calver
1992).
3.2.4 Plethysmography : Infusion protocol
All forearm studies were performed in a sealed, sound-proofed, vascular research 
laboratory maintained at 24-26°C following the method of Petrie (Petrie 1998). 
Details of the set-up are given in Chapter 2. Baseline measurements of FBF were 
obtained at 10 minute intervals for 30 minutes to allow acclimatisation to inflation 
and deflation of the cuffs. The final baseline reading was used as the baseline FBF.
After an acclimatisation period of 30 minutes with infusion of 0.9% saline, 
incremental infusions of carbachol (0.1, 0.3, 1.0, 3.0 pg/min) and sodium 
nitroprusside (0.3, 1.0, 3.0, 10.0 pg/min) were commenced. There was a 30 minute 
washout period with 0.9% saline between drug infusions and the order of drugs 
infused was randomised between subjects in blocks of ten. The protocol is illustrated 
in Figure 3.1. If subjects could tolerate the extra time required then after a further 30 
minutes washout, a single dose of L-NMMA (8pmol/min) was infused. All drug
solutions were prepared in 0.9% saline in the sterile pharmacy productions unit in the 
hospital. Each drug was infused for 7 minutes with FBF measurements taken from 
minutes 3-6, and blood pressure recorded in the seventh minute. During each drug 
infusion, several FBF measurements were made; the mean of the final five readings 
was taken as the FBF achieved for each dose of drug.
3.2.5 Statistical analysis
Results are expressed as median (range) unless otherwise specified. For each dose 
response curve, area under the curve (AUC) was calculated using the trapezoid rule 
(Matthews 1990). Comparison between groups is by Mann-Whitney test with 
statistical significance defined at the 5% level.
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3.3 RESULTS
The two groups had a similar age and sex distribution, and there were a similar 
number of cigarette smokers in each group (Table 3.1). Total serum cholesterol was 
similar in patients and controls, although the fasting serum triglyceride level was 
significantly greater in patients. Both systolic and diastolic blood pressure were higher 
in uraemic patients, and the uraemic patients had lower haemoglobin concentrations, 
as would be expected.
3.3.1 Effect of infusion of carbachol and SNP in all subjects
Overall there was no difference in response of the two groups to infusion of carbachol 
or SNP. Infusion of carbachol resulted in a (median(range)) AUC for “uraemics” of 
487.9 (150.8,1180.3) compared to 598.4 (191.5,1576.6) for controls, p=0.463 (Figure 
3.2). Infusion of SNP resulted in an AUC of 1867.4 (216.6,3521.4) for “uraemics” 
compared to 1734.6 (857.8,4717.1) for controls, p=0.986 (Figure 3.3). However, 
when performing the studies it became clear that there was a drug order effect which 
was introducing error. Despite a 30 minute wash-out period, infusion of SNP as the 
first drug appeared to have an unusually prolonged effect, such that the second 
baseline was rarely equivalent to the first. The infusion of SNP as the first drug 
therefore blunted the subsequent response to carbachol. This is illustrated in Figure 
3.4, where patients and controls combined as a group are split into those who received 
carbachol as the first or second drug. It can clearly be seen that the response to 
carbachol is markedly attenuated if it is infused after SNP.
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Figure 3.2 Dose response curves for infusion o f carbachol in all patients. Results are 
expressed as mean±sem. There was no significant difference for AUC between groups 
by Mann-Whitney test.
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Figure 3.3 Dose response curves for SNP in all patients. Results are expressed as 
mean±sem. There was no significant difference for AUC between groups by Mann- 
Whitney test.
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— •— Carbachol infused first SNP infused first
Figure 3.4 Dose-response curves for infusion o f carbachol in all subjects, divided into 
those who received carbachol as first drug infused and those who received carbachol 
second, after infusion o f SNP. Results expressed as m eants.e.m . with comparison o f 
AUC by Mann-Whitney test.
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3.3.2 Effect of infusion of carbachol and SNP in subgroup of subjects in whom 
SNP was infused last
When those patients (n=10) and controls (n=T0) who received carbachol first 
followed by SNP are examined as a subgroup, results are clearly different. The 
background characteristics of this subgroup are detailed in Table 3.2; patients and 
controls are again matched for age, sex, smoking habits and serum cholesterol.
CONTROL URAEMIC p value
number 10 10 -
male 6 8 >0.2
smoker (no.) 6 4 >0.2
age (years) 38 (25,50) 40 (21,59) 0.684
creatinine (jnmol/1) 80 (57,101) 821 (525,1197) <0.001
glucose (mmol/1) 4.9 (4.4,5.6) 5.0 (4.0,5.7) 0.905
cholesterol (mmol/1) 4.7 (3.5,6.6) 4.7 (2.8,8.8) 0.863
triglyceride (mmol/1) 1.1 (0.3,3.1) 1.9 (0.6,3.9) 0.190
haemoglobin (g/dL) 14.2(12.4,15.6) 10.1(8.9,12.5) <0.001
S.B.P. (mmHg) 114(104,140) 140(113,168) 0.013
D.B.P. (mmHg) 65 (50,75) 81 (62,101) 0.006
Body mass index 24.1 (22.8,34.7) 23.5 (19.9,32.0) 0.353
F.B.F. (ml 100ml'1) 2.74(1.68,4.98) 3.15 (1.85,8.22) 0.315
Table 3.2. Background characteristics for subgroup of uraemic patients and controls 
in whom SNP was infused last. Results are expressed as median (range). Comparison 
is by Mann-Whitney or Chi-Square test.
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The response to infusion of carbachol is depicted in Figure 3.5 and to SNP in Figure 
3.6. The AUC for carbachol was significantly reduced in uraemic patients (529.0 
(150.9,834.7)) compared to controls (703.9 (583.5,1576.6); p=0.028), while the AUC 
for SNP did not differ significantly between uraemics (1328.1 (216.6,3311.4)) and 
controls (1475.0 (857.8,4717.1); p=0.545).
Were responses different between pre-dialysis and CAPD patients?
Owing to difficulties recruiting patients for this study, there were insufficient numbers 
to formally compare responses between the 2 uraemic groups. Figures 3.7 and 3.8 
show the dose response curves for carbachol and SNP respectively, splitting the 
uraemic group into pre-dialysis and CAPD. Statistical comparison was not performed 
as the numbers were small. Similarly, I did not examine the order effect in the CAPD 
and pre-dialysis groups as the numbers were small.
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Figure 3.5 Dose response curves for infusion o f carbachol in the subgroup o f  20 
subjects who received carbachol followed by SNP. Results are mean±sem, and 
comparison o f AUC between groups is by Mann-Whitney test.
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Figure 3.6 Dose response curves for infusion o f SNP in the subgroup o f 20 subjects 
who received carbachol followed by SNP. Results are m eanisem  and comparison o f 
AUC by Mann-Whitney test was not significant.
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Figure 3.7 Dose response curves for carbachol in all subjects with uraemic group 
split into pre-dialysis and CAPD. Results are mean±sem.
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Figure 3.8 Dose response curves for SNP in all subjects with uraemic group split into 
pre-dialysis and CAPD. Results are mean±sem.
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3.3.3 Blood pressure
As the doses of drugs were chosen to act only on the forearm, blood pressure did not 
change significantly throughout the studies (Tables 3.3 and 3.4) except for a small 
decrease in DBP after infusion of SNP in controls.
There was no significant difference in response to carbachol or SNP between those 
subjects taking calcium antagonists and those who were not.
Before Carbachol After Carbachol p value
SBP control 116.7±11.7 120.3±16.6 0.057
DBP control 64.8±8.7 63.7±8.7 0.503
SBP uraemic 149.1±23.6 149.7±26.5 0.860
DBP uraemic 83.1±14.8 81.6±15.8 0.309
Table 3.3 Blood pressure values before and after infusion of carbachol. Results are 
expressed as mean±s.d., with comparison by paired t test.
Before SNP After SNP p value
SBP control 121.3±13.3 120.1±15.0 0.529
DBP control 66.8±8.6 64.8±7.3 0.033
SBP uraemic 149.6±27.0 150.3±22.7 0.785
DBP uraemic 82.4±16.3 81.4±15.5 0.648
Table 3.4 Blood pressure values before and after infusion of SNP. Results are 
expressed as mean±s.d., with comparison by paired t test.
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3.3.4 Homocysteine
Median (range) fasting total homocysteine (tHcy) levels were considerably higher in 
uraemic patients compared to controls : 28.4 jumol/1 (17.8,90.5) v 10.5 pmol/1 
(6.9,35.3), p<0.001, in keeping with other published work for this group. Previous 
studies have suggested an upper limit of normal for homocysteine in the general 
population of around 13.9 jumol/1 (Bostom 1999); all of our uraemic group therefore 
had hyperhomocysteinaemia, compared to 4 of our control group.
3.3.5 Factors correlating with responses to carbachol and SNP
To assess whether the response to carbachol or SNP was associated with any 
particular variable from the background characteristics or laboratory data a further 
correlation analysis was performed using the results of those 20 subjects who received 
carbachol first followed by SNP.
Bivariate Spearmann correlation coefficients were calculated for AUC carbachol, 
AUC SNP, haemoglobin, SBP, DBP, homocysteine, smoking status, age, cholesterol 
and triglyceride.
The only significant correlation was between AUC carbachol and triglyceride 
concentration : Spearmann’s correlation coefficient -0.572, p=0.013. While this may 
be a spurious result in view of small numbers, it suggests a poorer endothelial 
response with higher triglyceride levels. In particular, there was no relationship 
between SBP, DBP, homocysteine or cholesterol and endothelial responses, perhaps 
reflecting small numbers.
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3.3.6 Responses to L-NMMA 8pmoI/l
Following the concentration-response curves for carbachol and SNP, a single dose o f 
L-NMMA 8pmol/l was infused after a washout period o f 20minutes. Three controls 
and 2 uraemic patients were unable to tolerate the extra time required to complete this 
section o f the protocol, therefore data are available for 15 controls and 14 controls.
Results are depicted in Figure 3.9.
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Figure 3.9 Stem and leaf plots for response to L-NMMA 8pmol/l in controls and 
uraemic patients. The response is measured as % change FBF ratio from baseline. The 
plots show median, range and inter-quartile range, with outlying values. p=0.78 by 
Mann-Whitney U test.
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There was no significant difference in median (range) % change FBF ratio between 
controls [-38.1 (-60.2,-4.5)] and uraemic patients [ -34.0 (-60.9,-2.5)]; p=0.78. In 
addition, no significant correlation was found between the response to L-NMMA and 
background laboratory or blood pressure data, or indeed with responses to carbachol.
3.4 DISCUSSION
3.4.1 Results of these studies
The vascular endothelium provides a strategic barrier between the circulating blood 
and the tissues. Endothelial dysfunction is thought to be a key initial event in the 
development of atherosclerosis, principally through a loss or reduction in effect of the 
anti-atherogenic molecule nitric oxide. This study was designed to examine 
endothelium-dependent vasodilatation, and thus stimulated NO production, in adult 
patients with advanced uraemia.
Results from all subjects demonstrated similar vasodilatation to both carbachol 
(endothelium-dependent vasodilator) and SNP (endothelium-independent vasodilator) 
in both uraemic patients and controls without renal disease. However, the infusion of 
SNP first appeared to blunt the subsequent response to carbachol, perhaps owing to a 
more prolonged effect of SNP. This feature has not previously been described in 
plethysmography (although has been commented upon by other local workers in the 
field), and is important when planning future studies. We therefore excluded those 
patients and controls who received SNP first from subsequent analysis. This left ten
patients and controls in whom carbachol was infused first followed by SNP, and these 
groups were again comparable in age, sex, cholesterol and smoking habits. In this 
substudy the pattern of normal vasodilatation to SNP but impaired vasodilatation to 
carbachol indicates endothelial dysfunction. The main defect is likely to be a reduced 
ability of the endothelium in the uraemic group to produce and release NO on 
stimulation, but defects in the production and release of other endothelium-dependent 
vasodilators may also play a role.
To assess basal NO production, a single dose of L-NMMA 8pmol/l was infused at the 
end of the protocol. This vasoconstricted all subjects, reducing FBF ratio to a similar 
degree in both uraemic and control groups. While this does suggest that basal NO 
production is unaltered in uraemia, most subjects found the long protocol difficult and 
therefore other factors may be playing a role 2 hours into each study such as increased 
sympathetic tone. In addition, a control vasoconstrictor was not used owing to time 
constraints. Thus, in order to accurately assess basal NO production in CRF, a further 
study is required to construct dose-response curves to L-NMMA with noradrenaline 
as a control vasoconstrictor.
A similar pattern of endothelial dysfunction has previously been described in 
hypercholesterolaemia (Stroes 1995), smoking (Celermajer 1993), types 1 and 2 
diabetes mellitus (Johnstone 1993, Williams 1996) and with normal aging (Gerhard
1996) and is thought to predispose to the development of atherosclerosis. In our study, 
diabetics were excluded and patients had similar ages, smoking habits and serum 
cholesterol levels to controls. However, blood pressure was significantly higher in the
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uraemic patients as would be expected, although the median blood pressure in this 
group was only 140/81.
It is widely believed that hypertension is associated with endothelial dysfunction, 
although two early forearm plethysmography studies in this field gave conflicting 
results. Panza et al (Panza 1990) examined the response to intra-brachial infusion of 
acetylcholine and SNP in 18 hypertensive patients (mean age 50.7yrs) who had been 
treated with anti-hypertensive agents for at least 5 years, and 18 controls of a similar 
age with normal blood pressure. Mean arterial pressure was 117 in the hypertensive 
group. This study showed that while responses to SNP were similar between groups, 
there was a large, statistically significant, reduction in the vasodilatation produced by 
the highest dose of acetylcholine. They concluded that the pattern was in keeping with 
endothelial dysfunction in essential hypertension.
Four years later, Cockcroft’s group in London published a similar study : they 
compared the responses to intra-brachial acetylcholine, carbachol and SNP in 58 
patients with essential hypertension (MAP 114) and 37 normotensive controls 
(Cockcroft 1994). An initial study examined untreated hypertensives and a follow-on 
study looked at both treated and untreated hypertensives. Surprisingly, there were no 
differences between groups for the vasodilatation produced by these agents and they 
concluded that essential hypertension was not characterised by endothelial 
dysfunction. Key differences between Panza and Cockcroft’s studies were :
• the patients in Cockcroft’s study had newly diagnosed hypertension
• the patients in Cockcroft’s study were untreated hypertensives
• the patients in Cockcroft’s study were younger (mean age 41yrs)
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• lower doses of acetylcholine were used by Cockcroft
• the patients in Cockcroft’s study were heavier and had slightly higher BMIs 
than the controls (effectively meaning a slightly lower dose of drug per kg or 
unit of forearm volume). In Panza’s study, patients were lighter. However, 
none of these differences were statistically significant and their influence on 
the results is unclear
The two groups were unable to reconcile their differing results but it was suggested 
that the above factors might have been involved i.e. that Cockcroft’s study population 
was different.
However, there is now a large body of evidence, both in vivo and in vitro, supporting 
the results obtained by Panza et al and it is generally accepted that endothelium- 
dependent vasodilatation is impaired in essential hypertension (Taddei 1998, Ferro 
1997). Furthermore, studies have shown that basal NO production in essential 
hypertension is reduced (Calver 1992, Forte 1997). The mechanism underlying 
impaired endothelium-dependent vasodilatation in hypertension is sensitive to 
inhibition by indomethacin but not affected by L-arginine or L-NMMA. Thus, current 
opinion suggests that hypertension is characterised by over-production of oxygen- 
derived free radicals (which mop up NO) and/or endothelium-derived 
vasoconstricting prostanoids (Taddei 1998).
The predisposition to endothelial dysfunction in hypertension is at least partly 
genetically determined, as impaired endothelium-dependent vasodilatation has been 
demonstrated in normotensive children of hypertensive adults (Taddei 1992). That 
essential hypertension is not entirely attributable to endothelial dysfunction is
supported by the observations that endothelial dysfunction occurs in secondary forms 
of hypertension, and that endothelial dysfunction improves with anti-hypertensive 
treatment.
Unfortunately, we were unable in this present study to match patients and controls for 
blood pressure, and further larger studies are warranted to compare endothelial 
function in uraemic and essential hypertensive patients.
Our patient and control groups also differed with respect to triglyceride and 
haemoglobin levels. Hypertriglyceridaemia, while being an independent 
cardiovascular risk factor, is not thought to adversely affect endothelial function 
(Chowienczyk 1997). In contrast, as NO binds to the haem moiety of haemoglobin, 
changes in haemoglobin concentration would be expected to affect the response to 
endothelium-dependent vasodilators. Indeed, enhanced bioavailability of NO as a 
result of anaemia has been postulated as the mechanism underlying the hyperdynamic 
circulation seen with anaemia (Anand 1993), and recent animal work has 
demonstrated upregulation of NOS in iron-deficient rats (Ni 1997). In our study the 
uraemic patients had lower haemoglobin concentrations and would therefore be 
expected to have an exaggerated response to carbachol as NO would theoretically 
have a longer half-life. This was not seen, and the effects of anaemia on endothelial 
function in this situation are therefore not clear.
The pattern of endothelial dysfunction demonstrated by this technique in uraemic 
patients may reflect a direct inhibitory effect of circulating factors such as ADMA on 
NO synthase, supporting the findings of Zoccali that ADMA levels are correlated
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with cardiovascular outcomes (Zoccali 2001). It is also possible that the impaired 
endothelium-dependent vasodilatation is secondary to the damaging effects of 
increased oxidative stress in keeping with recently published data linking oxidative 
stress and endothelial function in uraemia (Annuk 2001a).
Another potential atherogenic ’’uraemic factor’’ may be homocysteine. 
Hyperhomocysteinaemia is associated with increased cardiovascular mortality in the 
general and CRF populations, and hyperhomocysteinaemia has been linked to 
impaired endothelium-dependent vasodilatation in uraemic (van Guldener 1998) and 
general populations (Tawakol 1997). Given that there is a close correlation between 
serum creatinine and homocysteine level, it would be extremely difficult, if not 
impossible, to perform a plethysmography study examining endothelial function in 
uraemia and controlling for all the other associated risk factors, and in particular, 
controlling for homocysteine. In this study there appeared to be no correlation 
between drug responses and homocysteine levels.
3.4.2 Other studies of endothelial function in uraemia
There are now a number of published studies looking at endothelial function in 
chronic renal disease. They fall into several broad groups :
a) Studies examining NO production/excretion
b) Studies measuring circulating markers of endothelial dysfunction
c) Cell culture studies with uraemic serum
d) Studies examining vascular reactivity in CRF
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I will briefly outline the findings of studies in the first 3 groups and then discuss in 
more detail the results of studies examining vascular reactivity, most of which are 
recent in vivo studies.
3.4.2.i Studies examining NO production/excretion in uraemia
• Remuzzi first showed in 1990 that the bleeding tendency of uraemic rats was 
reversed by L-NMMA suggesting that over-production of NO was responsible 
for the uraemic bleeding tendency (Remuzzi 1990).
• In 1993, Noris et al demonstrated that platelets from uraemic patients
produced more NO than platelets from controls, and that uraemic plasma
induced NO synthesis in cultured human endothelial cells (HLTVECs) (Noris
1993).
• In 1997, Remuzzi’s group again examined this issue. In rats undergoing
extensive renal mass reduction (RMR), urinary nitrite/nitrate excretion was
reduced, indirectly indicating reduced NO synthesis. Furthermore, they
showed reduced renal NOS activity and iNOS immunostaining, but normal 
eNOS staining. However, plasma nitrite/nitrate levels were elevated post 
RMR, and aortic tissue showed higher NOS activity, iNOS and eNOS 
immunostaining. They concluded that vascular NO production was enhanced 
in uraemia, while renal NO production was reduced (Aiello 1997).
• Similarly, a Japanese group demonstrated enhanced NO content in exhaled air 
and increased plasma nitrite/nitrate levels in dialysis patients compared to 
healthy controls (Matsumoto 1999).
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• Schmidt et al examined plasma levels and urinary excretion of nitrite and 
nitrate in haemodialysis patients and showed reduced NO output compared to 
controls (Schmidt 1999).
• A further method of analysing NO production indirectly is to measure the 
conversion of [15N2]-arginine to [15N2]-citrulline in plasma. Rabelink’s group 
used this method to show that basal NO production is reduced in CRF (Wever 
1999).
This field is therefore extremely confusing, partly a result of the great difficulty in 
measuring plasma NO concentration in vivo because NO has a very short half-life. 
One must try to reconcile 2 concepts : accelerated atherosclerosis in this group 
suggests reduced bioavailability of NO, while the uraemic bleeding tendency, and 
perhaps dialysis hypotension, suggest increased NO production. There may be a 
complex change in uraemia with downregulation of endothelial eNOS and 
concomitant upregulation of platelet iNOS.
3.4.2.ii Studies measuring circulating markers of endothelial dysfunction
• Several groups have now demonstrated raised circulating von Willebrand 
factor (vWf) levels in predialysis (Haaber 1995, Thambyrajah 2000a) and 
dialysis (Gris 1994, Bolton 2001) patients compared to controls. Von 
Willebrand factor is an endothelium-derived protein; raised levels have been
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associated with endothelial damage and cardiovascular events in the general 
population (Boneu 1975, Meade 1994).
• Further endothelium-derived proteins that are elevated in uraemia include 
soluble thrombomodulin (Nakayama 1994, Gris 1994) and tissue-type 
plasminogen activator (Gris 1994).
3.4.2.iii Cell culture studies with uraemic serum
• The first study in this area demonstrated that uraemic serum inhibited 
proliferation of lymphocytes and a malignant cell line in culture (Wessel-Aas 
1981).
• Delaporte et al showed that uraemic plasma and haemodialysis ultrafiltrate 
inhibited cell proliferation in vitro (Delaporte 1982).
• iNOS but not eNOS was inhibited in cell culture by uraemic serum (Arese 
1995).
• Finally, Aznar-Salatti et al found that uraemic serum affected human 
endothelial cells in culture, in that the cells produced a deficient matrix and 
were less firmly attached to the subendothelium (Aznar-Salatti 1995).
3.4.2.iv Studies examining vascular reactivity in CRF
The first, and in many ways, best study in this field was published in 1997 by Kari et 
al (after the work for this thesis commenced). This group controlled for blood 
pressure, cholesterol, smoking and anti-hypertensive drugs by examining 23 
normotensive, pre-dialysis children with CRF (mean GFR 17.5ml/min/1.73m2) who
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were on no vasoactive drugs and who had normal serum cholesterol levels (Kari
1997). Using high resolution ultrasound examination of the radial artery they showed 
that flow-mediated (endothelium-dependent) vasodilation was impaired in the 
uraemic children compared to controls, while vasodilatation to sublingual GTN 
(endothelium-independent) was similar in the two groups. The authors concluded that 
uraemia was associated with endothelial dysfunction and that this may predispose to 
accelerated atherosclerosis.
In keeping with our results in uraemic adults, several groups have also found impaired 
endothelium-dependent vasodilatation in CRF :
• Joannides et al 1997 -  non-invasive study using ultrasound examination of 
radial artery. Showed reduced flow-dependent vasodilatation but also slight 
reduction in GTN-mediated dilatation.
• Hand et al 1998 -  non-invasive study using dorsal hand vein diameter. They 
showed that venodilatation to acetylcholine was impaired in haemodialysis 
patients compared to controls, while venodilatation to GTN was similar. 
Haemodialysis and L-arginine (but not D-arginine) corrected the impaired 
response in the uraemic patients. They concluded that the results were in 
keeping with endothelial dysfunction caused by accumulation of NOS 
inhibitors that are cleared by dialysis.
• Thambyrajah et al 2000a -  non-invasive study using ultrasound of brachial 
artery. They showed impaired flow-mediated dilatation but preserved GTN- 
mediated dilatation in 80 uraemic (pre-dialysis) patients compared to controls, 
and found no difference in response between those patients with mild CRF
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and those with more advanced CRF, concluding that endothelial dysfunction 
is present early in uraemia.
• Annuk et al 2001b -  large forearm plethysmography study of 56 patients with 
moderate CRF compared with 56 controls. They showed impaired 
vasodilatation to methacholine (endothelium-dependent) with preserved 
responses to SNP. They controlled for blood pressure in multivariate analysis 
and found that the results were still valid.
• Bolton et al 2001 -  non-invasive study using brachial artery ultrasound. They 
showed impaired flow-mediated vasodilatation with preserved GTN-mediated 
dilatation in pre-dialysis and dialysis patients. This group also looked at 
oxidised LDL and pro-inflammatory cytokines (IL-6 and TNF a) and found 
no correlation between oxLDL levels and endothelial responses, but a 
significant negative correlation between the pro-inflammatory cytokines and 
endothelium-dependent vasodilatation.
3.5 Conclusion
In summary, this study has demonstrated endothelial dysfunction in uraemic patients 
compared to controls, as assessed by endothelium-dependent vasodilatation. Indirectly 
this suggests a reduced ability of the vascular endothelium in uraemia to produce and 
release NO (or enhanced NO breakdown/scavenging). Our results are in keeping with 
those of other methodologically-similar studies, and with those of a number of non- 
invasive studies. For the first time we showed that drug order should probably not be
i
143
randomised in plethysmography as SNP appears to affect the subsequent response to 
carbachol.
The mechanism underlying endothelial dysfunction in uraemia remains unclear. The 
only factor that appeared to correlate with the response to carbachol in this study was 
triglyceride level, and while this may be significant, a previous plethysmography 
study in non-uraemic patients showed no effect of severe hypertriglyceridaemia on 
endothelial responses (Chowienczyk 1997). As circulating factors may play a major 
role, a further study was performed examining vessels from patients with CRF 
removed from the uraemic milieu.
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Chapter 4
An in vitro study of endothelial function in uraemia
145
4.1 INTRODUCTION
The results of the forearm plethysmography study detailed in Chapter 3 indicate 
impaired endothelium-dependent vasodilatation in adult uraemic patients. Several 
other studies using forearm plethysmography or high-resolution ultrasound confirm 
these findings. The mechanism, however, remains unclear.
One postulated mechanism for uraemic endothelial dysfunction is the accumulation of 
endogenous uraemic toxins including ADMA, PTH, homocysteine and other 
unidentified factors that may directly harm the endothelium or alter its function.
This present study was designed to examine endothelial function in vitro, using 
uraemic vessels in an environment removed from the uraemic milieu. Wire 
myography was utilised to examine resistance vessels from patients with CRF either 
pre-dialysis or already undergoing dialysis. This technique has been in use for over 20 
years and is a powerful means of looking at vascular responses in vessels that control 
the peripheral resistance. Details of this method have been described in chapter 3.
4.2 METHODS
4.2.1 Materials
Acetylcholine, sodium nitroprusside and noradrenaline were purchased from Sigma- 
Aldrich, UK. Human endothelin-1 was purchased from ICN (U.K.). Experiments
were performed on a Mulvany-Halpem 4-channel myograph (JP Trading), connected 
to a Linseis pen recorder.
4.2.2 Subjects
Twelve patients with chronic renal failure agreed to have a subcutaneous fat biopsy at 
the time of CAPD catheter insertion (n=5) or renal transplantation (n=7) under 
general anaesthetic. Control tissue was obtained from 8 volunteers without known 
renal disease undergoing abdominal surgery or hernia repair. All patients and controls 
that were eligible over a 9-month period were asked to consent, and as there was a 
learning curve for the technique, the initial data from around 10-15 subjects was not 
included. Owing to technical problems, results from this initial period were 
incomplete. All subjects gave written informed consent and the protocol was 
approved by the local ethics committee.
The background characteristics of patients and controls are detailed in Table 4.1. The 
underlying renal disease was : chronic glomerulonephritis (6), unknown (4), 
obstructive uropathy (1) and hereditary nephritis (1). For the patients who had 
previously been dialysed the median (range) duration of ESRF was 27 (5-69) months. 
Exclusion criteria included known cardiovascular disease (angina pectoris, previous 
myocardial infarction or CABG), diabetes mellitus or systemic vasculitis.
Control (n=8) Uraemic (n=12) P Value
Male 5 8 ns
Smoker 3 4 ns
Age (yrs) 42 (31,73) 46 (20,77) 0.910
Urea (mmol/1) 5.5 (2.7,10.2) 21.8(7.2,35.1) <0.001
Creatinine (pmol/1) 85 (66,123) 735 (476,1041) <0.001
Glucose (mmol/1) 4.7 (4.3,6.0) 5.2 (3.4,6.8) 0.913
Cholesterol (mmol/1) 4.6 (2.8,7.4) 4.5 (3.7,5.3) 0.408
Triglyceride (mmol/1) 0.9 (0.7,3.2) 1.4 (0.8,2.0) 0.902
Haemoglobin (g/dL) 13.2(11.8,14.5) 9.8(7.9,11.1) <0.001
SBP (mmHg) 124 (106,152) 149(112,180) 0.043
DBP (mmHg) 78 (68,88) 82.5(52,110) 0.601
BMI 23.6(16.8,28.3) 25.2 (19.8,30.8) 0.315
Table 4.1 Background characteristics for uraemic patients and controls expressed as 
median (range) with comparison by Chi-Square or Mann-Whitney U tests. 
(SBP=systolic blood pressure; DBP=diastolic blood pressure; BMI=body mass index)
4.2.3 Human subcutaneous resistance arteries
At the time of operation, an ellipse of skin approximately 2cm x 1cm with adherent 
fat was removed from the anterior abdominal wall to a depth of 2cm. Resistance 
arteries were dissected from this tissue and mounted on a 4-chamber myograph, as 
described in Chapter 2.
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4.2.4 Protocol
After a 30-minute acclimatisation period, the vessel was normalised at internal 
diameter Lo (Aalkjaer 1986), the arteries were then exposed twice to KPSS (PSS with 
KC1 substituted for NaCl on an equimolar basis), and once to noradrenaline 10 
jumol/1. After a plateau contraction had been reached to noradrenaline, acetylcholine 3 
pmol/1 was added to assess endothelium-dependent vasodilatation and thus the 
presence of an intact endothelium. Vessels which failed to contract to KPSS or 
noradrenaline, or which failed to relax >50% to acetylcholine were discarded.
Two separate protocols were then carried out. A cumulative concentration-response 
curve to noradrenaline (10_9M to 3x1 O^M) was constructed with two of the vessels 
involving exposure to each dose of noradrenaline for 4 minutes or until a peak 
response at that concentration was reached. Following a washout period of 30 minutes 
and re-establishment of baseline, a cumulative concentration-response curve to 
endothelin-1 (10'12M to 3xlO‘6M) was constructed, with arteries exposed to each 
concentration of endothelin-1 for 10 minutes, or until a peak was reached.
With the two remaining vessels, after preconstriction with noradrenaline (3x1 O^M), a 
concentration response curve to acetylcholine (10'9 to 3x1 O'4 M) was constructed 
involving exposure to each concentration of acetylcholine for 2 minutes or until the 
maximum relaxation was achieved. Again, following a washout period of 30 minutes, 
the arteries were preconstricted with noradrenaline (3x10"^) and a concentration- 
response curve was performed for SNP (10'9 to 3x10*4 M) with arteries being in
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contact with each concentration of SNP for 2 minutes or until a plateau had been 
reached.
When a complete concentration-response curve was not possible for technical reasons 
the vessel was discarded. The number of vessels studied for each drug, and the 
corresponding size of these vessels, is detailed in Table 4.2.
Control Uraemic P value
Noradrenaline number 17 22
Lo 395.8(212.2,500.9) 360.9(241.2,536.4) 0.377
Endothelin-1 number 14 16
Lo 404.5(240.2,500.9) 374.6(262.8,530.5) 0.697
Acetylcholine number 19 23
Lo 413.3(212.2,500.9) 345.6(183.2,536.4) 0.114
Sodium nitro- 
prusside
number 12 20
Lo 358.6(212.2,474.4) 363.7(183.2,536.4) 0.833
Table 4.2. Background data for vessels. Number=number of vessels in which a 
complete concentration-response curve was obtained for that particular drug. 
Lo=normalized internal diameter of vessels. Comparison is by Mann-Whitney U test.
4.2.5 Statistical analysis
Contractile responses were expressed as an increase in active effective pressure (kPa), 
calculated as an increase in isometric tension above resting divided by the normalised
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internal radius. Agonist potency was expressed in terms of maximum response 
obtained and EC50 value, this being the concentration required to produce 50% of the 
maximum response. For SNP and acetylcholine, the response was expressed as 
maximum % relaxation from baseline. Comparison between groups was by Mann- 
Whitney U test. All analyses were performed using SPSS for Windows (version 7.5), 
with significance at a level of P<0.05. Concentration-response curves were generated 
using GraphPad Prism v 2.01.
4.3 RESULTS
Patients and controls were of a similar age and sex distribution, and had similar total 
serum cholesterols and smoking habits (Table 4.1). Haemoglobin was significantly 
lower in the uraemic patients and systolic blood pressure was significantly higher as 
expected. Table 4.2 details the number and size of the vessels used for each drug. 
There was no significant difference in vessel size between groups.
The results for the vasoconstrictors noradrenaline and endothelin-1 are shown in 
Table 4.3 and in Figures 4.1 and 4.2. The potency of noradrenaline and endothelin-1 
were similar in uraemic and control groups (no significant difference in EC50). 
However, from the concentration response curves it can be seen that there is a 
tendency for a more sustained contraction to these agents with the response (kPa) at 
the highest dose of norepinephrine being significantly greater in the uraemic group 
[16.89 (1.7,30.6) uraemic v 6.96 (0,25.9) control; p=0.001] and the response to the 
highest dose of endothelin-1 being significantly greater in the uraemic group 
[19.08(8.9,37.8) uraemic v 13.44(2.2,22.2) control; p=0.006].
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Control Uraemic P value
NA EC50 2.23xl0'7 (0.72x10 ;, 
21.30xl0'7)
6.78xl0'7 (0.23X1C7, 
58.10xl0"7)
0.163
ET-1 EC50 6.01xl0'10 (0.15x10''°, 
13.50xl0'10)
9.50xlC10 (2.69xlO'lU, 
71.04xl0‘10)
0.208
Ach EC50 4.81x10 s (0.69xl0'8, 
59.51X10-8)
7.35xl0'8 (0.74x1 O'8, 
37.73x1c8)
0.604
SNP EC50 5.40xl0'8 (0.58xl0'8, 
87.12x1c8)
5.43xl0'8 (0.40X10-8, 
19.05xl0'8)
0.716
Ach max % 
relaxation
98(78,100) 77(41,97) <0.001
SNP max % 
relaxation
94(71,100) 95(63,100) 0.751
Table 4.3 Potency (EC50 (Molar)) of noradrenaline, endothelin-1, acetylcholine and 
sodium nitroprusside in uraemic and control vessels expressed as median (range) with 
comparison by Mann-Whitney U test. (NA = norepinephrine, ET-1 = endothelin-1, 
ACh = acetylcholine, SNP = sodium nitroprusside). Maximum % relaxation from 
baseline of acetylcholine and sodium nitroprusside expressed as median (range).
The results for the endothelium-independent vasodilator SNP are detailed in Table 4.3 
and Figure 4.3. Again, the potency of this agent was similar in uraemic and control 
groups, and the same maximum relaxation was obtained in the two groups. However, 
when we examine the results for the endothelium-dependent vasodilator acetylcholine 
(Table 4.3 and Figure 4.4), the maximum relaxation obtained in uraemic patients 
(77% (41,97)) was significantly lower than that obtained in controls (98% (78,100);
p<0.001).
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Figure 4.1 Concentration response curves for the effect o f noradrenaline on uraemic 
and control resistance arteries. Response measured as active effective pressure (kPa) 
and expressed as mean ± sem. Comparison o f active effective pressure at highest 
concentration o f noradrenaline is by Mann-Whitney U test.
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Figure 4.2 Concentration-response curves for the effect o f endothelin-1 on uraemic 
and control resistance arteries. Response measured as active effective pressure (kPa) 
and expressed as mean ± sem. Comparison o f active effective pressure at highest 
concentration o f endothelin-1 is by Mann-Whitney U test.
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Figure 4.3 Concentration-response curves for the effect o f sodium nitroprusside on 
uraemic and control resistance arteries. Vessels were pre-constricted with 
noradrenaline (3x1 O^M). Response measured as active effective pressure (kPa) and 
expressed as mean ± sem. Comparison by Mann-Whitney U test at each concentration 
not significant.
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Figure 4.4 Concentration-response curves for the effect o f acetylcholine on uraemic 
and control resistance arteries. Vessels were pre-constricted with noradrenaline (3x10' 
6M). Response measured as active effective pressure (kPa) and expressed as mean ± 
sem. Comparison o f maximum % vasodilatation by M ann-Whitney U test.
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The factors influencing endothelium-dependent vasodilatation were further examined 
in all subjects. There was no significant difference between the median (range) 
maximum % relaxation to ACh in male subjects (82.7 (45.0,99.3)) compared to 
female subjects (89.0 (48.0,95.0); p=0.938 by Mann-Whitney test). In addition there 
was no significant difference for ACh response in smokers (85.5 (91.0,100)) 
compared to non-smokers (87.7 (45.0,99.3); p=0.817).
Spearman correlation coefficients were determined for maximum % relaxation to 
ACh, SBP, DBP, cholesterol, triglycerides, haemoglobin, age and glucose. None were 
statistically significant. The only factor approaching a statistically significant 
correlation with ACh response was triglyceride : Spearmann coefficient 0.532, 
p=0.05, however, this was a positive correlation which is at odds with the results for 
plethysmography and thus difficult to explain.
A similar analysis showed no significant difference in response to SNP, noradrenaline 
| or endothelin-1 between males and females, and between smokers and non-smokers.
i
! Spearmann correlation coefficients were determined for maximum response to NA,
maximum response to ET-1, EC50 for NA, EC50 for ET-1, urea, creatinine, glucose, 
age, cholesterol, haemoglobin and triglycerides. The following significant correlations 
were noted:
• max NA and cholesterol: Spearmanns coefficient 0.648, p=0.017
1
r
• EC50 NA and diastolic BP : Spearmanns coefficient 0.576, p==0.031
• EC50 ET-1 and creatinine : Spearmanns coefficient 0.644, p=0.007
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4.4 DISCUSSION
This in vitro study has demonstrated for the first time that there is impaired 
endothelium-dependent vasodilatation in isolated human uraemic resistance arteries. 
Responses to the endothelium-independent vasodilator SNP were preserved, thus the 
endothelium in these vessels is less able to produce and release endothelium- 
dependent vasodilators, predominantly NO, upon stimulation. These findings are in 
keeping with the results of the in vivo study detailed in chapter 2, and again are 
consistent with the published literature of forearm plethysmography and ultrasound 
studies in CRF.
In this study, we have shown that there is endothelial dysfunction in human uraemic 
vessels in vitro, when vessels are removed from the uraemic milieu, and therefore, in 
the absence of circulating factors such as ADMA or homocysteine. This suggests one 
of several possibilities:
• that a short-lived circulating factor such as ADMA is not involved in causing 
endothelial dysfunction in uraemia (although recent studies suggest that 
ADMA may accumulate intracellularly (A1 Baanchbouchi 2000))
• that storage of the uraemic resistance arteries overnight in cooled 
physiological saline solution does not remove circulating factors from the 
endothelium
• that the endothelial damage in uraemia is not easily reversible, and possibly 
permanent
• that there may be down-regulation of eNOS which takes some time to resolve
Our results are in direct contrast to those of a recently published study that found 
normal endothelium-dependent vasodilatation in resistance vessels from uraemic rats 
(Thuraisingham 1999). This group examined the effects of acetylcholine and SNP on 
preconstricted mesenteric resistance arteries from control and spontaneously 
hypertensive rats which had undergone 5/6 or sham nephrectomy 4 weeks previously. 
While there was no statistically significant difference in EC50 or maximum % 
relaxation for acetylcholine, their results do suggest a trend toward a reduced 
maximum % relaxation in the uraemic rats compared to control rats. Of course, this 
study used an animal model where the duration of uraemia was short and thus its 
limitations are clear. Interestingly, one major difference was that all experiments were 
performed in the presence of indomethacin : it is therefore possible that at least some 
of the differences seen in our study are not NO-dependent but rather related to 
changes in the production of a prostaglandin.
A similar study in rats with autosomal dominant polycystic kidney disease 
demonstrated (after sacrifice at 8 weeks, and therefore not uraemic) impaired 
endothelium-dependent vasodilatation that was attenuated with L-NAME, suggesting 
a defect in NO production &/or release early in renal disease (Wang 1999). They also 
showed a greater response to noradrenaline and a higher media/lumen ratio in the 
PKD rats. Following this study they examined resistance vessels from humans with 
adult polycystic kidney disease, normal blood pressure and normal serum creatinine 
levels (Wang 2000). Endothelium-dependent vasodilatation was again impaired in the 
APKD vessels and unaffected by L-arginine or L-NAME, suggesting an impairment 
of NO synthase in APKD.
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The only previously published wire myography study of human resistance artery 
function in CRF was by Mulvany’s group in 1986. Using a similar technique they 
examined anterior abdominal wall subcutaneous resistance arteries from 20 patients 
on haemodialysis and 11 controls, and found no changes in vascular morphology or 
sensitivity to noradrenaline, angiotensin II, potassium or calcium (Aalkjaer 1986). 
Endothelium-dependent and independent vasodilatation were not assessed. Their 
results were surprising and not easily explained, as the patients were of a similar age 
to ours and had been uraemic for a considerable period of time. Although we did not 
demonstrate any difference in the EC50 for noradrenaline or endothelin-1, the 
concentration-response curves are clearly different in the two groups with a 
significantly greater response to the maximal dose of each agonist in the uraemic 
patients, and a pattern suggesting a more prolonged contraction with each agent. 
There was also a trend toward a higher maximal contraction with both agonists that I 
suspect would be significant if more subjects had been studied.
One could postulate several reasons for an enhanced contraction to noradrenaline and 
endothelin in uraemic resistance arteries :
• there may be reduced counterbalancing basal or stimulated NO production, as 
both NA and ET-1 act via ot2 and ET-B receptors respectively to stimulate NO 
release (in a presumed protective negative feedback role)
• there may be upregulation of endothelin and adrenergic receptors by an 
unknown mechanism (although unlikely in the face of increased circulating 
levels of an agonist)
• there may be alterations in the signal transduction pathways
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• there may be structural changes in the vessel wall such as increased medial 
smooth muscle secondary to long-standing hypertension or uraemia itself. We 
know that essential hypertension is characterised by remodelling of small 
arteries with an increased media/lumen ratio. The increased pressor response 
in this present study may reflect the vascular changes of hypertension, and not 
be influenced by uraemia : previous studies in hypertension have shown an 
increased pressor response to infused agonists in both humans and 
spontaneously hypertensive rats (Mulvany 1990)
Despite controlling for smoking habit and serum cholesterol level, one potential 
confounding factor in our study was the higher systolic blood pressure in the patients 
compared to controls. It is extremely difficult to control for blood pressure in a study 
such as this, as obtaining subcutaneous fat biopsies from normal controls is difficult, 
let alone finding essential hypertensives undergoing abdominal surgery. As several 
studies in hypertension have demonstrated endothelial dysfunction we cannot 
conclude that the results of this study are entirely secondary to uraemia.
There were no obvious factors related to the degree of endothelium-dependent 
vasodilatation (EDV) in either uraemic or control vessels, and in particular, smokers 
had similar EDV compared with non-smokers. However, the lack of a correlation 
between any of the background biochemical or BP data may simply reflect the small 
numbers involved. Interestingly, DBP was associated with the EC50 for noradrenaline 
and creatinine with the EC50 for endothelin-1. Thus, uraemia (i.e. a higher creatinine) 
is related to a lower sensitivity to endothelin : this would fit with the known raised 
circulating endothelin levels in renal failure and presumed down-regulation of
161
endothelin receptors. However, this goes against the finding of a trend toward a 
greater pressor response to endothelin in uraemic patients : the mechanisms involved 
here are obviously complex and require further study. The relationship between DBP 
and noradrenaline sensivity is unclear and the opposite of what one would expect.
4.5 CONCLUSION
In conclusion, this study has demonstrated impaired endothelium-dependent 
vasodilatation with preserved endothelium-independent vasodilatation in uraemic 
resistance arteries in vitro. The results support in vivo studies in renal failure, but 
contrast with those of the only other published myography study in uraemia looking 
specifically at endothelial function (Thuraisingham 1999). Our results suggest 
endothelial dysfunction, a defect that may predispose these patients to accelerated 
atherosclerosis. The underlying patho-physiology remains unclear.
To further investigate the underlying mechanism, one would first have to repeat the 
above studies in the presence of indomethacin and L-NMMA to ascertain the degree 
of involvement of NO or prostaglandins. Assuming that these experiments reveal that 
the defect lies in the L-arginine/NO pathway then the studies could be repeated in the 
presence of anti-oxidants such as ascorbic acid, to assess the role of increased 
oxidative stress, or in the presence of L-arginine in an attempt to overcome the effects 
of circulating inhibitors of NOS.
Chapter 5
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A study of endothelial function in CAPD patients
i
5.1 INTRODUCTION
Continuous ambulatory peritoneal dialysis is an attractive method of renal 
replacement therapy for many patients with ESRF as it allows a degree of 
independence from the renal unit. Owing to selection bias, it has not been possible to 
accurately determine whether patient survival is better or worse on CAPD compared 
to haemodialysis, although most studies suggest survival is comparable on the two 
methods. There are no data to suggest that cardiovascular disease is any less common 
in CAPD patients; the reverse is probably true as patients with heart failure and IHD 
often tolerate CAPD better than haemodialysis.
CAPD patients are uraemic. They are maintained in a steady state with weekly 
creatinine clearances of around 60-70 litres, equating roughly to a GFR of 7-10 
ml/min. Thus, these patients are exposed to all the cardiovascular risks of patients 
with advanced CRF, and often over a longer period. Hyperhomocysteinaemia, 
hyperparathyroidism, dyslipidaemia (different pattern from HD; see Table 1.2), 
increased oxidative stress and hypertension, are all prevalent. Asymmetric 
dimethylarginine levels may be lower than those in haemodialysis patients (Kielstein 
1999). Nevertheless, one would expect endothelial dysfunction in CAPD patients as a 
result of uraemia and other cardiovascular risk factors. Our results for a forearm 
plethysmography study of endothelial function in uraemia detailed in chapter 3 
included those from 6 patients on CAPD. While the uraemic group overall exhibited 
impaired EDV, no differences could be seen between the pre-dialysis patients and the 
CAPD patients (Figures 3.7 and 3.8). Haemodialysis patients could not be included 
owing to forearm AV fistulae.
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Hypertension is common in CAPD patients, although the prevalence is lower than that 
in patients treated by haemodialysis (Cheigh 1999). In many patients there is a clear 
relationship between fluid balance and blood pressure, and CAPD patients are 
therefore a reasonable model for studying volume-dependent hypertension. The 
mechanisms underlying volume-dependent hypertension are complex : some studies 
have shown that the initial rise in cardiac output is transferred to the resistance 
vasculature with a resulting sustained increased peripheral resistance (Otsuka 1988). 
What is not clear is the role of the endothelium in this process. Increased intraluminal 
pressure or stretch of the vessel wall may stimulate contraction either through direct 
effects on the vascular smooth muscle cells or through endothelial release of 
contracting factors (or reduced relaxing factors). The role of shear stress is also 
unclear : shear stress is the result of contact of red blood cells with the endothelium 
and induces endothelial NO production. If a patient is volume overloaded and 
haemodilute, the RBCs may flow in the centre of the vessel and shear stress will be 
reduced with less endothelial NO production.
This small study was designed to examine basal and stimulated endothelial NO 
production in CAPD patients with varying intravascular volume.
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5.2 METHODS
5.2.1 Subjects
The initial plan was to enrol 10 patients. However, recruitment difficulties for this 
project resulted in only 3 patients being studied. This was related to the requirement 
for the CAPD regime to be altered and to the need for two separate visits to the 
plethysmography laboratory. The patients’ background characteristics are detailed in 
table 5.1. The patients were all non-smokers and not diabetic. In addition, none were 
taking aspirin, statins, ACE inhibitors or other antihypertensive drugs. All suitable 
patients attending the CAPD clinic were invited to participate (except those prone to 
pulmonary oedema).
Patient 1 Patient 2 Patient 3
Sex Female Male Male
Age 59 43 43
Renal Diagnosis Membranous GN Reflux nephropathy APKD
Months on CAPD 32 14 21
Cholesterol 8.8 7.8 4.4
Triglyceride 2.3 3.5 2.4
Haemoglobin 8.9 10.6 10.2
SBP 176 113 159
DBP 89 63 91
Table 5.1 Background data for 3 CAPD patients.
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5.2.2 Materials
Carbachol was obtained from Martindale Pharmaceuticals (England), sodium 
nitroprusside from Faulding DBL (England) and L-NMMA from ICN (U.K.). All 
solutions were prepared in 0.9% saline by the sterile pharmacy productions unit at the 
Western Infirmary, Glasgow.
5.2.3 Protocol
The study was approved by the local ethics committee. Two separate forearm 
plethysmography studies were performed. The first study was performed when the 
patients were felt to be at their dry weight. Following this, their CAPD regime was 
altered in such a way to encourage fluid gain. The aim was for weight to increase by 
2kg over a 7-14 day period, with a further forearm plethysmography study being 
performed at the higher weight. Patients were therefore studied “dry” and “wet” (or 
relatively fluid-overloaded. (Note : On all occasions, CAPD fluid was left within the 
abdomen during studies).
Forearm plethysmography was performed as described in Chapters 2 and 3.
All studies were performed in a quiet vascular research laboratory maintained at 24- 
26°C after an overnight fast. The same protocol was used as in Chapter 3 : 30 mins 
acclimatisation with 0.9% saline, then incremental doses of carbachol (0.1, 0.3, 1.0 
and 3.0 pg/min), then a 30 minute wash-out with saline followed by incremental
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doses of SNP (0.3, 1.0, 3.0, 10.0 pg/min). After a further 30 minutes washout with 
saline, a single dose of L-NMMA (8pmol/min) was infused (Figure 3.1).
5.2.4 Statistical Analysis
Results are simply expressed in graphical form (Microsoft Excel 97). No formal 
statistical analysis was performed in view of the small number of patients studied.
5.3 RESULTS
All subjects gained weight between the 2 studies. Subject 1 increased from 76.1kg to 
78.5kg, subject 2 from 70.0kg to 71.6kg and subject 3 from 89.0kg to 91.0kg. Results 
for infusion of carbachol and SNP are illustrated in Figure 5.1-5.3.
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Patient 1 : SNP
Dry Wet600
500 -
400 -
300 -
200  -
100  -
0.30 1.00 3.00 10.00
Dose SNP (ug/min)
Patient 1 : Carbachol
500 Dry' ■Wet'
400 -
300 -
200  -
100  -
0.10 0.30 1.00 3.00
Dose carbachol (ug/min)
Figures 5.1a and b. Dose response curves for infusion o f SNP and carbachol in Patient
la t dry weight and 2.4kg heavier.
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Patient 2 : SNP
350
Dry Wet
250 -
150 -
50 -
1.00 3.00 10.00
-50
Dose SNP (ug/min)
Patient 2 Carbachol
500
Dry Wet
400 -
300 -
200 -
100  -
T T T
0.10 0.30 1.00 3.00
Dose carbachol (ug/min)
Figures 5.2a and b. Dose response curves for infusion o f SNP and carbachol in Patient
2 at dry weight and l .6 kg heavier.
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Patient 3 : SNP
400
Dry Wet
300 -
200 -
100 -
0.30 1.00 3.00 10.00
Dose SNP (ug/min)
Patient 3 : Carbachol
400
Dry Wet
300 -
200  -
100 -
0.30 1.000.10 3.00
Dose Carbachol (ug/min)
Figures 5.3a and b. Dose response curves for infusion o f SNP and carbachol in Patient
3 at dry weight and 2 kg heavier.
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L-NMMA results are only available for patients 1 and 3. In patient 1 the % reduction 
in FBF ratio with L-NMMA was 23.5% dry and 27.3% wet. In patient 3 the % 
reduction in FBF ratio was 43.6% dry and 27.3% wet. Patient 2 was unable to tolerate 
the extra time required for the L-NMMA infusion.
5.4 DISCUSSION
This study was clearly limited by small numbers. Recruitment difficulties mainly 
resulted from the requirement for 2 visits to the vascular lab and patients were also 
concerned about manipulation of fluid balance. In the 3 patients studied there were no 
adverse effects of this study.
It is difficult to draw any conclusions from the results. The response to SNP was 
similar in all 3 patients when “dry” and “wet”, although there was a marked reduction 
in response to the highest dose in patient 1 when “wet”. Overall the response curves 
for SNP were rather flat, the reason for this being unclear. In patient 3 there was no 
difference in response to carbachol, whether “wet” or “dry”. In patient 1, the response 
to carbachol was greater when “dry” while the opposite was true for patient 2. No 
obvious pattern is therefore seen in these 3 patients.
L-NMMA was used to assess basal NO production and the effect of changes in fluid 
balance. Again the changes were different in the 2 patients studied and no firm 
conclusion can be made. If the numbers had been substantially higher then perhaps a
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pattern would appear. Power calculations are almost impossible in a study such as this 
where there is no precedent.
Thus, the mechanism of volume-dependent hypertension remains unclear. Many 
theories have been forwarded for this form of hypertension that is common in renal 
disease. Following an acute volume load, animal studies show that there is initially a 
rise in cardiac output (Otsuka 1988) followed, in some animals by a sustained rise in 
blood pressure associated with a raised peripheral resistance and normal circulating 
noradrenaline and vasopressin levels, and plasma renin activity. It is therefore likely 
that there are key alterations in resistance vessel function in volume-dependent 
hypertension.
Postulated changes in resistance vessel function in volume-dependent hypertension 
include:
• altered basal and stimulated NO production.
• altered endothelin production.
• the Bayliss effect : stretch of the vessel wall by raised intravascular volume 
leads to vasoconstriction (Bayliss 1902). The mechanism responsible for this 
is still unknown but is a property of the vascular smooth muscle cells.
• in vitro, raised pressure within small arteries leads to a reduction in lumen 
diameter that is endothelium-dependent (i.e. pressure induces release of an 
endothelium-dependent contracting factor) (Mulvany 1990). Increased flow 
however induces NO release.
• circulating NOS inhibitors.
• circulating Na+/K+ ATPase inhibitors.
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• changes in shear stress.
• changes in sympathetic tone.
• vessel wall oedema caused by salt and water retention leading to vessel 
dysfunction.
5.5 CONCLUSION
The mechanisms underlying volume-dependent hypertension are thus unclear. 
Unfortunately, this small study using the manipulation of CAPD patients’ volume 
status has added little to our understanding of this complicated subject. Further 
study is warranted.
Chapter 6
An in vivo study of endothelial function in 
renal transplant recipients
6.1 INTRODUCTION
The introduction of cyclosporin to standard immunosuppressive protocols in 1984 has 
greatly improved graft survival in renal transplantation, but patients continue to die 
prematurely of cardiovascular disease. Figures from the European Renal Association 
Registry show around a 10-fold increase in mortality from cardiovascular disease in 
renal transplant recipients compared to the general population.
Hypertension occurs in almost all patients by the time ESRF is reached, and then 
often improves significantly with adequate salt and water removal on dialysis. 
Paradoxically, hypertension again becomes extremely common (up to 90% of 
patients) following renal transplantation (Schwenger 2001), and is likely to play a 
major role in the development of cardiovascular disease in this group. In keeping with 
its role in native renal disease progression, systemic hypertension is also a major 
independent predictor of renal graft failure (Opelz 1998), with a recent multivariate 
analysis suggesting that for every lOmmHg increase in M.A.P. the relative risk of 
graft failure is 1.3 (Mange 2000). Furthermore, post-transplant hypertension is 
associated with poorer patient survival (Kasiske 1996). The potential causes of post­
transplant hypertension are manifold (Schwenger 2001):
• impaired renal function (secondary to chronic rejection/recurrence of original 
disease)
• excessive renin production by native kidneys
• calcineurin inhibitors : cyclosporin & tacrolimus
• corticosteroids (at least in the early post-transplant period)
• increased body weight
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• transplant renal artery stenosis
• polycythaemia
• genetic predisposition to hypertension in the donor
There is considerable evidence that cyclosporin (and possibly also tacrolimus) is the 
most important factor in the development of post-transplant hypertension. Prior to 
cyclosporin’s introduction, the incidence of post-transplant hypertension was 
approximately 10% in bone marrow and cardiac transplantation, and now with its 
regular use, hypertension occurs in 33-60% of bone marrow and 71-100% of cardiac 
transplant recipients (Textor 1997). In renal transplantation the incidence of 
hypertension has increased by around 30% since the introduction of cyclosporin 
(Textor 1997).
In keeping with most forms of hypertension, cyclosporin-induced hypertension 
involves an increased systemic vascular resistance (Luke 1991). Early organ bath 
work showed that cyclosporin vasoconstricted smooth muscle preparations, an effect 
partially blocked by a-adrenoceptor antagonists (Xue 1987). Since then, several 
clinical and in vitro studies have suggested a range of possible mechanisms for CsA- 
induced hypertension:
• Sodium retention (Ciresi 1992), possible secondary to afferent arteriolar 
constriction in the glomerulus.
• Calcium-sensitisation of vascular smooth muscle (Ventura 1997).
• Altered prostaglandin production (Petrie 1988).
177
• Activation of the sympathetic nervous system. The initial report came from 
animal studies in heart transplantation (Scherrer 1990), however subsequent 
work in humans has refuted this (Stein 1995, Kaye 1993, Ventura 1997).
• Increased plasma renin activity. This is certainly true in animals, but in 
humans there is either little change or a reduction in plasma renin activity (Lee
1997), although renin may be inappropriately high for the degree of blood 
pressure.
• Increased endothelin levels or action. Raised circulating endothelin-1 levels 
have been documented in both animals and humans with cyclosporin-induced 
hypertension (Ventura 1997). In rats, ET-A receptor mRNA expression is 
increased in the aorta and mesenteric arteries while ET-B receptor mRNA 
expression is reduced in the vascular endothelium (Iwai 1995). In addition, the 
concomitant administration of bosentan, a non-selective endothelin receptor 
antagonist, with cyclosporin in rats ameliorates the hypertensive response 
(Ventrua 1997). In humans, cyclosporin-induced glomerular hypoperfusion is 
associated with a marked increase in urinary endothelin levels (Perico 1992). 
Thus, there is a growing body of evidence for a role of endothelin in CsA- 
induced hypertension.
More recently, attention has focused on another aspect of endothelial function, the L- 
arginine/nitric oxide system. Over the years, data has accumulated to show that CsA 
is toxic to endothelial cells in culture, and that this effect is time- and dose-dependent 
(Zoja 1986). Animal work demonstrates attenuated acetylcholine (NO)-mediated 
vasodilatation in cyclosporin-treated dogs (Sudhir 1994) and rats (Takenaka 1992), 
and a reduction in iNOS gene expression in rats (Vaziri 1998). A recent study in
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humans failed to show any improvement in endothelium (NO)-dependent 
vasodilatation after conversion from cyclosporin to azathioprine (van der Dorpel
1998).
Using the in vivo technique of forearm strain-gauge plethysmography, the aims of this 
study were:
1. to establish the presence or absence of endothelial dysfunction in renal 
transplant recipients with stable graft function
2. to examine both basal and stimulated endothelial nitric oxide production in 
cyclosporin-treated renal transplant recipients
6.2 METHODS
6.2.1 Subjects
Renal transplant recipients, at least one year post-transplantation, and with stable 
allograft function, were recruited from the transplant follow-up clinic at the Western 
Infirmary, Glasgow. The recruitment process was random; one investigator (SM) 
attended the above clinic whenever possible for 1 year and asked all suitable patients 
if they were willing to participate. Controls without renal disease were obtained from 
hospital staff and by advertisement within the hospital and University grounds. Those 
obtained by advertisement were paid £50 to cover expenses and time away from 
work. All subjects gave written informed consent, and the protocol was approved by 
the local ethics committee.
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The results detailed below are from 39 subjects who completed the studies. There 
were around 10 additional patients and subjects who were unable to lie still for the 2- 
hour studies and their data are not included.
Two separate studies were performed. In study 1, stimulated NO production was 
assessed in 9 CsA-treated patients, in 7 patients taking an azathioprine-based regime 
and in 12 controls without renal disease. In study 2, basal NO production was 
assessed in 9 CsA-treated patients and in 11 controls. Patients in the cyclosporin- 
treated group were maintained on prednisolone (5-10mg/day), azathioprine (1- 
2mg/kg/day) and cyclosporin (3-5mg/kg/day). Patients in the azathioprine group were 
maintained on prednisolone (5-10mg/day) and azathioprine (l-2mg/kg/day). These 
patients were initially also treated with cyclosporin but this was withdrawn at 6-12 
months post-transplantation for a variety of reasons including hirsutism, gingival 
hyperplasia, gout and hypertension.
I The patient and control groups were of a similar age and sex distribution, and had
j
similar smoking habits and serum cholesterol concentrations. Background
characteristics of subjects enrolled into study 1 (stimulated NO production) are
depicted in Table 6.1, and of those enrolled into study 2 (basal NO production) in 
Table 6.2. Four of the controls and six of the cyclosporin-treated patients participated 
; in both studies.
Patients were excluded if they were anti-coagulated with warfarin, had forearm AV 
fistulae, had a history of diabetes mellitus, vasculitis or myocardial infarction, or were
taking anti-anginal medication or statins. Patients were also excluded if they had 
severe hypertension such that anti-hypertensive drugs could not be withheld prior to 
the study.
All subjects were studied in the morning after an overnight fast, and were asked to 
omit aspirin for 7 days and anti-hypertensive medication for at least 48 hours before 
the study. Immunosuppressive drugs were taken normally on the day of study. 
Subjects were asked to avoid caffeine and alcohol, and to refrain from smoking, for at 
least 12 hours prior to the study. As stimulated endothelial NO production was normal 
in azathioprine-treated patients in Study 1, only cyclosporin-treated patients and 
controls were examined further in Study 2.
6.2.2 Drugs and solutions
Throughout each plethysmography session, 0.9% saline (Baxter, U.K.) or drug 
solutions were infused at lml/min. The following drugs (supplier) were stored and 
diluted to the appropriate concentration by the sterile pharmacy production unit at the 
Western Infirmary, Glasgow : sodium nitroprusside (Faulding DBL, England), 
carbachol (Martindale Pharmaceuticals, England), L-NMMA (ICN, England) and 
noradrenaline (Abbott, England). The reasons for the drug choices have been given in 
chapter 3; noradrenaline was used as a control vasoconstrictor as in other published 
forearm plethysmography studies (Calver 1992).
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CONTROL AZA CsA P
value1
P
value2
male (total) 8 (1 2 ) 6 (7 ) 7 (9 ) 0.950 -
sm oker (no.) 7 4 4 0.950 -
age (years) 40(25 ,51) 45 (33,51) 36 (24,55) 0.681 -
urea (mmol/1) 4.4 (2.9,6.6) 6.9
(4.6,10.4)
7.6 (5.7,12.5) <0.001 0.210
creatinine (pmol/l) 85 (57,108) 133
(80,223)
143 (111,215) 0.001 0.837
glucose (mmol/1) 4.7 (4.3,5.6) 4.4 (3.8,6.4) 4.7 (4.3,6.5) 0.805 -
cholesterol (mmol/1) 5.3 (3.5,6.6) 5.4 (3.6,7.4) 5.6 (3.7,9.3) 0.360 -
triglyceride (mmol/1) 1.1 (0.6,3.1) 1.4 (0.5,2.8) 2.1 (0.6,5.4) 0.242 -
haem oglobin (g/dL) 14.5
(12.4,15.6)
13.6
(11.0,15.6)
12.9
(10.6,14.7)
0.020 0.351
S.B.P. (mmHg) 124(104,158) 130
(106,155)
158(127,184) 0.007 0.029
D .B.P. (mmHg) 71 (50,75) 80 (70,91) 89 (70,99) 0.002 0.054
F.B.F. (m l 100ml'1) 2.95
(1.68,4.98)
2.40
(1.75,3.88)
2.80
(1.67,7.84)
0.474
total R.R.T. (months) * 232
(112,348)
108 (51,231) “ 0.023
m onths since Tx 129
(83,312)
4 8 (1 4 ,2 1 6 ) " 0.142
CCBs (no.) - 1 6 - 0.200
(3 blockers (no.) - 2 3 - 0.900
aspirin (no.) - 1 1 - 0.900
trough CsA level 
(nmol/1)
82(41 ,121)
Table 6.1. Background characteristics for patients and controls in Study 1.
Results are expressed as median (range). Represents Kruskall-Wallis or Chi-Square 
comparison between 3 groups. Represents Mann-Whitney or Chi-Square test 
between CsA and AZA. (F.B.F.=baseline forearm blood flow in infused arm; R.R.T. 
=renal replacement therapy; CCBs=calcium channel blockers).
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CONTROL CsA p value
male (total) 11(11) 9(9) -
smoker (no.) 5 4 0.980
age (years) 38 (28,42) 36 (24,55) 0.492
urea (mmol/1) 4.5 (2.8,6.7) 8.2 (6.0,11.71) <0.001
creatinine (p.mol/1) 87 (73,100) 157 (90,164) <0.001
glucose (mmol/1) 5.0 (4.4,5.2) 5.2 (4.1,6.5) 0.182
cholesterol (mmol/1) 5.0 (3.1,6.8) 5.9 (3.6,6.5) 0.604
triglyceride (mmol/1) 1.2 (0.8,1.9) 2.0 (0.8,5.4) 0.211
haemoglobin (g/dL) 13.9(12.4,15.5) 13.2(10.5,13.6) 0.019
S.B.P. (mmHg) 125(101,144) 146 (108,169) 0.056
D.B.P. (mmHg) 72 (56,79) 84 (64,95) 0.002
F.B.F. (ml 100ml'1) 2.82(1.70,5.20) 3.06(1.40,5.00) 0.849
total RRT (months) - 65 (108,244) -
months since Tx - 20 (51,216) -
CCBs (no.) - 7 -
p blockers (no.) - 3 -
aspirin - 2 -
trough CsA level
(nmol/1)
96 (37,161)
Table 6.2 Background characteristics for patients and controls in study 2.
Results are expressed as median (range). Comparison is by Mann-Whitney or Chi- 
Square test.
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6.2.3 Plethysmography protocol
All studies were performed in a quiet, sealed vascular research laboratory maintained 
at 24-26°C. Details of the equipment and technique have been outlined in chapter 2. 
In study 1, incremental infusions of carbachol (0.1, 0.3, 1.0, 3.0 pg/min) followed by 
sodium nitroprusside (0.3, 1.0, 3.0, 10.0 pg/min) were used. In study 2, noradrenaline 
was infused first (60, 120, 240 pmol/min) followed by L-NMMA (1, 2, 4 pmol/min) 
in view of its long half-life. There was a 30-minute washout period with 0.9% saline 
between drug infusions. Each drug was infused for 7 minutes with FBF measurements 
taken from minutes 3-6, and blood pressure recorded in the seventh minute. During 
each drug infusion, several FBF measurements were made; the mean of the final five 
readings was taken as the FBF achieved for each dose of drug. Forearm blood flow 
was expressed as ml blood flow min'1 100ml'1 forearm, and bilateral FBF 
measurements were made with the results expressed as a ratio of infused:non-infused 
arm.
6.2.4 Blood sampling and laboratory evaluation
Prior to each plethysmography session, a 21 gauge cannula was inserted into the 
dominant arm, and blood drawn after a 20-minute period of supine rest. Thirty ml of 
blood were drawn into EDTA, lithium heparin or plain tubes, spun and frozen 
immediately. In addition to standard haematological and biochemical analyses, assays 
were performed for renin (Millar 1980) and noradrenaline (Goldstein 1981), and for 
endothelin-1 using a commercially available kit (Cozart Bioscience, England).
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6.2.5 Statistical Analysis
All results are expressed as median (range) unless otherwise specified. Comparison 
between groups is by MANOVA with repeated measures. When significant, post-hoc 
analyses were performed by Mann-Whitney U to compare individual groups at each 
drug dose level. Statistical significance was defined at the 5% level.
In keeping with the method used in chapter 3, data for area under the curve are also 
presented. All statistics were performed using SPSS package for Windows version 
7.0.
6.3 RESULTS
6.3.1 Neurohumoral data
The neurohumoral data from studies 1 and 2 are detailed in Tables 6.3 and 6.4 
respectively. In study 1, there was a trend toward higher endothelin levels in patients 
compared to controls (this was significant for azathioprine-treated patients (0.48 
(0.10,1.15) fmol/ml) compared to controls (0.19 (0.01,0.49); p=0.022)). Renin levels 
were similar for all groups studied, however there was a trend toward lower 
noradrenaline levels in CsA patients compared to AZA patients and controls.
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CONTROL AZA CsA P
value1
P
value2
P
value3
endothelin-1
(fmol/ml)
0.19
(0.01,0.49)
0.48
(0.1,1.15)
0.36
(0.18,2.1)
0.019 0.068 0.397
renin (uU/ml) 20 (2,44) 27 (16,74) 20 (6,57) 0.104 0.840 0.281
noradrenaline
(nmol/1)
1.15
(0.01,4.20)
0.30
(0.01,5.30)
0.05
(0.01,4.30)
0.596 0.238 0.463
Table 6.3. Neurohumoral data for study 1. Results expressed as median (range). 
Statistical comparison is by Mann-Whitney tes t: between control & AZA; 2between 
control & CsA; 3between AZA &CsA.
CONTROL CsA p value
endothelin-1 (fmol/ml) 0 .12(0 .01,0 .30) 0.13 (0.01,0.30) 0.439
renin (uU/ml) 12.0 (6.0,28.0) 14.0 (7.0,56.0) 0.385
noradrenaline (nmol/1) 0 .70(0 .01,1 .90) 0 .30(0 .01 ,1 .00) 0.558
Table 6.4. Neurohumoral data from study 2. Results expressed as median (range), and 
comparison is by Mann-Whitney test
6.3.2 Effect of infusion of carbachol and SNP in transplant recipients and 
controls
Results for study 1 are illustrated in dose-response curve form, with results for 
infusion of S.N.P. in Fig. 6.1 and 6.2 and for carbachol in Fig. 6.3 and 6.4.
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Sodium  Nitroprusside400
Control
Transplant
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200  -
100 -
0.3 1 3 10
Dose SNP (ug/min)
Figure 6.1 Dose-response curves for infusion o f SNP in 12 controls and 16 renal 
transplant recipients. Data are mean ± sem.
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350 Sodium  Nitroprusside
300 -
control
aza250 -
cya
200  -
o»
w 150 -
100 -
50 -
0.3 1.0 3.0 10.0
Dose of SNP (mcg/min)
Figure 6.2 Dose response curves for infusion o f sodium nitroprusside in renal 
transplant recipients maintained on CsA (n=9) or not (aza; n=7), and 12 normal 
controls. Results are mean ± sem. Comparison by MANOVA showed no significant 
difference between groups.
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All three groups vasodilated similarly to S.N.P. (p=0.985 by MANOVA) 
demonstrating that endothelium-independent vasodilatation was comparable between 
groups. However, vasodilatation to carbachol (Fig. 6.3) was attenuated in the renal 
transplant recipients although did not reach statistical significance by MANOVA 
(p=0.10). Figure 6.4 shows the results for carbachol when the transplant recipients are 
divided into those taking a CsA-based regime and those taking an azathioprine-based 
regime. Vasodilatation to carbachol was attenuated in cyclosporin-treated patients 
(p=0.008 by MANOVA) with a significant reduction in response to 3pg/min 
carbachol in the cyclosporin group (188.8 (72.5,385.0) %change FBF ratio) compared 
to controls ( 303.8 (124.8, 813.3) p=0.028) and to the azathioprine group (378.1 
(124.0,548.9); p=0.042).
For study 1 the corresponding area under the curve data are as follows. The AUC for 
carbachol was 660.9 (259.6,1576.6) for controls, 471.6 (150.4,939.4) for CsA group 
and 698.4 (241.9,959.4) for AZA group; p=0.09 by Kruskall-Wallis test. The AUC 
for SNP was 1417.0 (857.8,4717.1) for controls, 1010.5 (736.7,4311.2) for CsA group 
and 1504.8 (1192.6,4939.2) for Aza group; p=0.26 by Kruskall-Wallis.
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Figure 6.3. Dose response curves for infusion o f carbachol in 12 controls and 16 
renal transplant recipients. Results are mean ± sem, and comparison is by MANOVA.
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Figure 6.4. Dose response curves for infusion o f carbachol in renal transplant 
recipients maintained on CsA (n=9) or not (n=7; aza), and 12 normal controls. Results 
are mean ± sem. Comparison is by MANOVA.
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6.3 Effect of infusion of L-NMMA and noradrenaline in CsA patients and 
controls
In study 2, the response to infusion o f L-NMMA is illustrated in Fig. 6.5. There was a 
graphical trend toward reduced vasoconstriction in the cyclosporin group, (overall 
MANOVA p=0.378), with the difference bordering on statistical significance at 
4pmol/min L-NMMA ( -39.4 (-15.7,-52.8) controls v -19.5 (-4.7,-63.1) for CsA; 
p=0.056 by Mann-Whitney test).
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Figure 6.5. Dose-response curves for infusion o f the NOS inhibitor L-NMMA in 
CsA-treated renal transplant recipients (n=9) and normal controls (n=l 1). Comparison 
by MANOVA was not statistically significant, but at 4|Limol/min comparison by 
Mann-Whitney approached significance (p=0.056). Results are mean ± sem.
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Results for infusion o f noradrenaline are illustrated in Fig. 6.6. Cyclosporin-treated 
patients as a group tended to vasodilate slightly while controls vasoconstricted as 
expected (p=0.016 by MANOVA). The maximum %change FBFratio for 
240pmol/min noradrenaline was -27.0 (-1.4, -38.6) for controls compared to +7.9 (- 
36.8, +92.6) for CsA-treated patients (p=0.02 by Mann-Whitney test).
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Figure 6.6. Dose response curves for infusion o f noradrenaline in CsA-treated renal 
transplant recipients and normal controls. Results are mean ± sem. Comparison by 
MANOVA showed a significant difference between the 2 groups (p=0.016).
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The error bars indicate a considerable degree of variation in the response to 
noradrenaline amongst the CsA-treated patients. When these results are examined 
more closely, it is clear that the patients are behaving differently : 3 vasoconstrict 
normally (to a similar degree as the control group). One patient had a minimal 
vasoconstrictor response, while 5 vasodilated. These patients were therefore divided 
into those who vasoconstricted (n=4) and those who did not (n=5) to see if any factors 
could be identified from the background history and results that would explain the 
discrepancy. These data are presented in Table 6.5
Of the patients who vasodilated, 2 were taking aspirin, 4 were taking CCBs and 1 was 
taking a beta-blocker. Of the (normal) vasoconstrictors, none were taking aspirin, 3 
were taking CCBs and 2 were taking beta-blockers. No patients were taking alpha- 
blockers. As the numbers were so small in each group, there was no statistically 
significant difference in drug use between groups. In addition, there were no 
significant differences between the neurohumoral data in vasodilators compared to 
vasoconstrictors. Spearmann correlation coefficients were performed for each factor 
in Table 6.5 and the response to 240pmol/min noradrenaline. None were significantly 
correlated, except for age. The plot for this correlation is demonstrated in Figure 6.7
Pulse and blood pressure did not change significantly throughout the studies, as the 
doses of drugs infused were chosen to exert only local effects in the forearm.
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NA Vasodilators NA Vasoconstrictors p value
Age 46.4 (9.3) 28.7(5.1) 0.016 *
Creatinine (pmol/l) 137.8(16.9) 144.0 (36.2) 0.286
Glucose (mmol/1) 5.2 (0.7) 5.2 (0.7) 0.730
Hb (g/dL) 12.8(0.7) 12.8(1.6) 0.556
Cholesterol (mmol/1) 5.3 (1.1) 5.6 (0.9) 0.730
Triglyceride (mmol/1) 1.74 (0.87) 2.38 (2.04) 0.556
SBP (mmHg) 144.6 (25.7) 136.5(16.1) 0.730
DBF (mmHg) 86.0 (7.3) 79.2 (10.2) 0.413
CsA level* 108.5 (44.7) 80.4 (42.3) 0.556
Tx time 88.6 (77.4) 49.7 (28.5) 0.413
Table 6.5 Background data for CsA-treated patients split into those who 
vasoconstricted normally to NA (n=4) and those who vasodilated (n=5). In view of 
small numbers data are mean ± sd, comparison by Mann-Whitney U test. # CsA level 
is mean of last 3 trough levels prior to the study.
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Figure 6.7 Scatter plot to illustrate the correlation between age and response to 
infusion o f 240 pmol/min noradrenaline in CsA treated renal transplant recipients.
6.4 DISCUSSION
The first aim o f this study was to examine endothelial function in renal transplant 
recipients compared to controls. The results from Study 1 show that, among 12 
controls and 16 renal transplant recipients, there was a trend toward attenuated 
endothelium-dependent vasodilatation in the transplant group compared to controls 
which may have reached statistical significance if  more subjects had been recruited. 
Responses to the endothelium-independent vasodilator, SNP, were preserved. Thus
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the pattern suggests endothelial dysfunction in the transplant group, and in particular, 
a reduced ability of the vascular endothelium to produce and release NO upon 
stimulation, or indeed, a reduced effect of NO through increased inactivation. It is 
also possible, that there is impairment of production and release of other endothelium- 
dependent vasodilators such as EDHF. To test for the relative contribution of NO and 
other vasodilators, one would have to repeat the studies in the presence of a NOS 
inhibitor such as L-NMMA. This was not done in these studies as it proved difficult 
for subjects to lie still for over 2 hours, and a second study would have been required 
in all cases.
With knowledge of the association between cyclosporin and hypertension, the second 
aim of this study was to examine the effects of cyclosporin treatment on basal and 
stimulated endothelial NO production. The results for Study 1 were therefore 
examined with the transplant group split into those patients taking cyclosporin and 
those who were not. This time, there was a statistically significant reduction in the 
response to carbachol in the CsA-treated patients compared to controls and the 
azathioprine-treated group. In study 2, the CsA-treated group vasoconstricted less 
well to the NO synthase inhibitor, L-NMMA, suggesting reduced basal endothelial 
NO production. The results of both studies indicate endothelial dysfunction in 
cyclosporin-treated renal transplant recipients.
This is unlikely to represent the effects of renal transplantation itself, as azathioprine- 
treated patients had preserved stimulated NO production. Neither is it likely to reflect 
years of uraemia prior to transplantation, as the azathioprine group had a longer total 
time on renal replacement therapy (Table 6.1). Endothelial dysfunction has been
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demonstrated in several conditions including hypercholesterolaemia, cigarette 
smoking, diabetes mellitus, hypertension and cardiac failure. However, diabetics were 
excluded from this study and both groups were matched for smoking habit and total 
cholesterol, although blood pressure was higher in the cyclosporin group (both 
compared to controls and compared to azathioprine-treated patients). As stated before, 
it is difficult to control for blood pressure in studies of this nature and the results are 
therefore limited by the possibility that the endothelial dysfunction is related to 
hypertension and not to treatment with cyclosporin. Another "unmatched" variable 
was triglyceride level, although studies in severe hypertriglyceridaemia have shown 
preserved endothelial function (Chowienczyk 1997).
Thus it remains possible that endothelial dysfunction in the CsA-treated patients is a 
direct effect of cyclosporin therapy, a theory supported by evidence from other 
studies. Bossaller et al demonstrated in 1988 that aortic rings from rats treated with 
cyclosporin showed attenuated relaxation to acetylcholine with preserved responses to 
GTN (Bossaller 1988). A similar picture was observed by adding cyclosporin to 
human subcutaneous resistance arteries in a wire myograph (Richards 1990) although 
this group felt the main inhibitory action was on the production of endothelium- 
derived prostanoids.
A more recent and well-designed study examined responses of thoracic aortic rings 
from rats treated with either cyclosporin or control (olive oil) (Oriji 1998). Rings from 
the CsA-treated animals demonstrated a 35% increase in tension when exposed to 
endothelin-1 compared to rings from control animals. Furthermore, the subsequent 
vasorelaxation to acetylcholine was reduced by 65% in the CsA rings, and this
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inhibitory action was prevented by pre-treatment of the rats with L-arginine. In whole 
animals, mean arterial pressure rose by 42% after administration of CsA and this was 
again prevented by pre-treatment with L-arginine. The rise in MAP was accompanied 
by a significant fall in the urinary nitrite, nitrate and cGMP levels, suggesting that 
cyclosporin-induced hypertension, at least in rats, is associated with inhibition of NO 
production. Similarly, Gonzalez-Santiago et al found that treatment of rats with CsA 
reduced endothelial NOS mRNA expression and increased ECE mRNA expression 
(Gonzalez-Santiago 2000). In humans, Schrama found evidence of endothelial 
dysfunction in CsA-treated renal transplant recipients (Schrama 2001). This group 
measured von Willebrand factor and sP-selectin (both markers of endothelial injury) 
during stepwise withdrawal of cyclosporin and found elevated levels during treatment 
with full dose CsA that subsequently fell after withdrawal of the drug.
Thus there is a growing body of evidence that cyclosporin-induced hypertension is 
related to endothelial dysfunction, and in particular reduced production &/or effect of 
NO. Cyclosporin-related haemolytic uraemic syndrome may simply be a more 
extreme manifestation of the endothelial damage produced by this drug.
A surprising finding of this study was a trend toward reduced vasoconstriction or a 
slight vasodilatation to noradrenaline in cyclosporin-treated patients. In a study using 
isolated rat aortic strips, cyclosporin added to the organ bath induced a slowly- 
developing contraction that could be blocked by either the calcium-channel blocker 
verapamil, or by the a-antagonist phenoxybenzamine (Xue 1987). It is therefore
II
possible that cyclosporin interferes with a-mediated vasoconstriction, such that 
infusion of noradrenaline at plethysmography has little effect or vasodilates through
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the P2 adrenoceptor. The reason for the age effect is unclear. The strong correlation 
would suggest that this is a true effect and not a type II error, but a possible 
mechanism is hard to explain as there was no correlation between the time since 
transplantation or total RRT duration. No previous studies have documented a change 
in adrenoceptor function with aging and this finding merits further investigation.
A limitation of study 2 was the absence of a non-CsA treated group, thus it is 
plausible that the results could reflect years of uraemia rather than the effects of 
cyclosporin. A larger study is warranted to examine the effects of noradrenaline 
further.
The neurohumoral studies failed to demonstrate significantly raised circulating 
endothelin levels in the cyclosporin-treated patients as reported previously (Textor 
1992), perhaps reflecting the small numbers studied. Interestingly, the azathioprine- 
treated group tended to have higher endothelin levels, although this failed to alter the 
response of this group to vasodilators. There was a trend toward lower noradrenaline 
levels in CsA patients compared to other groups in both studies, in contrast to a 
previous study where the noradrenaline level was elevated along with increased 
sympathetic nerve activity in CsA treated patients (Scherrer 1990). The reason for the 
lower noradrenaline levels and any possible link to the paradoxical vasodilatation is 
unclear and requires further study. Renin levels were lower in study 2, again perhaps 
reflecting the small numbers studied. There was no difference in diuretic use between 
studies.
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Forearm plethysmography studies are often small as recruitment of patients for 
brachial artery cannulation can be difficult. We therefore accept that a limitation of 
this study is the relatively small study group, and that a larger study is warranted to 
examine the effect of noradrenaline infusion in more detail.
6.5 CONCLUSION
In conclusion, this study demonstrates attenuated endothelium-dependent 
vasodilatation in cyclosporin-treated renal transplant recipients compared to controls 
and azathioprine-treated patients. As endothelium-independent vasodilatation 
remained intact, this pattern implies altered endothelial function in CsA-treated 
patients (rather than altered smooth muscle action). Basal NO production was also 
reduced in CsA-treated patients compared to controls. Cyclosporin-induced 
endothelial dysfunction may therefore explain at least some of the increased 
cardiovascular risk in this group, and provide a potential mechanism to explain 
cyclosporin-induced hypertension. The most surprising finding of this study, that 
some (predominantly older) CsA-treated patients reacted abnormally to infusion of 
noradrenaline, requires further study.
Chapter 7
General Discussion & Conclusions
7.1 Endothelial function in uraemia
The principal aim of this project was to examine endothelial function in patients with 
chronic renal failure. The work contained in this thesis concentrates on endothelium- 
dependent vasodilatation, as this is the most amenable aspect of endothelial cell 
function to study in humans. Two methods were employed, one in vivo, the other in
vitro.
Using forearm venous occlusion plethysmography it was demonstrated that 
endothelium-independent vasodilatation to SNP was similar in 10 uraemic patients 
(pre-dialysis and on CAPD) and 10 controls. In contrast, endothelium-dependent 
vasodilatation to carbachol was impaired in the uraemic patients compared to 
controls, and the pattern therefore suggests endothelial dysfunction in uraemia. As 
many authors have previously suggested that there may be a circulating “uraemic 
factor” that promotes atherosclerosis (presumably through endothelial damage) a 
similar study was performed using the in vitro technique of wire myography. This 
confirmed the findings of the plethysmography study and would suggest that a short­
lived, readily-reversible circulating factor is not entirely responsible. However, the 
effects of years of exposure of the endothelium to one or many “circulating factors” 
(including traditional cardiovascular risk factors such as oxLDL) may not reverse 
easily on short-term removal of the offending agents, and thus it remains unproved 
that circulating factors are not involved. One particular lesson that was learned from 
the study described in Chapter 3 is that the order of drugs infused in plethysmography 
should probably not be randomised, especially with SNP as this has a long-lasting
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influence on basal vascular tone. Randomising drug order also increases variability 
and necessitates an increased sample size to show a difference between two groups.
What is likely to be the mechanism underlying endothelial dysfunction in chronic 
renal failure? The studies performed in this thesis do not allow an adequate 
explanation, and further work is required. Repeating the experiments in the presence 
of a NOS inhibitor, such as L-NMMA, would allow a more accurate assessment of the 
degree of involvement of NO. However, work performed by Newby et al (Newby
1997) has previously demonstrated that endothelium-dependent vasodilatation in the 
resistance vasculature is predominantly through NO, thus one could speculate that the 
results from the above experiments suggest dysfunction of the L-arginine/NO 
pathway in uraemia. This may occur at various levels :
1. altered expression of endothelial receptors
2. impaired signal transduction mechanisms
3. decreased activity of NO synthase
4. reduced intracellular availability of L-arginine
5. increased breakdown of NO
6. reduced responsiveness of the VSMC to NO
7. increased production of an endogenous inhibitor of NOS
Further studies are required in uraemia to elucidate the underlying defect(s).
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7.2 Risk factors linked to endothelial dysfunction
The mechanism whereby uraemia leads to endothelial dysfunction has not been 
elucidated. Patients with CRF often have several traditional cardiovascular risk 
factors and we may simply be seeing the cumulative effect of these factors rather than 
an effect specific to uraemia itself. The following risk factors have been linked to 
endothelial dysfunction:
7.2.1 Essential hypertension
Despite Cockcroft’s initial report (Cockcroft 1994), there are now considerable data 
supporting an association between essential hypertension and impaired endothelium- 
dependent vasodilatation (Panza 1990; Taddei 1998; Ferro 1997; Iiyama 1996). In 
animals, chronic inhibition of NOS leads to hypertension, and mice that overproduce 
NO are chronically hypotensive. However, in humans it remains to be seen whether 
endothelial dysfunction is the cause or effect of hypertension, and genetic studies 
have thus far failed to show a link between hypertension and a defect in the eNOS 
gene (Bonnardeaux 1995). As hypertension is an almost invariable accompaniment of 
CRF it is likely that if essential hypertension is associated with endothelial 
dysfunction then uraemia will also be associated with endothelial dysfunction. 
Designing studies to control for the effect of hypertension is difficult as most uraemic 
adults will be hypertensive, and thus a second hypertensive control arm would be 
necessary. Kari et al (Kari 1997) bypassed this problem by examining endothelial 
function in normotensive children with CRF, and found that endothelial dysfunction
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was present despite the absence of hypertension. This group concluded that uraemia 
per se was associated with endothelial dysfunction.
7.2.2 Aging
In a study of 119 healthy subjects aged from 19 to 69 years it was shown by venous 
occlusion plethysmography that endothelium-dependent vasodilatation declined with 
increasing age, while endothelium-independent vasodilatation remained constant 
(Gerhard 1996). Endothelial dysfunction was apparent from age 30-39 onwards. This 
group proposed that the reduction in NO production &/or release with advancing age 
may explain the increased risk of atherosclerosis with aging. Their results were 
supported by a subsequent study demonstrating reduced vasoconstriction to L- 
NMMA in elderly subjects compared to younger controls (with preserved constriction 
to noradrenaline) inferring reduced basal NO production in old age (Lyons 1997). In 
the studies performed in this thesis age is not likely to be relevant as the study and 
control groups were matched for age.
7.2.3 Tobacco smoking
Smoking is a major risk factor for the development of atherosclerosis in the general 
population and has been linked to adverse cardiovascular outcome in CRF. The first 
study to examine the effects of cigarette smoking on endothelial function was 
published in 1993 (Jacobs 1993) and had surprising results - in this small forearm 
plethysmography study stimulated endothelium-dependent vasodilatation appeared to 
be preserved in young cigarette smokers. A subsequent larger study by Kiowski et al
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looked at basal NO production using L-NMMA and showed that long-term smokers 
had attenuated vasoconstriction to this agent implying reduced basal NO production 
in smokers (Kiowski 1994). Several studies have confirmed this finding and it is now 
well established that chronic, acute and passive cigarette smoking are all associated 
with endothelial dysfunction (Schoenberger 2001). The mechanisms underlying the 
adverse effects of smoking on endothelial function are complex but in part are related 
to the generation of oxLDL by free radicals contained in cigarette smoke (Miller
1997). Again, the results from the studies contained within this thesis are unlikely to 
be influenced by smoking, as there were a similar number of smokers in both the 
study and control groups.
7.2.4 Diabetes Mellitus
Patients with diabetes mellitus were excluded from the studies performed in this thesis 
as diabetes is an established risk factor for endothelial dysfunction. The most obvious 
manifestation of endothelial dysfunction in diabetes mellitus is the characteristic 
increased permeability of the microcirculation with resultant microalbuminuria. One 
of the earliest human studies to examine endothelial responses demonstrated impaired 
endothelium-dependent vasodilatation of isolated vessels from the corpus cavemosum 
of impotent diabetic males, with preserved responses to SNP and normal responses in 
non-diabetic impotent males (De Tejada 1989). Subsequent studies, many utilising 
forearm plethysmography, have confirmed these findings in type I and type II diabetic 
patients (Williams 1996; O’Driscoll 1997; Watts 1996) and also with acute 
hyperglycaemia induced by glucose loading in normal subjects and in people with 
impaired glucose tolerance (Kawano 1999).
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Diabetes mellitus is likely to cause endothelial dysfunction in several ways including 
decreased availability of NADPH (a co-factor for eNOS), increased production of 
oxygen free-radicals, increased shear stress through insulin-mediated increased flow 
and hyperinsulinaemia-induced alterations in post-receptor pathways such as PI3 
kinase (Storey 2001). In addition, diabetes is associated with inflammation, 
dyslipidaemia and hypertension, all of which are linked to endothelial dysfunction.
7.2.5 Dyslipidaemia
Dyslipidaemia is common in chronic renal failure and is likely to contribute to the 
pathogenesis of endothelial dysfunction. While total cholesterol may be normal, 
uraemia is characterised by hypertriglyceridaemia, increased total:HDL cholesterol 
ratio and increased small dense LDL concentrations. Most of the human studies 
examining endothelial function in dyslipidaemia have demonstrated impaired 
endothelium-dependent vasodilatation in patients with raised total cholesterol levels 
(Creager 1992; Stroes 1995), although recent studies have shown a link between low 
HDL levels and endothelial dysfunction in healthy young men (Toikka 1999), and 
LDL particle size and endothelial responses in diabetics (Skyrme-Jones 2000). 
Studies in hypertriglyceridaemia have given conflicting results with Chowienczyk 
(1997) finding preserved endothelial function and Lewis et al (1999) finding impaired 
endothelium-dependent vasodilatation in patients with high fasting triglyceride levels 
and normal LDL cholesterols. In chapters 3 and 4, patients had higher triglyceride 
levels than controls and this may be a confounding issue, and again an issue for which 
it is extremely difficult to control.
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There is clear evidence that dyslipidaemia is intimately related to endothelial 
dysfunction, even in patients without clinically apparent atherosclerosis. The 
pathogenesis of the endothelial dysfunction is again likely to be multifactorial, but 
several pieces of information are known :
■ Oxidised LDL more potently impairs endothelial function than does native LDL 
(Vogel 1999). Oxidised lipoprotein(a) is of even greater potency.
■ HDL counteracts the inhibitory effect of oxLDL on endothelium-dependent vaso­
dilatation (Matsuda 1993).
■ Oxidised LDL inhibits NO synthase in cultured endothelial cells (Vogel 1999).
■ Hypercholesterolaemia increases platelet aggregability and endothelial cell 
adhesion molecule expression, thereby generating a pro-thrombotic state (Vogel 
1999).
■ Hypercholesterolaemia may increase ADMA levels (Luscher 1997).
■ Oxidised LDL may stimulate endothelin-1 production (Luscher 1997), and 
enhance the sensitivity of the VSMC to endothelin-1.
■ Hypercholesterolaemia is associated with reduced bioavailability of NO, through 
increased inactivation of NO by superoxide anion generation (Vogel 1999).
Thus, many traditional cardiovascular risk factors are prevalent in patients with 
chronic renal failure and are likely to be involved in the pathogenesis of endothelial 
dysfunction. Several less traditional risk factors may also be involved including 
ADMA, homocysteine, inflammation, oxidative stress and hyperparathyroidism, and 
these have been discussed in more detail in chapter 1. The degree of interplay
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between these various risk factors in the pathogenesis of endothelial dysfunction in 
uraemia remains unknown. Nor do we know if other, unidentified, uraemic factors are 
involved.
The clinical relevance of endothelial dysfunction in uraemia is visible to all clinical 
nephrologists : accelerated atherosclerosis, manifest as angina and myocardial 
infarction, stroke, renovascular disease, mesenteric ischaemia and peripheral vascular 
disease. While many deaths in our patients occur suddenly, often out-of-hospital, and 
may be related to left ventricular hypertrophy and arrhythmias, we are increasingly 
seeing patients with atherosclerotic complications leading to significant morbidity and 
mortality. With an aging and increasingly diabetic population on RRT, then perhaps 
the biggest problem facing nephrologists in the near future will be the morbidity and 
use of resources associated with peripheral vascular disease and cerebrovascular 
disease.
7.3 Endothelial function following renal transplantation
While renal transplantation undoubtedly improves the quality of life of patients on 
dialysis, there remains a debate as to whether survival is prolonged, as studies are 
confounded by selection bias. Cardiovascular disease, common in dialysis patients, 
remains the commonest cause of death following renal transplantation and death with 
a functioning allograft (most often from cardiovascular causes) is now the main 
reason for graft loss.
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The most likely explanation for this is that by the time a patient reaches renal 
transplantation the damage is already done. It is widely believed that increased 
cardiovascular risk begins at a very early stage in a patient’s “renal life”, with 
hypertension, dyslipidaemia, hyperhomocysteinaemia and other factors increasing in 
prevalence and severity as GFR falls. Not surprisingly, endothelial dysfunction also 
begins at an early stage and in this thesis has been demonstrated in pre-dialysis 
uraemic patients, as well as in uraemic children (Kari 1997). Thus by the time a 
patient is commenced on dialysis they already have established endothelial 
dysfunction, early (or possibly advanced) atherosclerosis and left ventricular 
hypertrophy. It is not surprising that endothelial dysfunction is also found in patients 
following renal transplantation.
Using forearm plethysmography it was demonstrated that endothelium-independent 
vasodilatation to SNP was similar in 16 renal transplant recipients and 12 controls, 
while there was a trend toward impaired endothelium-dependent vasodilatation in the 
transplant recipients. When this group was divided into those taking cyclosporin and 
those not, it was clear that there was endothelial dysfunction in the CsA group. One 
would have expected some impairment of endothelium-dependent vasodilatation in 
the azathioprine and prednisolone group, but this was not seen perhaps reflecting 
small numbers. The CsA group also had less vasoconstriction to L-NMMA implying 
that basal NO production was impaired. Thus, CsA-treated patients had impaired 
stimulated and basal NO production and this may partly explain the pathogenesis of 
CsA-induced hypertension and the increased cardiovascular risk in renal transplant 
recipients.
A most surprising finding was of paradoxical vasodilatation to noradrenaline in some 
of the CsA-treated patients -  this was difficult to explain but seemed to be related to 
age. The clinical relevance of this is unclear but may suggest that CsA, at least in 
some patients, interferes with ai-adrenoceptors such that infusion of noradrenaline 
vasodilates through the (32-adrenoceptor. Whether this mechanism is involved in CsA- 
induced hypertension is not known.
7.4 Therapies that may improve endothelial function
Given that patients with CRF, both pre-dialysis, on dialysis and following renal 
transplantation have endothelial dysfunction and unacceptably high death rates from 
cardiovascular disease, can we reverse endothelial dysfunction and use this as a 
surrogate marker for reducing cardiovascular events?
There have been several published reports of improvements in endothelial function 
following drug therapy and lifestyle changes :
7.4.1 ACE-Inhibitors
Theoretically, angiotensin II may induce endothelial dysfunction through increased 
ET-1 and prostaglandin H2 production, inhibition of NOS activity by activation of 
protein kinase C, and through increased free radical production (Virdis 1998). In 
cigarette smokers (Butler 2001), type I diabetics (O’Driscoll 1997a) and patients with 
IHD (Prasad 1999), ACE inhibitor treatment has been shown to improve endothelium-
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dependent vasodilatation. In essential hypertension the situation is less clear, with 
some studies showing improved endothelium-dependent vasodilatation in the 
subcutaneous microcirculation but others demonstrating no benefit in the forearm 
circulation (Virdis 1998). The reason for the discrepancy is poorly understood. To 
date, no studies have looked at the effect of ACE inhibitors on vascular endothelial 
function in uraemia.
7.4.2 Calcium Antagonists
In patients with essential hypertension, data are available showing that 
dihydropyridine calcium channel blockers improve endothelial dysfunction in various 
vascular beds : subcutaneous resistance vessels (Schiffrin 1996), the coronary 
circulation (Frielingsdorf 1996) and the forearm vasculature (Taddei 1997). 
Interestingly, in the forearm study there was no immediate benefit of intra-arterial 
infusion of lacidipine while an improvement in endothelial function was apparent 
after 2 months of oral treatment. Moreover, this improvement persisted for 2 weeks 
after discontinuation of the drug suggesting that the drug acted independently of blood 
pressure reduction. Similar improvements in endothelial function have also been 
demonstrated in patients with hyperlipidaemia (Bracht 2001) but not yet in CRF.
The reason for the beneficial effect of calcium antagonists is uncertain as these drugs 
act on voltage-dependent calcium channels that are not expressed on endothelial cells, 
but rather on vascular smooth muscle cells. Some authors have postulated that the 
inhibition of calcium influx into the smooth muscle cell simply potentiates the 
vasodilatory effect of NO. However, if this were the case then the responses to
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endothelium-independent vasodilators would also be enhanced, and this was not the 
case in the forearm plethysmography study detailed above. More likely is that calcium 
antagonists act via an antioxidant mechanism that involves endothelial protection 
through free radical scavenging (Virdis 1998; Cominacini 1998). In addition, there 
may be a direct effect of these drugs on the endothelium with some evidence available 
to suggest that they alter the redox potential of endothelial cells and that there may be 
an effect on endothelial stretch-operated calcium channels (Bom 1998).
7.4.3 Beta Blockers
“Standard” beta-blockers such as atenolol have no specific effect on endothelial 
function. However, newer drugs such as nebivolol and carvedilol may be different. In 
two separate studies nebivolol, infused into normotensive volunteers, vasodilated 
preconstricted dorsal hand veins and increased forearm blood flow, with the effects 
being blocked by L-NMMA (Bowman 1994; Cockcroft 1995). These data suggest 
that nebivolol acts partly through increased NO release. Carvedilol is another newer 
beta-blocker with vasodilating activity in vivo and anti-oxidant effects in vitro. A 
recent study has demonstrated that this dmg also improves endothelial function in 
patients with coronary artery disease (Matsuda 2000). No studies are available in 
renal failure.
7.4.4 Cholesterol reduction
LDL plays a pivotal role in the pathogenesis of atherosclerosis as discussed in 
Chapter 1, and there are considerable data linking hypercholesterolaemia to
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endothelial dysfunction in patients without renal impairment. In this “non-CRF” 
population there are now over 20 published studies demonstrating improved 
endothelial function with lowering of serum cholesterol. While the majority of these 
studies have examined the effects of HMG CoA reductase inhibitors or “statins” on 
endothelial function, there is reasonable evidence that endothelial function can be 
improved by any method of cholesterol lowering, including apheresis (Tamai 1997), 
cholestyramine (Leung 1993) and bezafibrate (Seiler 1995).
Most interest, however, has focused on statin therapy as these drugs offer the most 
potent therapeutic means of lowering total, and more specifically, LDL cholesterol. 
Some of these agents are also associated with a modest increase in beneficial HDL 
cholesterol levels. The first study to demonstrate an improvement in endothelial 
function with statins was published in 1989 and looked at the effect of lovastatin on 
rabbits fed a cholesterol-rich diet (Osborne 1989). Subsequent publications have 
confirmed that statins improve endothelial function in humans with (O’Driscoll 
1997b; Drury 1996) and without coronary heart disease (Stroes 1995; Laufs 2001), as 
well as in a range of other conditions including diabetes (Mullen 2000) and 
hypertension (Wassmann 2001). In addition, the benefits may be seen in patients who 
would traditionally have been classed as normocholesterolaemic (Laufs 2001).
The mechanism of action of statins in restoring endothelial function may be more 
complex than simple cholesterol reduction. Initial studies suggested that the beneficial 
effects of these drugs on endothelial function could be observed after 4 weeks of 
treatment (O’Driscoll 1997). Recent work, however, suggests that these drugs may 
work over a much shorter timescale with one group demonstrating an improvement in
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endothelial function after 3 days treatment of elderly diabetics with cerivastatin 
(Tsunekawa 2001) and quite remarkably, another group within 24 hours of treatment 
of normocholesterolaemic, healthy men with high dose (80mg/day) atorvastation 
(Laufs 2001). In both of these studies the improvements in endothelial function 
occurred before there was a significant fall in serum cholesterol, implying that the 
statin improved endothelial function via a cholesterol-independent mechanism. These 
findings are supported by work on cultured endothelial cells that demonstrates 
upregulation of eNOS by statins (Laufs 1998) and activation of eNOS by 
atorvastation via a reduction in the concentration of the eNOS inhibitory substance 
caveolin-1 (Feron 2001). An antioxidant mechanism may also be involved 
(Wassmann 2001).
Thus, there is a large body of evidence to support the lowering of LDL-cholesterol 
with statin therapy in high-risk groups (and possibly lower risk groups) without CRF 
to improve endothelial function and reduce cardiovascular events. Unfortunately there 
are currently no published outcome studies looking at cholesterol reduction in patients 
with CRF. Nevertheless, in renal transplant recipients we now have evidence that 
statin therapy improves endothelium-dependent vasodilatation (Asberg 2001; 
Hausberg 2001) and on-going studies will soon report on the effect of statins on 
cardiovascular outcomes in this group.
7.4.5 L-Arginine
The rationale behind the use of L-arginine to improve endothelial function is simple : 
either restore availability of the substrate for NO synthesis to normal (if deficient) or
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increase the substrate concentration above normal levels in order to compete with 
antagonists for the enzyme such as ADMA. Under normal conditions however, L- 
arginine is neither deficient nor rate-limiting with intracellular concentrations being in 
the millimolar range and the Michaelis constant for NOS being in the micromolar 
range (Maxwell 1998). The observation that L-arginine improves NO-dependent 
vasodilatation in a number of clinical scenarios is therefore difficult to explain, 
although intracellular concentrations of ADMA may be many times greater than 
circulating levels in these conditions.
Early animal studies demonstrated that supplemental dietary L-arginine reduced 
atherosclerotic plaque formation in hypercholesterolaemic rabbits (Cooke 1992) while 
intravenous L-arginine improved endothelium-dependent vasodilatation in a similar 
rabbit model (Girerd 1990). Subsequent studies in humans have confirmed these 
findings with the demonstration of improved endothelium-dependent vasodilatation 
with L-arginine in healthy young adults (Imaizumi 1992), in hypercholesterolaemia 
(Creager 1992), heart failure (Hirooka 1994) and ischaemic heart disease (Maxwell
1998). In contrast, L-arginine infusion had no effect on endothelial responses in 
patients with essential hypertension (Panza 1993).
In uraemia, the effects of L-arginine are controversial. Using a dorsal hand vein 
technique, Hand et al (1998) showed that endothelium-dependent responses were 
impaired in patients undergoing haemodialysis and that these responses were 
improved with dialysis, with infusion of L-arginine but not with D-arginine. This 
group hypothesised that their results supported the belief that accumulation of 
endogenous NOS inhibitors in uraemia is functionally important. However, a
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subsequent study using forearm plethysmography failed to demonstrate any effect of 
local or systemic infusion of L-arginine in pre-dialysis and haemodialysis patients 
(Cross 2001), and therefore, without outcome studies, the potential therapeutic benefit 
of L-arginine supplementation in CRF remains unclear. A further problem may be 
tolerability as many studies have used over 20g of arginine powder. In patients who 
are already subject to polypharmacy, this may prove unpalatable.
7.4.6 Antioxidants
Oxidative stress, particularly in CRF, is thought to play an important role in the 
development of atherosclerosis. On this premise, it has been hoped that antioxidant 
therapy with ascorbic acid (vitamin C) &/or alpha-tocopherol (vitamin E) would 
improve endothelial function and slow or prevent the development of atherosclerosis 
in general and CRF populations. The mechanisms underlying the potentially 
beneficial effects of antioxidants include (Carr 2000):
■ Scavenging of free radicals by ascorbate thereby preventing oxidation of LDL
■ Prevention of LDL lipid peroxidation by alpha-tocopherol (contained within the 
LDL particle)
■ Prevention of the pro-oxidant activity of vitamin E by ascorbate
■ Inhibition of leucocyte-endothelial cell interaction
■ Reduction in oxLDL and superoxide levels to enhance bio-availability of 
endothelium-derived NO
■ Ascorbate may also increase endothelial cell NO production directly by assisting 
in the regeneration of tetrahydrobiopterin
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In keeping with these theoretical benefits, there have been numerous studies 
demonstrating improved endothelial function with vitamin C and vitamin E in a range 
of condition including diabetes (Ting 1996), hyperhomocysteinaemia (Chambers
1999), heart failure (Homig 1998), hypertension (Solzbach 1997) and 
hypercholesterolaemia (Green 1998). Unfortunately, in the general population these 
effects on endothelial function have not been translated into clinical benefits with the 
HOPE and GISSI studies failing to show any effect of antioxidant therapy on 
cardiovascular endpoints.
In CRF, the coating of haemodialysis membranes with vitamin E has been shown to 
reduce oxidised LDL formation and endothelial dysfunction associated with the 
haemodialysis process (Miyazaki 2000). In renal transplant recipients, oral 
administration of 2g ascorbic acid 2 hours prior to plethysmography significantly 
increased endothelium-dependent vasodilatation (Williams 2001). Furthermore, a 
recent study by Fellstrom’s group has shown a significant relationship between 
several markers of oxidative stress and endothelial dysfunction in patients with CRF 
(Annuk 2001). This suggests that increased oxidative stress, perhaps mediated 
through hyperhomocysteinaemia, may be the principal mechanism underlying 
endothelial dysfunction in uraemia. Supporting evidence for this theory comes from 
the SPACE study, a prospective, randomised, double-blind study of high dose vitamin 
E or placebo in 196 haemodialysis patients with pre-existing cardiovascular disease 
(Boaz 2000). Remarkably, after a median follow-up period of only 1.5 years there was 
a 54% reduction in cardiovascular endpoints in the vitamin E treated group.
I
i
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7.4.7 Folic Acid
Hyperhomocysteinaemia is extremely prevalent in patients with CRF and is now 
established as a major risk factor for atherosclerotic cardiovascular disease in this 
group and in the general population. Folic acid, vitamin B6 and vitamin B12 are 
required for the metabolism of homocysteine to methionine and cysteine, with 
deficiencies of these vitamins being associated with hyperhomocysteinaemia and 
atherosclerosis (Robinson 1998).
In subjects without renal failure, dietary supplementation with folic acid (0.5- 
5mg/day) reduces blood homocysteine concentration by around 25% (Anonymous,
1998), with an additional 7% reduction with vitamin B12 0.5mg/day. Vitamin B6 had 
no effect in this meta-analysis. To date, there are no published studies examining the 
effect of homocysteine-lowering on cardiovascular outcomes although one small 
unblinded study reported a reduction in the progression of carotid artery plaque 
thickness with a combination of folic acid, vitamin B6 and vitamin B12 (Peterson
1998). In contrast, many studies have examined the effect of homocysteine-lowering 
on endothelial function in patients without CRF. Several have shown improved 
endothelium-dependent vasodilatation (Chambers 2000; Title 2000; Bellamy 1999) 
while others have not (van Dijk 2001, Pullin 2001), and the reason for the discrepancy 
is unclear.
In CRF, folic acid supplementation (5-15mg/day) lowers fasting tHcy by around 30- 
50% although only a third of patients reach “normal” tHcy levels (Bostom 1996). In 
keeping with the general population, there is a paucity of information on the long­
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term effects of folic acid supplementation on cardiovascular events. Additionally, 
three published studies have failed to show any benefit of homocysteine-lowering 
(with 5mg folic acid daily) on endothelial function in pre-dialysis patients 
(Thambyrajah 2000b), CAPD patients (van Guldener 1998a) and haemodialysis 
patients (van Guldener 1998b). Thus the role of folic acid and B vitamin 
supplementation in this group is unclear, and it is possible that severe, irreversible 
endothelial dysfunction occurs at an early stage in CRF and that interventions will be 
required before GFR has significantly declined. Alternatively, significantly higher 
doses of folic acid may be required in CRF with or without B vitamins and anti­
oxidants, and the studies have not yet been performed to identify the best dose and 
regime.
7.4.8 Lifestyle Changes/Miscellaneous
In addition to the drug therapies described above, there are many other potential 
means of improving endothelial function in populations without CRF including 
hormone replacement therapy (de Kleijn 2001), weight reduction (Ziccardi 2002), 
smoking cessation (Moreno 1998) and physical exercise (DeSouza 2000). It remains 
to be seen if these methods will also improve endothelial function in CRF.
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7.5 CONCLUSIONS
■ Cardiovascular disease is the commonest cause of death in patients with chronic 
renal failure, both pre-dialysis and on renal replacement therapy. The incidence is 
several folds greater than that of the general population and indeed of diabetics.
■ The increased cardiovascular risk is related to changes in both the heart and the 
vessels. Left ventricular hypertrophy with resultant arrhythmias and cardiac 
failure is an extremely common problem in ESRF.
■ There are also changes in the blood vessels in uraemia with several reports 
suggesting accelerated atherosclerosis. As the vascular endothelium protects 
against the development of atherosclerosis, it is likely that there are fundamental 
changes in endothelial function in uraemia.
■ Studies contained within this thesis demonstrate endothelial dysfunction in adult 
patients with chronic renal failure, both pre-dialysis and on CAPD. In addition, 
post-transplant patients receiving cyclosporin therapy also exhibited endothelial 
dysfunction.
■ Endothelial dysfunction in uraemia was demonstrated both in vivo using forearm 
plethysmography, and in vitro using wire myography. This would suggest (but not 
prove) that a short-lived, readily-reversible circulating factor was not entirely 
responsible. The studies do not allow a more detailed analysis of the aetiology of 
endothelial dysfunction in uraemia.
■ Endothelial dysfunction was demonstrated in CsA-treated renal transplant 
recipients and this may partly explain the mechanism underlying CsA-related 
hypertension. Some of these patients had abnormal responses to infusion of 
noradrenaline, suggesting an abnormality of adrenergic receptors or post-receptor
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signalling. The relevance of this to the pathogenesis of CsA-related hypertension 
is unclear, and the underlying mechanism remains to be elucidated.
■ The clinical relevance of endothelial dysfunction in uraemia is a predisposition to 
atherosclerosis. Traditional cardiovascular risk factors are highly prevalent in CRF 
patients and may simply act synergistically to accelerate atherosclerosis. 
However, there may also be more unusual risk factors at play including 
homocysteine, ADMA, increased oxidative stress, low-grade inflammation and 
other, as yet unidentified, uraemic factors.
■ In the general population, reversal of endothelial dysfunction has been 
successfully demonstrated using anti-hypertensive agents, cholesterol-lowering, 
L-arginine, lifestyle changes, folic acid and some antioxidants. It remains to be 
seen if these methods will also be beneficial in uraemic patients. If so, then 
reversal of endothelial dysfunction may be viewed as a surrogate marker for 
treatments to reduce cardiovascular endpoints in this high-risk group.
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